<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-972-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIPRALEX 20MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESCITALOPRAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        129.23
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="H. LUNDBECK" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            H. LUNDBECK
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AJA PHARMACEUTICAL INDUSTRIES
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Cipralex contains the active substance escitalopram. Cipralex belongs to a group of antidepressants called selective serotonin reuptake inhibitors (SSRIs). Disturbances in the serotonin-system are considered an important factor in the development of depression and related diseases.</p><p>&nbsp;</p><p>Cipralex contains escitalopram and is used to treat depression (major depressive episodes) and anxiety disorders (such as panic disorder with or without agoraphobia, social anxiety disorder, generalised anxiety disorder and obsessive-compulsive disorder).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Cipralex</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have allergic to escitalopram or any of the other ingredients of this medicine (listed in section 6).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take other medicines which belong to a group called MAO inhibitors, including moclobemide (used in the treatment of depression).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at the same time as taking pimozide.</p><p>&nbsp;</p><p>Warning and Precautions</p><p>Please tell your doctor if you have any other condition or illness, as your doctor may need to take this into consideration. In particular, tell your doctor:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have epilepsy. Treatment with Cipralex should be stopped if seizures occur for the first time, or if there is an increase in the seizure frequency (see also section 4 &ldquo;Possible side effects&quot;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from impaired liver or kidney function. Your doctor may need to adjust your dosage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes. Treatment with Cipralex may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a decreased level of sodium in the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a tendency to easily develop bleedings or bruises, or if you are pregnant (see &lsquo;Pregnancy, breast-feeding and fertility&rsquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are receiving electroconvulsive treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have coronary heart disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have or have previously had eye problems, such as certain kinds of glaucoma (increased pressure in the eye).</p><p>Please note</p><p><strong>&nbsp;</strong></p><p>Some patients with manic-depressive illness may enter into a manic phase. This is characterised by unusual and rapidly changing ideas, inappropriate happiness and excessive physical activity. If you experience this, contact your doctor.</p><p>&nbsp;</p><p>Symptoms such as restlessness or difficulty to sit or stand still can also occur during the first weeks of the treatment. Tell your doctor immediately if you experience these symptoms.</p><p>&nbsp;</p><p>Thoughts of suicide and worsening of your depression or anxiety disorder</p><p><strong>&nbsp;</strong></p><p>If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have previously had thoughts about killing or harming yourself.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a <strong>young adult</strong>. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.</p><p>If you <u>have</u> thoughts of harming or killing yourself at any time, <strong>contact your doctor or go to a hospital straight away.</strong></p><p>&nbsp;</p><p><strong>You may find it helpful to tell a relative <u>or close friend</u> </strong>that you are depressed or <u>have</u> an anxiety disorder and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.</p><p>&nbsp;</p><p><u>Children and adolescents</u></p><p>Cipralex should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side effects such as suicide attempts, suicidal thoughts and hostility (predominately aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe Cipralex for patients under 18 because he/she decides that this is in their best interest. If your doctor has prescribed Cipralex for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any symptoms listed above develop or worsen when patients under 18 are taking Cipralex. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of Cipralex in this age group have not yet been demonstrated.</p><p>&nbsp;</p><p>Other medicines and Cipralex</p><p><strong>&nbsp;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Tell your doctor if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rdquo;Non-selective monoamine oxidase inhibitors (MAOIs)&rdquo;, containing phenelzine, iproniazid, isocarboxazid, nialamide, and tranylcypromine as active ingredients. If you have taken any of these medicines, you will need to wait 14 days before you start taking Cipralex. After stopping Cipralex you must allow 7 days before taking any of these medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ldquo;Reversible, selective MAO-A inhibitors&rdquo;, containing moclobemide (used to treat depression).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ldquo;Irreversible MAO-B inhibitors&rdquo;, containing selegiline (used to treat Parkinson&rsquo;s disease). These increase the risk of side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The antibiotic linezolid.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (used in the treatment of manic-depressive disorder) and tryptophan.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Imipramine and desipramine (both used to treat depression).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sumatriptan and similar medicines (used to treat migraine) and tramadol and similar medicines (used against severe pain). These increase the risk of side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cimetidine and omeprazole (used to treat stomach ulcers), fluvoxamine (antidepressant) and ticlopidine (used to reduce the risk of stroke). These may cause increased blood levels of Cipralex.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&#39;s Wort (hypericum perforatum) - a herbal remedy used for depression.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acetylsalicylic acid and non-steroidal anti-inflammatory drugs (medicines used for pain relief or to thin the blood, so called anti-coagulant).These may increase bleeding- tendency.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warfarin, dipyridamole, and phenprocoumon (medicines used to thin the blood, so called anti-coagulant). Your doctor will probably check the coagulation time of your blood when starting and discontinuing Cipralex in order to verify that your dose of anti- coagulant is still adequate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mefloquin (used to treat malaria), bupropion (used to treat depression) and tramadol (used to treat severe pain) due to a possible risk of a lowered threshold for seizures.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neuroleptics (medicines to treat schizophrenia, psychosis) due to a possible risk of a lowered threshold for seizures, and antidepressants.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flecainide, propafenone and metoprolol (used in cardiovascular diseases), clomipramine and nortriptyline (antidepressants) and risperidone, thioridazine and haloperidol (antipsychotics). The dosage of Cipralex may need to be adjusted.</p><p>Taking Cipralex with food, drink and alcohol</p><p>Cipralex can be taken with or without food (see section 3 &ldquo;How to take Cipralex&rdquo;).</p><p>As with many medicines, combining Cipralex with alcohol is not advisable, although Cipralex is not expected to interact with alcohol.</p><p>Pregnancy, breast-feeding and fertility</p><p>Inform your doctor if you are pregnant or planning to become pregnant. Do not take Cipralex if you are pregnant or breast-feeding, unless you and your doctor have discussed the risks and benefits involved.</p><p>&nbsp;</p><p>If you take Cipralex during the last 3 months of your pregnancy you should be aware that the following effects may be seen in your newborn baby: trouble with breathing, blueish skin, fits, body temperature changes, feeding difficulties, vomiting, low blood sugar, stiff or floppy muscles, vivid reflexes, tremor, jitteriness, irritability, lethargy, constant crying, sleepiness and sleeping difficulties. If your newborn baby has any of these symptoms, please contact your doctor immediately.</p><p>If used during pregnancy Cipralex should never be stopped abruptly.</p><p>&nbsp;</p><p>Make sure your midwife and/or doctor know you are on Cipralex. When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like Cipralex may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.</p><p>&nbsp;</p><p>If you take Cipralex near the end of your pregnancy there may be an increased risk of heavy vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife should be aware that you are taking Cipralex so they can advise you.</p><p>&nbsp;</p><p>If used during pregnancy Cipralex should never be stopped abruptly.</p><p>&nbsp;</p><p>It is expected that Cipralex will be excreted into breast milk.</p><p>&nbsp;</p><p>Citalopram, a medicine like escitalopram, has been shown to reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, bit impact on human fertility has not been observed as yet.</p><p>&nbsp;</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p>Driving and using machines</p><p><strong>&nbsp;</strong></p><p>You are advised not to drive a car or operate machinery until you know how Cipralex affects you.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong><u>Adults</u></strong></p><p><strong>&nbsp;</strong></p><p>Depression</p><p>The normally recommended dose of Cipralex is 10 mg taken as one daily dose. The dose may be increased by your doctor to a maximum of 20 mg per day.</p><p>Panic disorder</p><p>The starting dose of Cipralex is 5 mg as one daily dose for the first week before increasing the dose to 10 mg per day. The dose may be further increased by your doctor to a maximum of 20 mg per day.</p><p>Social anxiety disorder</p><p>The normally recommended dose of Cipralex is 10 mg taken as one daily dose. Your doctor can either decrease your dose to 5 mg per day or increase the dose to a maximum of 20 mg per day, depending on how you respond to the medicine.</p><p>&nbsp;</p><p>Generalised anxiety disorder</p><p>The normally recommended dose of Cipralex is 10 mg taken as one daily dose. The dose may be increased by your doctor to a maximum of 20 mg per day.</p><p>&nbsp;</p><p>Obsessive-compulsive disorder</p><p>The normally recommended dose of Cipralex is 10 mg taken as one daily dose. The dose may be increased by your doctor to a maximum of 20 mg per day.</p><p>&nbsp;</p><p>Elderly patients (above 65 years of age)</p><p>The normally recommended starting dose of Cipralex is 5 mg taken as one daily dose</p><p>&nbsp;</p><p><u>Use in children and adolescents</u></p><p>Cipralex should not normally be given to children and adolescents. For further information please see section 2 &ldquo;Before you take Cipralex&rdquo;</p><p>You can take Cipralex with or without food. Swallow the tablet with some water. Do not chew them, as the taste is bitter.</p><p>&nbsp;</p><p>If necessary, you can divide the tablets 10, 15 and 20mg by firstly placing the tablet on a flat surface with the score facing upwards. The tablets may then be broken by pressing down on each end of the tablet, using both forefingers as shown in the drawing.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="Image_x0020_3" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;margin-left:1in;margin-top:18pt;width:204pt;
  height:66pt;z-index:-15728640;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
   o:title=""/>
  <o:lock v:ext="edit" aspectratio="f"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="272" height="88" alt="" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>The tablets 10, 15 and 20 mg can be divided into equal doses.</p><p>&nbsp;</p><p>Duration of treatment</p><p><strong>&nbsp;</strong></p><p>It may take a couple of weeks before you start to feel better. Continue to take Cipralex even if it takes some time before you feel any improvement in your condition.</p><p>&nbsp;</p><p>Do not change the dose of your medicine without talking to your doctor first.</p><p>&nbsp;</p><p>Continue to take Cipralex for as long as your doctor recommends. If you stop your treatment too soon, your symptoms may return. It is recommended that treatment should be continued for at least 6 months after you feel well again.</p><p>&nbsp;</p><p>If you take more Cipralex than you should</p><p>If you take more than the prescribed dose of Cipralex, contact your doctor or nearest hospital emergency department immediately. Do this even if there are no signs of discomfort. Some of the signs of an overdose could be dizziness, tremor, agitation, convulsion, coma, nausea, vomiting, change in heart rhythm, decreased blood pressure and change in body fluid/salt balance. Take the Cipralex carton with you when you go to the doctor or hospital.</p><p>&nbsp;</p><p>If you forget to take Cipralex</p><p><strong>&nbsp;</strong></p><p>Do not take a double dose to make up for forgotten doses. If you do forget to take a dose, and you remember before you go to bed, take it straight away. Carry on as usual the next day. If you only remember during the night, or the next day, leave out the missed dose and carry on as usual.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>If you stop taking Cipralex</p><p>&nbsp;</p><p>Do not stop taking Cipralex until your doctor tells you to do so. When you have completed your course of treatment, it is generally advised that the dose of Cipralex is gradually reduced over a number of weeks.</p><p>&nbsp;</p><p>When you stop taking Cipralex, especially if it is abruptly, you may feel discontinuation symptoms. These are common when treatment with Cipralex is stopped. The risk is higher, when Cipralex has been used for a long time or in high doses or when the dose is reduced too quickly. Most people find that the symptoms are mild and go away on their own within two weeks.</p><p>However, in some patients they may be severe in intensity or they may be prolonged (2-3 months or more). If you get severe discontinuation symptoms when you stop taking Cipralex, please contact your doctor. He or she may ask you to start taking your tablets again and come off them more slowly.</p><p>&nbsp;</p><p>Discontinuation symptoms include: Feeling dizzy (unsteady or off-balance), feelings like pins and needles, burning sensations and (less commonly) electric shock sensations, including in the head, sleep disturbances (vivid dreams, nightmares, inability to sleep), feeling anxious, headaches, feeling sick (nausea), sweating (including night sweats), feeling restless or agitated, tremor (shakiness), feeling confused or disorientated, feeling emotional or irritable, diarrhoea (loose stools), visual disturbances, fluttering or pounding heartbeat (palpitations).</p><p>&nbsp;</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The side effects usually disappear after a few weeks of treatment. Please be aware that many of the effects may also be symptoms of your illness and therefore will improve when you start to get better.</p><p>See your doctor if you get any of the following side effects during treatment: Uncommon (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual bleeds, including gastrointestinal bleeds</p><p>&nbsp;</p><p>Rare (may affect up to 1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you experience swelling of skin, tongue, lips, or face, or have difficulties breathing or swallowing (allergic reaction), contact your doctor or go to a hospital straight away.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a high fever, agitation, confusion, trembling and abrupt contractions of muscles these may be signs of a rare condition called serotonin syndrome. If you feel like this contact your doctor.</p><p>If you experience the following side effects you should contact your doctor or go to the hospital straight away:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulties urinating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures (fits), see also section &rdquo;Warnings and precautions&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin and the white in the eyes are signs of liver function impairment/hepatitis.</p><p>In addition to above the following side effects have been reported: Very common (may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea).</p><p>Common (may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blocked or runny nose (sinusitis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased or increased appetite.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, restlessness, abnormal dreams, difficulties falling asleep, feeling sleepy, dizziness, yawning, tremors, prickling of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea, constipation, vomiting, dry mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased sweating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in muscle and joints (arthralgia and myalgia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual disturbances (delayed ejaculation, problems with erection, decreased sexual drive and women may experience difficulties achieving orgasm).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue, fever.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased weight.</p><p>Uncommon (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nettle rash (urticaria), rash, itching (pruritus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grinding one&rsquo;s teeth, agitation, nervousness, panic attack, confusion state.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbed sleep, taste disturbance, fainting (syncope).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlarged pupils (mydriasis), visual disturbance, ringing in the ears (tinnitus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of hair.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Excessive menstrual bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular menstrual period.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased weight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heart beat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the arms or legs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nosebleeds.</p><p>Rare (may affect up to 1 in 1,000 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aggression, depersonalisation, hallucination.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart beat.</p><p>Not known (frequency cannot be estimated from the available data):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thoughts of harming yourself or thoughts of killing yourself, see also section &ldquo;Warnings and precautions&rdquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased levels of sodium in the blood (the symptoms are feeling sick and unwell with weak muscles or confused).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness when you stand up due to low blood pressure (orthostatic hypotension).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function test (increased amounts of liver enzymes in the blood).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Movement disorders (involuntary movements of the muscles).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Painful erections (priapism).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding disorders including skin and mucous bleeding (ecchymosis) and low level of blood platelets (thrombocytopenia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heavy vaginal bleeding shortly after birth (postpartum haemorrhage), see &lsquo;Pregnancy, breast-feeding and fertility&rsquo; in section 2 for more information.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of skin or mucosa (angioedemas).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in the amount of urine excreted (inappropriate ADH secretion).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased blood levels of the prolactin hormone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flow of milk in men &amp; women that are not nursing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mania.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased risk of bone fractures has been observed in patients taking this type of medicines.</p><p>In addition, a number of side effects are known to occur with drugs that work in a similar way to escitalopram (the active ingredient of Cipralex). These are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Motor restlessness (akathisia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anorexia.</p><p>If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date, which is stated on the carton and blister foil after EXP. The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">&nbsp;</p><p>The active substance is escitalopram. Each Cipralex film-coated tablet contains 5 mg, 10 mg, 15 mg or 20 mg escitalopram as oxalate.</p><p>&nbsp;</p><p>&nbsp;</p><p>The other ingredients are:</p><p>&nbsp;</p><p>Core: microcrystalline cellulose silicified, talc, croscarmellose sodium and magnesium stearate. Coating: hypromellose, macrogol 400 and titanium dioxide (E-171).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Cipralex is presented as 5 mg, 10 mg, 15 mg and 20 mg film-coated tablets. The tablets are described below:

5 mg:	Round, white biconvex film-coated tablets marked with “EK” on one side.

10 mg: Oval, white film-coated tablets. The tablets are scored and marked with “E” and “L” on each side of the score on one side of the tablet.

15 mg: Oval, white film-coated tablets. The tablets are scored and marked with “E” and “M” on each side of the score on one side of the tablet.

20 mg: Oval, white film-coated tablets. The tablets are scored and marked with “E” and “N” on each side of the score on one side of the tablet.
Cipralex is available in the following pack sizes: Blisters in cardboard box
14, 28 and 98 tablets

Not all strengths or pack sizes may be marketed in your country.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><br />AJA Pharmaceutical indusrries Co,Ltd.<br />Hail, Saudi Arabia</p><p><strong>Manufacturer</strong><br />H. Lundbeck A/S<br />Ottiliavej 9<br />2500 Valby<br />Denmark</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in January 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ﺳﯿﺒﺮاﻟﻜﺲ ﯾﺤﺘﻮي ﻋﻠﻰ اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ اس ﺳﯿﺘﺎﻟﻮﺑﺮام. ﺳﯿﺒﺮاﻟﻜﺲ&nbsp;ﯾﻨﺘﻤﻰ ﻟﻤﺠﻤﻮﻋﺔ اﻷدوﯾﺔ اﻟﻤﻀﺎدة ﻟﻺﻛﺘﺌﺎب و اﻟﺘﻲ ﺗﺴﻤﻰ ﺑﻤﺜﺒﻄﺎت اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ ) اس اس آر آى ( . إن ﻋﺪم إﻧﺘﻈﺎم ﻣﺴﺘﻮى ﻣﺎدة اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ ﯾﻌﺘﺒﺮ ﻋﺎﻣﻞ ﻣﮭﻢ في ﺗﻄﻮر ﻣﺮض اﻹﻛﺘﺌﺎب واﻷﻣﺮاض ذات اﻟﺼﻠﺔ.</p><p>&nbsp;</p><p dir="RTL">ﯾﺤﺘﻮى ﺳﺒﺮاﻟﯿﻜﺲ ﻋﻠﻰ ﻣﺎدة اسﺳﯿﺘﺎﻟﻮﺑﺮام وﯾﺴﺘﺨﺪم ﻟﻌﻼج اﻹﻛﺘﺌﺎب ) ﺣﺎﻻت اﻹﻛﺘﺌﺎب اﻟﻌﺎﻣﺔ ( و إﺿﻄﺮاﺑﺎت اﻟﻘﻠﻖ )ﻣﺜﻞ إﺿﻄﺮاب اﻟﮭﻠﻊ ﻣﻊ او ﺑﺪون رھﺎب اﻟﻤﯿﺎدﯾﻦ ، إﺿﻄﺮاب اﻟﻘﻠﻖ اﻹﺟﺘﻤﺎﻋﻲ، إﺿﻄﺮاب اﻟﻘﻠﻖ اﻟﺸﻤﻮﻟﻲ</p><p dir="RTL">و إﺿﻄﺮاب اﻟﻮﺳﻮاس اﻟﻘﮭﺮي.(</p><p>&nbsp;</p><p dir="RTL">ﻗﺪ ﯾﺴﺘﻐﺮق اﻷﻣﺮ أﺳﺒﻮﻋﯿﻦ ﻗﺒﻞ أن ﺗﺒﺪأ ﻓﻲ اﻟﺸﻌﻮر ﺑﺎﻟﺘﺤﺴﻦ. اﺳﺘﻤﺮ ﻓﻲ ﺗﻨﺎول ﺳﺒﺮاﻟﯿﻜﺲ ﺣﺘﻰ ﻟﻮ</p><p dir="RTL">ﯾﺴﺘﻐﺮق اﻷﻣﺮ ﺑﻌﺾ اﻟﻮﻗﺖ ﻗﺒﻞ أن ﺗﺸﻌﺮ ﺑﺄي ﺗﺤﺴﻦ ﻓﻲ ﺣﺎﻟﺘﻚ. ﯾﺠﺐ ﻋﻠﯿﻚ اﻟﺘﺤﺪث إﻟﻰ اﻟﻄﺒﯿﺐ إذا ﻛﻨﺖ ﻻ ﺗﺸﻌﺮ ﺑﺘﺤﺴﻦ أو إذا ﻛﻨﺖ ﺗﺸﻌﺮ ﺑﺴﻮء</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ﻻ ﺗﺘﻨﺎول ﺳﯿﺒﺮاﻟﻜﺲ</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL">) راﺟﻊ اﻟﺠﺰء رﻗﻢ 6 (</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; اذا ﻛﺎﻧﺖ ﻟﺪﯾﻚ ﺣﺴﺎﺳﯿﺔ ﻣﻦ ﻣﺎدة اس ﺳﯿﺘﺎﻟﻮﺑﺮام او اى ﻣﻦ اﻟﻤﻜﻮﻧﺎت اﻻﺧﺮى ل ﺳﯿﺒﺮاﻟﻜﺲ</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; اذا اﺧﺬت أي أدوﯾﺔ اﺧﺮى ﺗﻨﺘﻤﻰ ﻟﻤﺠﻤﻮﻋﺔ اﻷدوﯾﺔ اﻟﺘﻰ ﺗﺴﻤﻰ ﺑﻤﺜﺒﻄﺎت أم اﯾﮫ ﺑﺎﻻﺿﺎﻓﺔ اﻟﻰ ﻣﺴﺘﺤﻀﺮ ﺳﯿﻠﯿﺠﯿﻨﯿﻦ ) ﯾﺴﺘﺨﺪم ﻟﻌﻼج ﻣﺮض اﻟﺒﺎرﻛﻨﺴﻮن ( و ﻣﻮﻛﻠﻮﺑﯿﻤﺎﯾﺪ ) ﯾﺴﺘﺨﺪم ﻟﻌﻼج اﻹﻛﺘﺌﺎب( و ﻟﯿﻨﺰوﻟﯿﺪ ) ﻣﻀﺎد</p><p dir="RTL">ﺣﯿﻮي( ﻓﻲ ﻧﻔﺲ اﻟﻮﻗﺖ ﻣﻊ ﻣﺴﺘﺤﻀﺮ ﺑﯿﻤﻮزاﯾﺪ.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_4" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;margin-left:41.1pt;margin-top:17.1pt;width:762.6pt;
  height:12.7pt;z-index:-15728640;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal dir=RTL style='margin-right:4.15pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><b><span lang=AR-SA style='color:black;
     letter-spacing:-.1pt'>اﻟﺘﺤﺬﯾﺮات</span><span lang=AR-SA style='color:black;
     letter-spacing:-.45pt'> </span><span lang=AR-SA style='color:black'>واﻻﺣﺘﯿﺎطﺎت</span></b><b><span
     dir=LTR style='color:black'><o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="19" alt="Text Box: اﻟﺘﺤﺬﯾﺮات واﻻﺣﺘﯿﺎطﺎت" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p dir="RTL">اﻟﺮﺟﺎء إﺧﻄﺎر اﻟﻄﺒﯿﺐ إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ أي ﻣﺸﺎﻛﻞ طﺒﯿﺔ أﺧﺮى، ﺣﯿﺚ ﯾﺠﺐ أن ﯾﺄﺧﺬ اﻟﻄﺒﯿﺐ ذﻟﻚ ﻓﻲ ﻋﯿﻦ اﻹﻋﺘﺒﺎر ﺧﺼﻮﺻﺎً:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; اذا ﻛﺎن ﻟﺪﯾﻚ ﺻﺮع. ﯾﺠﺐ إﯾﻘﺎف اﻟﻌﻼج ﺑﻮاﺳﻄﺔ ﺳﺒﺮاﻟﻜﺲ اذا ﺣﺪﺛﺖ ﻧﻮﺑﺎت اﻟﺼﺮع ﻷول ﻣﺮة، او اذا ﻛﺎن ھﻨﺎﻟﻚ زﯾﺎدة ﻓﻰ ﺗﻜﺮار اﻟﻨﻮﺑﺎت ) راﺟﻊ اﻟﺠﺰء رﻗﻢ 4 &quot; اﻻﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺤﺘﻤﻠﺔ(&quot;</p><p dir="RTL">&middot;&nbsp; اذا ﻛﻨﺖ ﺗﻌﺎﻧﻰ ﻣﻦ ﺧﻠﻞ ﻓﻲ وظﺎﺋﻒ اﻟﻜﺒﺪ او اﻟﻜﻠﻰ. ﻗﺪ ﯾﺤﺘﺎج طﺒﯿﺒﻚ ﻟﺘﻌﺪﯾﻞ اﻟﺠﺮﻋﺔ ﻟﻚ.</p><p dir="RTL">&middot;&nbsp; اذا ﻛﺎن ﻟﺪﯾﻚ ﻣﺮض اﻟﺴﻜﺮي. اﻟﻌﻼج ﺑﺴﺒﺮاﻟﯿﻜﺲ ﻗﺪ ﯾﻐﯿﺮ ﻣﻦ اﻟﺴﯿﻄﺮة ﻋﻠﻰ ﺳﻜﺮ اﻟﺪم. ﻗﺪ ﺗﺤﺘﺎج إﻟﻰ ﺗﻌﺪﯾﻞ ﺟﺮﻋﺎت اﻻﻧﺴﻮﻟﯿﻦ و/أو ﺟﺮﻋﺔ اﻷدوﯾﺔ اﻟﻤﺨﻔﻀﺔ ﻟﺴﻜﺮ اﻟﺪم.</p><p dir="RTL">&middot;&nbsp; اذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ اﻧﺨﻔﺎض ﻓﻲ ﻣﺴﺘﻮى اﻟﺼﻮدﯾﻮم ﻓﻰ اﻟﺪم .</p><p dir="RTL">&middot;&nbsp; إذا ﻛﺎن ﻟﺪﯾﻚ اﺣﺘﻤﺎﻟﯿﺔ ﻟﻺﺻﺎﺑﺔ ﺑﻨﺰﯾﻒ أو ﻛﺪﻣﺎت ﺑﺴﮭﻮﻟﺔ ، أو إذا ﻛﻨﺘﻲ ﺣﺎﻣﻼً&nbsp;)أﻧﻈﺮ &ldquo;اﻟﺤﻤﻞ واﻟﺮﺿﺎﻋﺔ واﻟﺨﺼﻮﺑﺔ.(&quot;</p><p dir="RTL">&middot;&nbsp; اذا ﻛﻨﺖ ﺗﺘﻠﻘﻰ اﻟﻌﻼج ﺑﺎﻟﺼﺪﻣﺎت اﻟﻜﮭﺮﺑﺎﺋﯿﺔ.</p><p dir="RTL">&middot;&nbsp; إذا ﻛﺎﻧﺖ ﺗﻌﺎﻧﻲ ﻣﻦ ﻣﺮض اﻟﻘﻠﺐ اﻟﺘﺎﺟﻲ<strong>.</strong></p><p dir="RTL">&bull;إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ أو ﻋﺎﻧﯿﺖ ﻣﻦ ﻗﺒﻞ ﻣﻦ ﻣﺸﺎﻛﻞ ﻓﻲ اﻟﻌﯿﻦ ، ﻣﺜﻞ أﻧﻮاع ﻣﻌﯿﻨﺔ ﻣﻦ اﻟﺠﻠﻮﻛﻮﻣﺎ )زﯾﺎدة اﻟﻀﻐﻂ ﻓﻲ اﻟﻌﯿﻦ(</p><p>&nbsp;</p><p>&nbsp;</p><p>ﻧﺄﻣﻞ ﻣﻼﺣﻈﺔ:</p><p dir="RTL">إن ﺑﻌﺾ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن ﻣﻦ اﻟﻤﺮض اﻟﮭﻮس اﻻﻛﺘﺌﺎب ﻗﺪ ﯾﺪﺧﻠﻮن ﻓﻲ ﻣﺮﺣﻠﺔ اﻟﮭﻮس. و ذﻟﻚ ﯾﺘﺼﻒ ﺑﺴﺮﻋﺔ و ﺗﻜﺮار ﺗﻐﯿﺮ اﻷﻓﻜﺎر, اﻟﻔﺮح اﻟﻐﯿﺮ ﻣﻼﺋﻢ و ﻓﺮط اﻟﻨﺸﺎط اﻟﺠﺴﺪي. أﺧﺒﺮ طﺒﯿﺒﻚ ﻓﻮراً&nbsp;اذا ﺗﻌﺮﺿﺖ ﻟﻤﺜﻞ ھﺬه</p><p dir="RTL">اﻷﻋﺮاض.</p><p>&nbsp;</p><p dir="RTL">إن اﻷﻋﺮاض ﻣﺜﻞ اﻟﻘﻠﻖ أو ﺻﻌﻮﺑﺔ اﻟﺠﻠﻮس او اﻟﻮﻗﻮف ﻗﺪ ﺗﺤﺪث ﺧﻼل اﻻﺳﺒﻮع اﻻول ﻣﻦ اﻟﻌﻼج. أﺧﺒﺮ طﺒﯿﺒﻚ ﻓﻮراً&nbsp;اذا ﺗﻌﺮﺿﺖ ﻟﻤﺜﻞ ھﺬه اﻷﻋﺮاض.</p><p>&nbsp;</p><p>اﻷﻓﻜﺎر اﻹﻧﺘﺤﺎرﯾﺔ و ﺳﻮء ﺣﺎﻟﻚ ﻣﻊ اﻹﻛﺘﺌﺎب أو إﺿﻄﺮاب اﻟﻘﻠﻖ</p><p>&nbsp;</p><p dir="RTL">ُﻣﻜﺘﺌﺐ و/أو ﻟﺪﯾﻚ اﺿﻄﺮاب اﻟﻘﻠﻖ ﻓﻘﺪ ﺗﺮد ﻟﺪﯾﻚ أﺣﯿﺎﻧﺎً&nbsp;ﻓﻜﺮة إذاء ﻧﻔﺴﻚ أو اﻹﻧﺘﺤﺎر. و ﻗﺪ ﯾﺰﯾﺪ ذﻟﻚ ﻋﻨﺪ إﺳﺘﺨﺪاﻣﻚ ﻟﻤﻀﺎدة اﻹﻛﺘﺌﺎب ﻷول ﻣﺮة ، ﺣﯿﺚ أن ھﺬا اﻟﻨﻮع ﻣﻦ اﻷدوﯾﺔ ﻗﺪ ﯾﺴﺘﻐﺮق وﻗﺖ ﺣﺘﻰ ﯾﺒﺪأ اﻟﻌﻤﻞ و ﻗﺪ ﯾﺼﻞ</p><p>&nbsp;</p><p dir="RTL">اذا ﻛﻨﺖ</p><p>&nbsp;</p><p dir="RTL">ذﻟﻚ إﻟﻰ أﺳﺒﻮﻋﯿﻦ أو أﻛﺜﺮ ﺑﻘﻠﯿﻞ.</p><p dir="RTL"><strong>رﺑﻤﺎ</strong> ﺗﻜﻮن ﻋﺮﺿﺔ أﻛﺜﺮ ﻟﻠﺘﻔﻜﯿﺮ ﺑﺬﻟﻚ إذا :</p><p dir="RTL">&middot;&nbsp; اذا ﻛﺎﻧﺖ ﻟﺪﯾﻚ أﻓﻜﺎر ﻣﺴﺒﻘﺔ ﻹذاء ﻧﻔﺴﻚ أو اﻹﻧﺘﺤﺎر.</p><p dir="RTL">&middot;&nbsp; اذا ﻛﻨﺖ<strong> ﺷﺎﺑﺎ</strong><strong>ً&nbsp;ﺑﺎﻟﻐﺎً</strong><strong>.</strong>&nbsp;إن اﻟﻤﻌﻠﻮﻣﺎت اﻟﻨﺎﺗﺠﺔ ﻋﻦ اﻟﺪراﺳﺎت اﻟﺴﺮﯾﺮﯾﺔ ﺗﺸﯿﺮ إﻟﻰ إزدﯾﺎد ﻣﺨﺎطﺮ اﻟﺴﻠﻮك اﻹﻧﺘﺤﺎري ﻟﺪى اﻟﺒﺎﻟﻐﯿﻦ ﻣﻦ ﻋﻤﺮ 25&nbsp;ﺳﻨﺔ ﻓﺄﻗﻞ و اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن ﻣﻦ أﻣﺮاض ﻧﻔﺴﯿﺔ و ﯾُﻌﺎﻟﺠﻮن ﺑﻤﻀﺎدات اﻹﻛﺘﺌﺎب.</p><p dir="RTL">اذا ﻛﺎﻧﺖ ﻟﺪﯾﻚ أﻓﻜﺎر ﻹذاء ﻧﻔﺴﻚ أو اﻹﻧﺘﺤﺎر<strong>, ﻓﺄﺗﺼﻞ ﺑﻄﺒﯿﺒﻚ أو إذھﺐ إﻟﻰ اﻟﻤﺴﺘﺸﻔﻰ ﻣﺒﺎﺷﺮةً</strong>. <strong>ﻗﺪ ﺗﺠﺪ أﻧﮫ ﻣﻦ اﻟﻤﻔﯿﺪ ﻟﻚ أن ﺗﺨﺒﺮ ﻗﺮﯾﺒﻚ أو ﺻﺪﯾﻘﻚ اﻟﻤﻘﺮب</strong> ﺑﺄﻧﻚ ﺗﻌﺎﻧﻲ ﻣﻦ اﻹﻛﺘﺌﺎب أو إﺿﻄﺮاب اﻟﻘﻠﻖ، ﻋﻨﺪﺋ ٍﺬ اطﻠﺐ ﻣﻨﮭﻢ ﻗﺮاءة ھﺬه اﻟﻨﺸﺮة. و ﻛﺬﻟﻚ أطﻠﺐ ﻣﻨﮭﻢ إﺧﺒﺎرك ﻓﻲ ﺣﺎﻟﺔ ﻣﻼﺣﻈﺘﮭﻢ ﺑﺄن ﻣﺮﺿﻚ ﻗﺪ إزداد ﺳﻮ ًء ، أو ﻓﻲ</p><p dir="RTL">ﺣﺎﻟﺔ ﻗﻠﻘﮭﻢ ﻣﻦ اﻟﺘﻐﯿﺮات ﻓﻲ ﺳﻠﻮﻛﻚ.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><u>اﻷطﻔﺎل واﻟﻤﺮاھﻘﯿﻦ</u></p><p dir="RTL">ﻏﺎﻟﺒﺎً&nbsp;ﻻ ﯾﻮﺻﻒ ﺳﺒﺮاﻟﯿﻜﺲ ﻟﻸطﻔﺎل واﻟﻤﺮاھﻘﯿﻦ ﺗﺤﺖ ﺳﻦ 18&nbsp;ﺳﻨﺔ .&nbsp;أﯾﻀﺎً&nbsp;ﯾﺠﺐ أن ﺗﻌﻠﻢ ﺑﺄن اﻟﻤﺮﺿﻰ ﺗﺤﺖ ﺳﻦ 18&nbsp;ﺳﻨﺔ ﺗﺰداد ﻟﺪﯾﮭﻢ ﻣﺨﺎطﺮ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ ﻣﺜﻞ ﻣﺤﺎوﻟﺔ اﻹﻧﺘﺤﺎر أو اﻷﻓﻜﺎر اﻹﻧﺘﺤﺎرﯾﺔ واﻟ&nbsp;ِﻌﺪاﺋﯿﺔ )&nbsp;اﻟﺴﻠﻮك اﻟﻌﺪاﺋﻰ ، ﺳﻠﻮك اﻟﻤﻌﺎرﺿﺔ واﻟﻐﻀﺐ ( ﻋﻨﺪ اﺳﺘﺨﺪاﻣﮭﻢ ﻟﮭﺬا اﻟﻨﻮع ﻣﻦ اﻷدوﯾﺔ. و ﺑﺎﻟﺮﻏﻢ ﻣﻦ ذﻟﻚ ﻓﻘﺪ ﯾﺼﻒ طﺒﯿﺒﻚ ﺳﺒﺮاﻟﯿﻜﺲ ﻟﻠﻤﺮﺿﻰ ﺗﺤﺖ ﺳﻦ 18 ﺳﻨﺔ ﻷﻧﮫ ﻗﺮر ﺑﺄن ذﻟﻚ أﻓﻀﻞ ﻟﮭﻢ. اذا وﺻﻒ طﺒﯿﺒﻚ ﺳﺒﺮاﻟﯿﻜﺲ ﻟﻠﻤﺮﯾﺾ ﺗﺤﺖ ﺳﻦ 18 ﺳﻨﺔ وﺗﻮد ﻣﻨﺎﻗﺸﺔ ذﻟﻚ ، ﻧﺄﻣﻞ ﻣﻨﻚ ﻣﺮاﺟﻌﺔ طﺒﯿﺒﻚ. ﯾﺠﺐ ان ﺗﺨﺒﺮ طﺒﯿﺒﻚ ﺑﺄى ﺗﻄﻮر ﻟﻸﻋﺮاض اﻟﻤﺬﻛﻮرة أو ﺗﺪھﻮر اﻟﺤﺎﻟﺔ ﻋﻨﺪ ﺗﻨﺎول اﻟﻤﺮﯾﺾ ﺗﺤﺖ ﺳﻦ 18 ﺳﻨﺔ ﺳﺒﺮاﻟﯿﻜﺲ ، اﯾﻀﺎ اﻵﺛﺎر اﻷﻣﻨﺔ اﻟﻄﻮﯾﻠﺔ اﻟﻤﺪى</p><p dir="RTL">اﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻟﻨﻤﻮ ،اﻟﻨﻀﺞ ، اﻟﻤﻌﺮﻓﺔ واﻟﺘﻄﻮر اﻟﺴﻠﻮﻛﻲ ﺳﺒﺮاﻟﯿﻜﺲ ﻓﻰ ھﺬه اﻟﻔﺌﺔ ﻣﻦ اﻟﻌﻤﺮ ﻟﻢ ﯾﺘﻢ إﺛﺒﺎﺗﮭﺎ ﺑﻌﺪ.</p><p>&nbsp;</p><p>اﻻدوﯾﺔ اﻻﺧﺮى و ﺳﯿﺒﺮاﻟﻜﺲ</p><p dir="RTL">اﺧﺒﺮ طﺒﯿﺒﻚ او اﻟﺼﯿﺪﻟﻲ إذا ﻛﻨﺖ ﺗﺴﺘﺨﺪم او اﺳﺘﺨﺪﻣﺖ ﺣﺪﯾﺜﺎً&nbsp;أي أدوﯾﺔ أﺧﺮى.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ٌي ﻣﻦ اﻷدوﯾﺔ اﻟﺘﺎﻟﯿﺔ :</p><p>&nbsp;</p><p dir="RTL">أﺧﺒﺮ طﺒﯿﺒﻚ اذا ﻛﻨﺖ ﺗﺴﺘﺨﺪم أ</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ٌي ﻣﻦ ھﺬه اﻷدوﯾﺔ ﻓﺈﻧﻚ ﺗﺤﺘﺎج أن ﺗﻨﺘﻈﺮ ﻟﻤﺪة 14ﯾﻮﻣﺎً</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; ﻣﺜﺒﻄﺎت اﻟﻤﻮﻧﻮأﻣﯿﻨﻮأوﻛﺴﯿﺪﯾﺰ(MAOIs) ، اﻟﺘﻲ ﺗﺤﺘﻮى ﻋﻠﻰ ﻓﻨﻠﺰﯾﻦ ، أﺑﺮوﻧﺎﯾﺰﯾﺪ، اﯾﺰوﻛﺎرﺑﻮﻛﺴﺎزاﯾﺪ، ﻧﯿﺎﻻﻣﺎﯾﺪ، وﺗﺮاﻧﯿﻠﺴﺒﺮوﻣﺎﯾﻦ ﻛﻤﻜﻮﻧﺎت ﻓﻌﺎﻟﺔ. إذا اﺳﺘﺨﺪﻣﺖ أ</p><p>&nbsp;</p><p dir="RTL">ﻗﺒﻞ ان ﺗﺒﺪء ﻓﻲ إﺳﺘﺨﺪام ﺳﺒﺮاﻟﯿﻜﺲ. وﺑﻌﺪ اﻟﺘﻮﻗﻒ ﻋﻦ إﺳﺘﺨﺪام ﺳﺒﺮاﻟﯿﻜﺲ ﯾﺠﺐ أن ﺗﻨﺘﻈﺮ ﻟﻤﺪة 7 أﯾﺎم ﻗﺒﻞ أن ﺗﺄﺧﺬ ھﺬه اﻷدوﯾﺔ .</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; &quot;اﻟﻤﺜﺒﻄﺎت اﻟﻌﻜﺴﯿﺔ ﻟﻤﺎدة ام اﯾﮫ او- اﯾﮫ,&quot; و اﻟﺘﻲ ﺗﺤﺘﻮى ﻋﻠﻰ ﻣﺎدة ﻣﻮﻛﻠﻮﺑﻤﺎﯾﺪ ) ﯾﺴﺘﺨﺪم ﻟﻌﻼج اﻹﻛﺘﺌﺎب(</p><p dir="RTL">&middot;&nbsp; &quot;اﻟﻤﺜﺒﻄﺎت اﻻﻋﻜﺴﯿﺔ ﻟﻤﺎدة ام اﯾﮫ او- ﺑﻲ,&quot; و اﻟﺘﻲ ﺗﺤﺘﻮى ﻋﻠﻰ ﻣﺎدة ﺳﯿﻠﯿﻘﯿﻠﯿﻦ )اﻟﻤﺴﺘﺨﺪم ﻟﻌﻼج ﻣﺮض اﻟﺒﺎرﻛﻨﺴﻮن( .ھﺬه ﺗﺰﯾﺪ ﻣﻦ ﻣﺨﺎطﺮ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ.</p><p dir="RTL">&middot;&nbsp; اﻟﻤﻀﺎد اﻟﺤﯿﻮى ﻻﯾﻨﺰوﻟﯿﺪ.</p><p dir="RTL">&middot;&nbsp; ﻟﯿﺜﯿﻮم ) اﻟﻤﺴﺘﺨﺪم ﻟﻌﻼج إﺿﻄﺮاب اﻹﻛﺘﺌﺎب اﻟﮭﻮﺳﻲ ( و ﺗﺮﯾﺒﺘﻮﻓﺎن.</p><p dir="RTL">&middot;&nbsp; إﻣﯿﺒﺮاﻣﺎﯾﻦ ودﯾﺴﺈﺑﺮاﻣﺎﯾﻦ) ﻛﻼھﻤﺎ ﯾﺴﺘﺨﺪم ﻟﻌﻼج اﻹﻛﺘﺌﺎب(</p><p dir="RTL">&middot;&nbsp; ﺳﻮﻣﺎﺗﺮﺑﺎﺗﺎن واﻷدوﯾﺔ اﻟﻤﻤﺎﺛﻠﺔ ) اﻟﻤﺴﺘﺨﺪﻣﺔ ﻟﻌﻼج اﻟﺼﺪاع اﻟﻨﺼﻔﻲ( واﻟﺘﺮاﻣﺎدول واﻷدوﯾﺔ اﻟﻤﻤﺎﺛﻠﺔ )اﻟﻤﺴﺘﺨﺪم ﺿﺪ اﻷﻟﻢ اﻟﺸﺪﯾﺪ.( ھﺬه اﻷدوﯾﺔ ﺗﺰﯾﺪ ﻣﻦ ﻣﺨﺎطﺮ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ.</p><p dir="RTL">&middot;&nbsp; ﺳﯿﻤﯿﺘﺪﯾﻦ وأوﻣﯿﺒﺮازول ) اﻟﻤﺴﺘﺨﺪم ﻟﻌﻼج ﻗﺮﺣﺔ اﻟﻤﻌﺪة( ، ﻓﻠﻮﻓﻮﻛﺴﺎﻣﯿﻦ )ﻣﻀﺎد ﻟﻺﻛﺘﺌﺎب( وﺗﻜﻠﻮﺑﺪﯾﻦ ) اﻟﻤﺴﺘﺨﺪم ﻟﺘﻘﻠﯿﻞ ﻣﺨﺎطﺮ اﻹﺻﺎﺑﺔ ﺑﺎﻟﺴﻜﺘﺔ .( ھﺬه اﻷدوﯾﺔ ﻗﺪ ﺗﺰﯾﺪ ﻣﻦ ﺗﺮﻛﯿﺰ ﺳﺒﺮاﻟﯿﻜﺲ ﻓﻲ اﻟﺪم.</p><p dir="RTL">&middot;&nbsp; اس ﺗﻰ ﺟﻮن ورت) ھﺎﯾﺒﺮﻛﯿﻢ ﺑﯿﺮﻓﻮراﺗﯿﻢ ( دواء ﻋﺸﺒﻰ ﯾﺴﺘﺨﺪم ﻟﻺﻛﺘﺌﺎب.</p><p>&nbsp;</p><p dir="RTL">ھﺬا ﻗﺪ ﯾﺰﯾﺪ ﻣﻦ اﺣﺘﻤﺎﻻت اﻟﻨﺰف.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; ﺣﺎﻣﺾ اﻻﺳﺘﯿﻞ ﺳﺎﻟﯿﺴﯿﻠﻚ و ﻣﻀﺎدات اﻹﻟﺘﮭﺎب اﻻ إﺳﺘﺮوﯾﺪﯾﺔ ) ادوﯾﺔ ﻣﺴﺘﺨﺪﻣﺔ ﻟﺘﺨﻔﯿﻒ اﻷﻟﻢ أو زﯾﺎدة ﺳﯿﻮﻟﺔ اﻟﺪم ، ﻟﺬﻟﻚ ﺗﺴﻤﻰ ﻣﻀﺎدات اﻟﺘﺨﺜﺮ .(</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; وورﻓﺎرﯾﻦ، دﯾﺒﯿﺮﯾﺪاﻣﻮل ، و ﻓﯿﻨﺒﺮوﻛﻮﻣﻮن ) اﻷدوﯾﺔ اﻟﺘﻲ ﺗﺴﺘﺨﺪم ﻟﺰﯾﺎدة ﺳﯿﻮﻟﺔ اﻟﺪم ، ﻟﺬا ﺗﺴﻤﻰ ﻣﻀﺎدات اﻟﺘﺨﺜﺮ( ﺳﯿﻘﻮم طﺒﯿﺒﻚ ﺑﻔﺤﺺ ﻣﺪة ﺗﺨﺜﺮ اﻟﺪم ﻋﻨﺪ ﺑﺪاﯾﺔ اﻟﺘﺪاوي ﺑﺴﺒﺮاﻟﯿﻜﺲ و ﻋﻨﺪ اﻟﺘﻮﻗﻒ ﻣﻦ اﺟﻞ اﻟﺘﺤﻘﻖ ﻣﻦ أن</p><p dir="RTL">ﺟﺮﻋﺘﻚ ﻣﻦ ﻣﻀﺎد اﻟﺘﺨﺜﺮ ﻣﺎزاﻟﺖ ﻣﻨﺎﺳﺒﺔ.</p><p dir="RTL">&middot;&nbsp; ﻣﯿﻔﻠﻮﻛﻮﯾﻦ ) اﻟﻤﺴﺘﺨﺪم ﻟﻌﻼج اﻟﻤﻼرﯾﺎ( ﺑﻮﺑﺮوﺑﯿﻮن ) اﻟﻤﺴﺘﺨﺪم ﻟﻌﻼج اﻹﻛﺘﺌﺎب ( و ﺗﺮاﻣﺎدول ) اﻟﻤﺴﺘﺨﺪم ﻟﻌﻼج اﻷﻟﻢ اﻟﺸﺪﯾﺪ( و ذﻟﻚ ﻹﺣﺘﻤﺎﻟﯿﺔ ﻣﺨﺎطﺮ اﻟﻨﻮﺑﺎت اﻟﺼﺮﻋﯿﺔ .</p><p dir="RTL">&middot;&nbsp; ﻧﯿﺮوﻟﺒﻜﺘﺲ ) أدوﯾﺔ ﺗﺴﺘﺨﺪم ﻟﻌﻼج ﻣﺮض اﻟﻔُﺼﺎم و اﻟﺬُھﺎن( و ذﻟﻚ ﻹﺣﺘﻤﺎﻟﯿﺔ زﯾﺎدة اﻟﻨﻮﺑﺎت اﻟﺼﺮﻋﯿﺔ وﻣﻀﺎدات ﻟﻺﻛﺘﺌﺎب.</p><p dir="RTL">&middot;&nbsp; ﻓﻠﯿﻜﺎﯾﻨﯿﺪ، ﺑﺮوﺑﺎﻓﯿﻨﻮن وﻣﯿﺘﻮﺑﺮوﻟﻮل ) اﻟﻤﺴﺘﺨﺪم ﻓﻰ اﻣﺮاض اﻷوﻋﯿﺔ اﻟﺪﻣﻮﯾﺔ( , ﻛﻠﻮﻣﯿﺒﺮاﻣﯿﻦ، وﻧﻮرﺗﺮﯾﺒﺘﺎﻟﯿﻦ)ﻣﻀﺎد ﻟﻺﻛﺘﺌﺎب( و رﯾﺴﺒﯿﺮﯾﺪون، ﺛﯿﻮرﯾﺪازﯾﻦ و ھﺎﻟﻮﺑﯿﺮﯾﺪول ) ﻣﻀﺎدات اﻟﺬھﺎن( . ﻗﺪ ﺗﺤﺘﺎج ﺟﺮﻋﺔ ﺳﺒﺮاﻟﯿﻜﺲ</p><p dir="RTL">ﻟﻠﺘﻌﺪﯾﻞ.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_5" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:41.1pt;margin-top:11.4pt;width:762.6pt;height:108.7pt;z-index:-15728128;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText dir=RTL style='margin-top:0in;margin-right:1.4pt;
     margin-bottom:0in;margin-left:50.5pt;margin-bottom:.0001pt;text-align:
     right;text-indent:432.9pt;line-height:190%;direction:rtl;unicode-bidi:
     embed'><span lang=AR-SA style='color:black'>ﻻ<span style='letter-spacing:
     -.15pt'> </span>ﺗﺘﻨﺎول<span style='letter-spacing:-.2pt'> </span>ﺳﺒﺮاﻟﯿﻜﺲ<span
     style='letter-spacing:-.15pt'> </span>إذا<span style='letter-spacing:-.15pt'>
     </span>ﻛﻨﺖ<span style='letter-spacing:-.15pt'> </span>ﺗﺘﻨﺎول<span
     style='letter-spacing:-.15pt'> </span>أدوﯾﺔ<span style='letter-spacing:
     -.15pt'> </span>ﻟﻤﺸﺎﻛﻞ<span style='letter-spacing:-.15pt'> </span>ﺿﺮﺑﺎت<span
     style='letter-spacing:-.15pt'> </span>اﻟﻘﻠﺐ<span style='letter-spacing:
     -.15pt'> </span>أو<span style='letter-spacing:-.15pt'> </span>أدوﯾﺔ<span
     style='letter-spacing:-.15pt'> </span>ﻗﺪ<span style='letter-spacing:-.15pt'>
     </span>ﺗﻜﻮن <span style='letter-spacing:-.2pt'>ﺗﺆﺛﺮ </span>ﻋﻠﻰ<span
     style='letter-spacing:-.2pt'> </span>إﯾﻘﺎع<span style='letter-spacing:
     -.25pt'> </span>اﻟﻘﻠﺐ<span style='letter-spacing:-.2pt'> </span>،<span
     style='letter-spacing:-.2pt'> </span>ﻣﺜﻞ<span style='letter-spacing:-.25pt'>
     </span>ﻣﻀﺎدات<span style='letter-spacing:-.2pt'> </span>اﺿﻄﺮاب<span
     style='letter-spacing:-.2pt'> </span>اﻟﻨﻈﻢ<span style='letter-spacing:
     -.25pt'> </span>ﻣﻦ<span style='letter-spacing:-.2pt'> </span>اﻟﺼﻨﻒ<span
     style='letter-spacing:-.25pt'> </span>اﻷول<span style='letter-spacing:
     -.2pt'> </span>أ<span style='letter-spacing:-.2pt'> </span>واﻟﺜﺎﻟﺚ<span
     style='letter-spacing:-.25pt'> </span>وﻣﻀﺎدات<span style='letter-spacing:
     -.2pt'> </span>اﻟﺬھﺎن<span style='letter-spacing:-.2pt'> </span></span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>)</span><span
     lang=AR-SA style='color:black'>ﻋﻠﻰ<span style='letter-spacing:-.25pt'> </span>ﺳﺒﯿﻞ<span
     style='letter-spacing:-.2pt'> </span>اﻟﻤﺜﺎل<span style='letter-spacing:
     -.2pt'> </span>ﻣﺸﺘﻘﺎت<span style='letter-spacing:-.25pt'> </span>اﻟﻔﯿﻨﻮﺛﯿﺎزﯾﻦ<span
     style='letter-spacing:-.25pt'> </span>،<span style='letter-spacing:-.25pt'>
     </span>ﺑﯿﻤﻮزﯾﺪ<span style='letter-spacing:-.3pt'> </span>،<span
     style='letter-spacing:-.25pt'> </span>ھﺎﻟﻮﺑﯿﺮﯾﺪول</span><span dir=LTR></span><span
     dir=LTR style='color:black'><span dir=LTR></span>(</span><span dir=RTL></span><span
     style='color:black;letter-spacing:-.2pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>،<span style='letter-spacing:-.25pt'> </span>ﻣﻀﺎدات<span
     style='letter-spacing:-.2pt'> </span>اﻻﻛﺘﺌﺎب<span style='letter-spacing:
     -.2pt'> </span>ﺛﻼﺛﯿﺔ<span style='letter-spacing:-.25pt'> </span>اﻟﺤﻠﻘﺎت<span
     style='letter-spacing:-.2pt'> </span>،<span style='letter-spacing:-.25pt'>
     </span>ﻣﻌﯿﻨﺔ</span><span dir=LTR style='color:black'><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-right:1.4pt;text-align:right;
     line-height:12.6pt;mso-line-height-rule:exactly;direction:rtl;unicode-bidi:
     embed'><span lang=AR-SA style='color:black;letter-spacing:-.1pt'>اﻟﻌﻮاﻣﻞ</span><span
     lang=AR-SA style='color:black;letter-spacing:-.25pt'> </span><span
     lang=AR-SA style='color:black'>اﻟﻤﻀﺎدة<span style='letter-spacing:-.25pt'>
     </span>ﻟﻠﻤﯿﻜﺮوﺑﺎت<span style='letter-spacing:-.25pt'> </span></span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>)</span><span
     lang=AR-SA style='color:black'>ﻣﺜﻞ<span style='letter-spacing:-.25pt'> </span>ﺳﺒﺎرﻓﻠﻮﻛﺴﺎﺳﯿﻦ<span
     style='letter-spacing:-.25pt'> </span>،<span style='letter-spacing:-.25pt'>
     </span>ﻣﻮﻛﺴﯿﻔﻠﻮﻛﺴﺎﺳﯿﻦ<span style='letter-spacing:-.3pt'> </span>،<span
     style='letter-spacing:-.25pt'> </span>إرﯾﺜﺮوﻣﯿﺴﯿﻦ<span style='letter-spacing:
     -.35pt'> </span></span><span dir=LTR style='color:black'>IV</span><span
     dir=RTL></span><span style='color:black;letter-spacing:-.25pt'><span
     dir=RTL></span> </span><span lang=AR-SA style='color:black'>،<span
     style='letter-spacing:-.25pt'> </span>ﺑﻨﺘﺎﻣﯿﺪﯾﻦ<span style='letter-spacing:
     -.25pt'> </span>،<span style='letter-spacing:-.25pt'> </span>ﻣﻀﺎد</span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>-</span><span
     dir=RTL></span><span style='color:black;letter-spacing:-.25pt'><span
     dir=RTL></span> </span><span lang=AR-SA style='color:black'>ﻋﻼج<span
     style='letter-spacing:-.25pt'> </span>اﻟﻤﻼرﯾﺎ<span style='letter-spacing:
     -.25pt'> </span>ﺧﺎﺻﺔ<span style='letter-spacing:-.3pt'> </span>ھﺎﻟﻮﻓﺎﻧﺘﺮﯾﻦ</span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>(</span><span
     dir=RTL></span><span style='color:black;letter-spacing:-.25pt'><span
     dir=RTL></span> </span><span lang=AR-SA style='color:black'>،<span
     style='letter-spacing:-.25pt'> </span>ﺑﻌﺾ<span style='letter-spacing:-.25pt'>
     </span>ﻣﻀﺎدات<span style='letter-spacing:-.25pt'> </span>اﻟﮭﯿﺴﺘﺎﻣﯿﻦ<span
     style='letter-spacing:-.25pt'> </span></span><span dir=LTR></span><span
     dir=LTR style='color:black'><span dir=LTR></span>)</span><span lang=AR-SA
     style='color:black'>ﻣﺜﻞ<span style='letter-spacing:-.25pt'> </span>أﺳﺘﯿﻤﯿﺰول<span
     style='letter-spacing:-.3pt'> </span>ﻣﯿﺰوﻻﺳﺘﯿﻦ</span><span dir=LTR></span><span
     dir=LTR style='color:black'><span dir=LTR></span>.(<o:p></o:p></span></p>
     <p class=MsoBodyText><span style='color:black'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText style='margin-top:10.0pt'><span style='color:black'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoBodyText align=right dir=RTL style='margin-top:.05pt;
     margin-right:0in;margin-bottom:0in;margin-left:497.65pt;margin-bottom:
     .0001pt;text-align:left;direction:rtl;unicode-bidi:embed'><span
     lang=AR-SA style='color:black;letter-spacing:-.25pt'>إذا</span><span
     lang=AR-SA style='color:black;letter-spacing:-.15pt'> </span><span
     lang=AR-SA style='color:black'>ﻛﺎن<span style='letter-spacing:-.15pt'> </span>ﻟﺪﯾﻚ<span
     style='letter-spacing:-.15pt'> </span>أي<span style='letter-spacing:-.2pt'>
     </span>أﺳﺌﻠﺔ<span style='letter-spacing:-.15pt'> </span>أﺧﺮى<span
     style='letter-spacing:-.15pt'> </span>ﺣﻮل<span style='letter-spacing:-.15pt'>
     </span>ھﺬا<span style='letter-spacing:-.15pt'> </span>اﻷﻣﺮ<span
     style='letter-spacing:-.15pt'> </span>،<span style='letter-spacing:-.15pt'>
     </span>ﯾﺠﺐ<span style='letter-spacing:-.15pt'> </span>ﻋﻠﯿﻚ<span
     style='letter-spacing:-.15pt'> </span>اﻟﺘﺤﺪث<span style='letter-spacing:
     -.15pt'> </span>إﻟﻰ<span style='letter-spacing:-.2pt'> </span>طﺒﯿﺒﻚ</span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="147" alt="Text Box: ﻻ ﺗﺘﻨﺎول ﺳﺒﺮاﻟﯿﻜﺲ إذا ﻛﻨﺖ ﺗﺘﻨﺎول أدوﯾﺔ ﻟﻤﺸﺎﻛﻞ ﺿﺮﺑﺎت اﻟﻘﻠﺐ أو أدوﯾﺔ ﻗﺪ ﺗﻜﻮن ﺗﺆﺛﺮ ﻋﻠﻰ إﯾﻘﺎع اﻟﻘﻠﺐ ، ﻣﺜﻞ ﻣﻀﺎدات اﺿﻄﺮاب اﻟﻨﻈﻢ ﻣﻦ اﻟﺼﻨﻒ اﻷول أ واﻟﺜﺎﻟﺚ وﻣﻀﺎدات اﻟﺬھﺎن )ﻋﻠﻰ ﺳﺒﯿﻞ اﻟﻤﺜﺎل ﻣﺸﺘﻘﺎت اﻟﻔﯿﻨﻮﺛﯿﺎزﯾﻦ ، ﺑﯿﻤﻮزﯾﺪ ، ھﺎﻟﻮﺑﯿﺮﯾﺪول( ، ﻣﻀﺎدات اﻻﻛﺘﺌﺎب ﺛﻼﺛﯿﺔ اﻟﺤﻠﻘﺎت ، ﻣﻌﯿﻨﺔ
اﻟﻌﻮاﻣﻞ اﻟﻤﻀﺎدة ﻟﻠﻤﯿﻜﺮوﺑﺎت )ﻣﺜﻞ ﺳﺒﺎرﻓﻠﻮﻛﺴﺎﺳﯿﻦ ، ﻣﻮﻛﺴﯿﻔﻠﻮﻛﺴﺎﺳﯿﻦ ، إرﯾﺜﺮوﻣﯿﺴﯿﻦ IV ، ﺑﻨﺘﺎﻣﯿﺪﯾﻦ ، ﻣﻀﺎد- ﻋﻼج اﻟﻤﻼرﯾﺎ ﺧﺎﺻﺔ ھﺎﻟﻮﻓﺎﻧﺘﺮﯾﻦ( ، ﺑﻌﺾ ﻣﻀﺎدات اﻟﮭﯿﺴﺘﺎﻣﯿﻦ )ﻣﺜﻞ أﺳﺘﯿﻤﯿﺰول ﻣﯿﺰوﻻﺳﺘﯿﻦ.(


إذا ﻛﺎن ﻟﺪﯾﻚ أي أﺳﺌﻠﺔ أﺧﺮى ﺣﻮل ھﺬا اﻷﻣﺮ ، ﯾﺠﺐ ﻋﻠﯿﻚ اﻟﺘﺤﺪث إﻟﻰ طﺒﯿﺒﻚ.
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>إﺳﺘﺨﺪام ﺳﯿﺒﺮاﻟﻜﺲ ﻣﻊ اﻟﻄﻌﺎم و اﻟﺸﺮاب و اﻟﻜﺤﻮﻟﯿﺎت</p><p><strong>&nbsp;</strong></p><p dir="RTL">ﯾﻣﻛن أﺧذ ﺳﯾﺑراﻟﻛس ﻣﻊ أو ﻣن ﻏﯾر اﻟطﻌﺎم )أﻧﻈﺮ اﻟﻘﺴﻢ 3 &quot; ﻛﯿﻒ ﺗﺄﺧﺬ ﺳﯿﺒﺮاﻟﻜﺲ &quot; (</p><p dir="RTL">ﻛﺒﺎﻗﻲ اﻷدوﯾﺔ ﯾﻮﺻﻲ ﺑﻌﺪم إﺳﺘﺨﺪام ﺳﺒﺮاﻟﯿﻜﺲ ﻣﻊ اﻟﻜﺤﻮل, ﻣﻊ أن ﺳﺒﺮاﻟﯿﻜﺲ ﻻ ﯾﺘﺄﺛﺮ ﺑﺎﻟﻜﺤﻮل.</p><p>&nbsp;</p><p>&nbsp;</p><p>اﻟﺤﻤﻞ واﻟﺮﺿﺎع و اﻟﺨﺼﻮﺑﺔ</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL">ُﻣﺮﺿﻊ ﻣﺎ ﻟﻢ ﺗﻨﺎﻗﺸﻲ اﻟﻤﺨﺎطﺮ واﻟﻤﻨﺎﻓﻊ ﻣﻊ اﻟﻄﺒﯿﺐ.</p><p>&nbsp;</p><p dir="RTL">ِﺖ ﺣﺎﻣﻞ ، أو</p><p>&nbsp;</p><p dir="RTL">ِﺖ ﺣﺎﻣﻞ او ﺗﺨﻄﻄﯿﻦ ﻟﻠﺤﻤﻞ. ﻻ ﺗﺄﺧﺬي ﺳﺒﺮاﻟﯿﻜﺲ اذا ﻛﻨ</p><p>&nbsp;</p><p dir="RTL">اﺧﺒﺮي طﺒﯿﺒﻚ إذا ﻛﻨ</p><p>&nbsp;</p><p dir="RTL">إذا إﺳﺘﺨﺪﻣﺘﻲ ﺳﺒﺮاﻟﯿﻜﺲ أﺛﻨﺎء اﻟﺜﻼﺛﺔ أﺷﮭﺮ اﻷﺧﯿﺮة ﻣﻦ اﻟﺤﻤﻞ ﯾﺠﺐ أن ﯾﻜﻮن ﻣﻌﻠﻮﻣﺎً&nbsp;ﻟﺪﯾﻚ ﺑﺄن اﻟﺘﺄﺛﯿﺮات اﻟﺘﺎﻟﯿﺔ ﻗﺪ ﺗﻈﮭﺮ ﻋﻠﻰ طﻔﻠﻚ ﺑﻌﺪ اﻟﻮﻻدة: ﻣﺸﺎﻛﻞ ﻓﻰ اﻟﺘﻨﻔﺲ، إزرﻗﺎق ﻟﻮن اﻟﺠﻠﺪ، ﻧﻮﺑﺎت ﻣﺮﺿﯿﺔ، ﺗﻐﯿﺮات ﻓﻰ درﺟﺔ ﺣﺮارة</p><p>&nbsp;</p><p dir="RTL">ﻧﻌﺎس&nbsp;، ﺑُﻜﺎء ﻣﺘﺼﻞ ,&nbsp;ﻗﻠﺔ وﺻﻌﻮﺑﺎت ﻓﻰ اﻟﻨﻮم.&nbsp;إذا ﻛﺎن ﻟﺪﯾﻚ طﻔﻞ ﺣﺪﯾﺚ اﻟﻮﻻدة ﻟﺪﯾﮫ اى</p><p>&nbsp;</p><p dir="RTL">اﻟﺠﺴﻢ ، ﺻﻌﻮﺑﺎت ﻓﻰ اﻟﺘﻐﺬﯾﺔ ، ﻗﻲء ، اﻧﺨﻔﺎض ﻓﻰ ﺳﻜﺮ اﻟﺪم ، ﺗﯿﺒﻮس اﻟﻌﻀﻼت ، ﻧﺸﺎط أﻧﻌﻜﺎﺳﻲ ، رﻋﺎش, ﻋﺼﺒﻲ اﻟﻤﺰاج ، ھﯿﺠﺎن,</p><p dir="RTL">ﻣﻦ ھﺬه اﻻﻋﺮاض ﯾﺮﺟﻰ اﻹﺗﺼﺎل ﺑﺎﻟﻄﺒﯿﺐ ﻓﻮراً.</p><p dir="RTL">إذا إﺳﺘﺨﺪﻣﺘﻲ ﺳﺒﺮاﻟﯿﻜﺲ أﺛﻨﺎء اﻟﺤﻤﻞ ﻓﺈﻧﮫ ﯾﺠﺐ ﻋﺪم اﻟﺘﻮﻗﻒ ﻋﻦ إﺳﺘﺨﺪاﻣﮫ ﺑﺸﻜﻞ ﻣﻔﺎﺟﺊ.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﺗﺄﻛﺪ ﻣﻦ أن طﺒﯿﺐ اﻟﻮﻻدة ﯾﻌﻠﻢ أﻧﻚ ﺗﺴﺘﺨﺪﻣﯿﻦ ﺳﺒﺮاﻟﯿﻜﺲ. ﻋﻨﺪ اﺧﺬه اﺛﻨﺎء اﻟﺤﻤﻞ و ﺧﺼﻮﺻﺎً&nbsp;ﻓﻰ اﻟﺜﻼﺛﺔ أﺷﮭﺮ اﻻﺧﯿﺮة ، ﻓﺈن اﻷدوﯾﺔ ﻣﺜﻞ ﺳﺒﺮاﻟﯿﻜﺲ ﻗﺪ ﺗﺰﯾﺪ ﻣﻦ ﻣﺨﺎطﺮ اﻟﺤﺎﻻت اﻟﻤﺮﺿﯿﺔ ﻓﻰ اﻷطﻔﺎل و اﻟﺘﻲ ﺗﺴﻤﻰ إرﺗﻔﺎع اﻟﻀﻐﻂ اﻟﻮرﯾﺪي اﻟﻤﺴﺘﺪﯾﻢ ) ﺑﻰ ﺑﻰ اﺗﺶ ان( ، ﻣﻤﺎ ﯾﺠﻌﻞ اﻟﻄﻔﻞ ﯾﺘﻨﻔﺲ ﺑﺴﺮﻋﺔ وﯾﻈﮭﺮ اﻟﻠﻮن اﻟﻤﺎﺋﻞ ﻟﻸزرق. ھﺬه اﻻﻋﺮاض ﻋﺎدةً&nbsp;ﻣﺎ ﺗﻈﮭﺮ ﺧﻼل اﻟـ 24 ﺳﺎﻋﺔ اﻷوﻟﻰ ﺑﻌﺪ وﻻدة اﻟﻄﻔﻞ. إذا ﺣﺼﻞ ھﺬا ﻟﻄﻔﻠﻚ ﻓﺈﻧﮫ ﯾﺠﺐ أن ﺗﺘﺼﻠﻰ طﺒﯿﺐ</p><p dir="RTL">اﻟﻮﻻدة ﻓﻮراً.</p><p dir="RTL">إذا ﻛﻨ ِﺖ ﺗﺘﻨﺎول ﺳﺒﺮاﻟﯿﻜﺲ وﺑﺎﻟﻘﺮب ﻣﻦ ﻧﮭﺎﯾﺔ اﻟﺤﻤﻞ ، ﻓﻘﺪ ﯾﻜﻮن ھﻨﺎك ﺧﻄﺮ ﻣﺘﺰاﯾﺪ ﻣﻦ ﺣﺪوث ﻧﺰﯾﻒ ﻣﮭﺒﻠﻲ ﺣﺎد ﺑﻌﺪ اﻟﻮﻻدة ﺑﻔﺘﺮة ﻗﺼﯿﺮة ، ﺧﺎﺻﺔ إذا ﻛﺎن ﻟﺪﯾﻚ ﺗﺎرﯾﺦ ﻣﻦ اﺿﻄﺮاﺑﺎت اﻟﻨﺰﯾﻒ. ﯾﺠﺐ أن ﯾﻜﻮن طﺒﯿﺒﻚ أو ﻣﻤﺮﺿﺔ</p><p dir="RTL">اﻟﺘﻮﻟﯿﺪ ﻋﻠﻰ ﻋﻠﻢ ﺑﺄﻧﻚ ﺗﺘﻨﺎول ﺳﺒﺮاﻟﯿﻜﺲ ﺣﺘﻰ ﯾﺘﻤﻜﻨﻮا ﻣﻦ ﺗﻘﺪﯾﻢ اﻟﻨﺼﺢ ﻟﻚ.</p><p dir="RTL">ﯾﺠﺐ ﻋﺪم اﻟﺘﻮﻗﻒ ﺑﺼﻮرة ﻣﻔﺎﺟﺌﺔ إذا اﺳﺘﺨﺪﻣﺘﻲ ﺳﯿﺒﺮاﻟﻜﺲ ﺧﻼل ﻓﺘﺮة اﻟﺤﻤﻞ.</p><p dir="RTL">وﻣﻦ&nbsp;اﻟﻤﺘﻮﻗﻊ أن ﺳﯿﺒﺮاﻟﯿﻜﺲ ﺳﻮف ﯾُﻔﺮز ﻓﻲ ﺣﻠﯿﺐ اﻟﺜﺪي.</p><p dir="RTL">ﺛﺒﺖ أن دواء ﺳﯿﺘﺎﻟﻮﺑﺮام ) دواء ﻣﺜﯿﻞ ﻻس ﺳﯿﺘﺎﻟﻮﺑﺮام( ﯾﻘﻠﻞ ﻣﻦ ﺟﻮدة اﻟﺤﯿﻮاﻧﺎت اﻟﻤﻨﻮﯾﺔ ﻓﻲ اﻟﺪراﺳﺎت اﻟﺤﯿﻮاﻧﯿﺔ. ھﺬا ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ اﻟﺨﺼﻮﺑﺔ ﻧﻈﺮﯾﺎً, و ﻟﻜﻦ ذﻟﻚ ﻟﻢ ﯾﻼﺣﻆ ﺣﺘﻰ اﻻن.</p><p dir="RTL">إﺳﺄﻟﻰ اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻰ ﻟﻺرﺷﺎدك ﻗﺒﻞ اﺧﺬ أى دواء.</p><p>&nbsp;</p><p>&nbsp;</p><p>اﻟﻘﯿﺎدة واﺳﺘﺨﺪام اﻟﻤﻌﺪات</p><p><strong>&nbsp;</strong></p><p dir="RTL">ﻧﻨﺼﺤﻚ ﺑﻌﺪم ﻗﯿﺎدة اﻟﺴﯿﺎرة أو ﺗﺸﻐﯿﻞ اﻟﻤﻌﺪات ﺣﺘﻰ ﺗﺘﻌﺮف ﻋﻠﻰ ﺗﺄﺛﯿﺮ ﺳﺒﺮاﻟﯿﻜﺲ ﻋﻠﯿﻚ.</p><p>&nbsp;</p><p>ﯾﺤﺘﻮي ﺳﺒﺮاﻟﻜﺲ ﻋﻠﻰ اﻟﺼﻮدﯾﻮم</p><p dir="RTL">ﯾﺤﺘﻮي ھﺬا اﻟﺪواء ﻋﻠﻰ أﻗﻞ ﻣﻦ 1 ﻣﻠﯿﻤﻮل ﺻﻮدﯾﻮم 23) ﻣﻠﻎ( ﻟﻜﻞ ﻗﺮص ، وھﺬا ﯾﻌﻨﻲ ﺑﺸﻜﻞ أﺳﺎﺳﻲ &quot;ﺧﺎل ﻣﻦ اﻟﺼﻮدﯾﻮم&quot;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">داﺋﻣﺎً&nbsp;ﺧذ اﻟدواء ﻛﻣﺎ وﺻﻔﮫ ﻟك اﻟطﺑﯾب. وﯾﺟب اﻟﺗﺄﻛد ﻣن اﻟطﺑﯾب او اﻟﺻﯾدﻟﻰ اذا ﻛﻧت ﻏﯾر ﻣﺗﺄﻛد ﻣن اﻟﺟرﻋﺔ.</p><p>&nbsp;</p><p dir="RTL"><u>اﻟﺑﺎﻟﻐﯾن</u></p><p dir="RTL"><em>اﻹﻛﺗﺋﺎب</em></p><p dir="RTL">اﻟﺟرﻋﺔ اﻟﻣﻌﺗﺎدة اﻟ ُﻣوﺻﻰ ﺑﮭﺎ ﻣن ﺳﯾﺑراﻟﻛس ھﻲ 10ﻣﻠﺟم ﺗؤﺧذ ﻣرة واﺣدة ﻓﻰ اﻟﯾوم. ﻗد ﯾﻘوم طﺑﯾﺑك ﺑزﯾﺎدة اﻟﺟرﻋﺔ إﻟﻰ 20 ﻣﻠﺟم ﻓﻰ اﻟﯾوم.</p><p dir="RTL"><em>إﺿطراب</em><em> </em><em>اﻟﮭﻠﻊ</em></p><p dir="RTL">اﻟﺟرﻋﺔ اﻹﺑﺗداﯾﺋﺔ ﻣن ﺳﯾﺑراﻟﻛس ھﻰ 5 ﻣﻠﺟم ﯾوﻣﯾﺎ ﻟﻸﺳﺑوع اﻷول ﻗﺑل زﯾﺎدﺗﮭﺎ اﻟﻰ 10 ﻣﻠﺟم ﻓﻰ اﻟﯾوم. ﻗد ﯾﻘوم طﺑﯾﺑك ﺑزﯾﺎدة اﻟﺟرﻋﺔ إﻟﻰ 20 ﻣﻠﺟم ﻓﻰ اﻟﯾوم ﻛﺣد اﻗﺻﻰ .</p><p dir="RTL"><em>اﺿطراب</em><em> </em><em>اﻟﻘﻠﻖ</em><em> </em><em>اﻻﺟﺗﻣﺎﻋﻰ</em></p><p dir="RTL">اﻟﺟرﻋﺔ اﻟﻣﻌﺗﺎدة اﻟ ُﻣوﺻﻰ ﺑﮭﺎ ﻣن ﺳﯾﺑراﻟﻛس ھﻲ 10ﻣﻠﺟم ﺗؤﺧذ ﻣرة واﺣدة ﻓﻰ اﻟﯾوم.رﺑﻣﺎ ﯾﻘﻠل اﻟطﺑﯾب اﻟﺟرﻋﺔ اﻟﻰ 5 ﻣﻠﺟم ﻓﻰ اﻟﯾوم او ﯾزﯾدھﺎ ﻛﺣد اﻗﺻﻰ اﻟﻰ 20 ﻣﻠﺟم ﯾوﻣﯾﺎً، و ذﻟك ﯾﻌﺗﻣد ﻋﻠﻰ ﻣدى اﺳﺗﺟﺎﺑﺗك ﻟﻠدواء.</p><p dir="RTL"><em>اﺿطراب</em><em> </em><em>اﻟﻘﻠﻖ</em><em> </em><em>اﻟﺷﻣوﻟﻲ</em></p><p dir="RTL">اﻟﺟرﻋﺔ اﻟﻣﻌﺗﺎدة اﻟ ُﻣوﺻﻰ ﺑﮭﺎ ﻣن ﺳﯾﺑراﻟﻛس ھﻲ 10ﻣﻠﺟم ﺗؤﺧذ ﻣرة واﺣدة ﻓﻰ اﻟﯾوم. ﻗد ﯾﻘوم طﺑﯾﺑك ﺑزﯾﺎدة اﻟﺟرﻋﺔ إﻟﻰ 20 ﻣﻠﺟم ﻓﻰ اﻟﯾوم ﻛﺣد اﻗﺻﻰ.</p><p dir="RTL"><em>إﺿطراب</em><em> </em><em>اﻟوﺳواس</em><em> </em><em>اﻟﻘﮭري</em></p><p dir="RTL">اﻟﺟرﻋﺔ اﻟﻣﻌﺗﺎدة اﻟ ُﻣوﺻﻰ ﺑﮭﺎ ﻣن ﺳﯾﺑراﻟﻛس ھﻲ 10ﻣﻠﺟم ﺗؤﺧذ ﻣرة واﺣدة ﻓﻰ اﻟﯾوم. ﻗد ﯾﻘوم طﺑﯾﺑك ﺑزﯾﺎدة اﻟﺟرﻋﺔ إﻟﻰ 20 ﻣﻠﺟم ﻓﻰ اﻟﯾوم ﻛﺣد اﻗﺻﻰ.</p><p dir="RTL"><em>اﻟﻣرﺿﻰ</em><em> </em><em>ﻣن</em><em> </em><em>ﻛﺑﺎر</em><em> </em><em>اﻟﺳن</em><em> </em><em>)</em><em> </em><em>ﻓوق</em><em> </em><em>65</em><em> </em><em>ﺳﻧﺔ</em><em> </em><em>(</em></p><p dir="RTL">اﻟﺟرﻋﺔ اﻹﺑﺗداﺋﯾﺔ اﻟ ُﻣﺻﻰ ﺑﮭﺎ ﻣن ﺳﯾﺑراﻟﻛس ھﻰ 5 ﻣﻠﺟم ﻓﻰ اﻟﯾوم.</p><p>&nbsp;</p><p dir="RTL"><em>اﻻﺳﺗﺧدام</em><em> </em><em>ﻟﻼطﻔﺎل</em><em> </em><em>واﻟﻣراھﻘﯾن</em></p><p dir="RTL">ﻋﺎدةً&nbsp;ﯾﺟب أن ﻻ ﯾُﻌطﻰ ﺳﯾﺑراﻟﻛس ﻟﻸطﻔﺎل واﻟﻣراھﻘﯾن.&nbsp;وﻟﻣزﯾدا ﻣن اﻟﻣﻌﻠوﻣﺎت اﻧظر اﻟﻘﺳم 2&nbsp;اﻟﺘﺤﺬﯾﺮات واﻻﺣﺘﯿﺎطﺎت</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Textbox_x0020_6" o:spid="_x0000_s1026" type="#_x0000_t202"
  style='position:absolute;margin-left:41.1pt;margin-top:21.65pt;width:762.6pt;
  height:13.8pt;z-index:-15727616;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal dir=RTL style='margin-right:1.4pt;text-align:right;
     line-height:13.8pt;mso-line-height-rule:exactly;direction:rtl;unicode-bidi:
     embed'><u><span lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;
     mso-hansi-font-family:"Times New Roman";color:black;letter-spacing:-.25pt'>ﻛﯾف</span></u><u><span
     lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;
     mso-hansi-font-family:"Times New Roman";color:black;letter-spacing:-.2pt'>
     </span></u><u><span lang=AR-SA style='font-size:12.0pt;font-family:"Arial",sans-serif;
     mso-hansi-font-family:"Times New Roman";color:black'>ﺗﺄﺧذ<span
     style='letter-spacing:-.25pt'> </span>اﻷﻗراص</span></u><span dir=LTR
     style='font-size:12.0pt;font-family:"Arial",sans-serif;mso-hansi-font-family:
     "Times New Roman";color:black'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="21" alt="Text Box: ﻛﯾف ﺗﺄﺧذ اﻷﻗراص" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﯾﻣﻛﻧك أﺧذ ﺳﯾﺑراﻟﻛس ﻣﻊ او ﺑدون اﻟطﻌﺎم. إﺑﻠﻊ اﻟﻘرص ﻣﻊ ﺑﻌض اﻟﻣﺎء.ﻻ ﺗﻣﺿﻐﮭﺎ ﻷن ﻣذاﻗﮭﺎ ُﻣر.</p><p>&nbsp;</p><p dir="RTL">إذا ﻛﺎن و ﻻﺑد ﻓﺈﻧﮫ ﯾﻣﻛﻧك ﺗﻘﺳﯾم اﻷﻗراص<strong> </strong><strong>ذات اﻟﺠﺮﻋﺔ </strong><strong>10,15</strong><strong> </strong><strong>أو </strong><strong>20</strong> ﻣﻠﺟم ﺑوﺿﻌﮭﺎ ﻋﻠﻰ ﺳطﺢ ﻣﺳﺗو و واﺟﮭﺔ اﻟﻘرص إﻟﻰ اﻷﻋﻠﻰ ﺛم ﺗُﻛﺳر اﻷﻗراص ﺑواﺳطﺔ اﻟﺿﻐط ﻋﻠﯾﮭﺎ ﻋﻠﻰ اﻟطرﻓﯾن ، ﻣﺳﺗﺧدﻣﺎً&nbsp;اﻷﺻﺑﻌﯾن ﻛﻣﺎ ھو ﻣﺑﯾن ﻓﻲ اﻟﺻورة.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Image_x0020_7" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:140.5pt;height:42.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="187" height="57" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg" /></p><p>&nbsp;</p><p>ﯾﻤﻜﻦ ﺗﻘﺴﯿﻢ اﻷﻗﺮاص 10 و15 و20 ﻣﻠﻎ إﻟﻰ ﺟﺮﻋﺎت ﻣﺘﺴﺎوﯾﺔ.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>ﻣﺪة اﻟﻌﻼج </strong><strong>:</strong></p><p dir="RTL">ﻗﺪ ﯾﺘﻄﻠﺐ اﻟﻌﻼج ﻋﺪة أﺳﺎﺑﯿﻊ ﻗﺒﻞ أن ﺗﺸﻌﺮ ﺑﺎﻟﺘﺤﺴﻦ. اﺳﺘﻤﺮ ﻓﻰ أﺧﺬ ﺳﺒﺮاﻟﯿﻜﺲ ﺣﺘﻰ ﻟﻮ اﺳﺘﻐﺮق ذﻟﻚ زﻣﻨﺎً&nbsp;طﻮﯾﻼً&nbsp;ﻗﺒﻞ اﻟﺸﻌﻮر ﺑﺎﻟﺘﺤﺴﻦ.</p><p>&nbsp;</p><p dir="RTL">ﻻ ﺗﻘﻢ ﺑﺘﻐﯿﯿﺮ ﺟﺮﻋﺔ اﻟﺪواء ﻗﺒﻞ أن ﺗﺴﺘﺸﯿﺮ اﻟﻄﺒﯿﺐ أوﻻً.</p><p>&nbsp;</p><p dir="RTL">إﺳﺘﻤﺮ ﻓﻰ أﺧﺬ ﺳﺒﺮاﻟﯿﻜﺲ ﺣﺴﺐ ﺗﻮﺻﯿﺔ اﻟﻄﺒﯿﺐ. .إذا ﺗﻮﻗﻔﺖ ﻋﻦ أﺧﺬ اﻟﺪواء ﻗﺒﻞ اﻟﻤﺪة اﻟ ُﻤﻮﺻﻰ ﺑﮭﺎ ﻓﺈن أﻋﺮاض ﻣﺮﺿﻚ ﻗﺪ ﺗﻌﻮد ﻣﺮة أﺧﺮى،. ﯾُﻮﺻﻰ ﺑﺈﺳﺘﻤﺮارﯾﺔ اﻟﻌﻼج ﻟﻤﺪة 6 ﺷﮭﻮرﻋﻠﻰ اﻷﻗﻞ ﺑﻌﺪ ﺷﻌﻮرك ﺑﺎﻟﺘﺤﺴﻦ.</p><p>&nbsp;</p><p>ﻓﻲ ﺣﺎﻟﺔ أﺧﺬت ﺳﺒﺮاﻟﯿﻜﺲ ﻣﯿﻠﺘﺰ ﺑﺠﺮﻋﺔ أﻛﺒﺮ ﻣﻦ اﻟﻼزم</p><p dir="RTL">إذا أﺧﺬت ﻛﻤﯿﺔ أﻛﺒﺮ ﻣﻦ اﻟﺠﺮﻋﺔ اﻟ ُﻤﻮﺻﻰ ﺑﮭﺎ ﻣﻦ ﺳﺒﺮاﻟﯿﻜﺲ ، ﻓﺄﺗﺼﻞ ﺑﺎﻟﻄﺒﯿﺐ أو أﻗﺮب ﻗﺴﻢ طﻮارىء ﻓﻰ اﻟﻤﺴﺘﺸﻔﻰ ﻣﺒﺎﺷﺮةً. ﻗُﻢ ﺑﺬﻟﻚ ﺣﺘﻰ ﻟﻮ ﻟﻢ ﺗﻈﮭﺮ ﻋﻠﯿﻚ أى ﻋﻼﻣﺎت ُﻣﺰﻋﺠﺔ. ﻗﺪ ﯾﻜﻮن ﻣﻦ ﻋﻼﻣﺎت اﻟﺠﺮﻋﺔ اﻟﺰاﺋﺪة اﻟﺪوﺧﺔ ،</p><p dir="RTL">اﻟﺮﺟﻔﺎن ، اﻟﺘﮭﯿﺞ ، اﻟﺘﺸﻨﺞ ، اﻟﻐﯿﺒﻮﺑﺔ، اﻟﻐﺜﯿﺎن، اﻟﻘﻲء , ﺗﻐﯿﺮ إﻧﺘﻈﺎم ﻧﺒﺾ اﻟﻘﻠﺐ, إﻧﺨﻔﺎض ﺿﻐﻂ اﻟﺪم و إﺧﺘﻼل ﺗﻮازن اﻷﻣﻼح و اﻟﺴﻮاﺋﻞ ﻓﻲ اﻟﺪم. ُﺧﺬ ﻋﻠﺒﺔ ﺳﺒﺮاﻟﯿﻜﺲ ﻣﯿﻠﺘﺰ ﻣﻌﻚ ﻋﻨﺪ ذھﺎﺑﻚ اﻟﻰ اﻟﻄﺒﯿﺐ أو اﻟﻤﺴﺘﺸﻔﻰ.</p><p>&nbsp;</p><p>إذا ﻧﺴﯿﺖ أن ﺗﺄﺧﺬ ﺳﺒﺮاﻟﯿﻜﺲ</p><p>&nbsp;</p><p dir="RTL">ُﺧﺬ ﺟﺮﻋﺔ اﻟﯿﻮم اﻟﺘﺎﻟﻰ ﻛﺎﻟ ُﻤﻌﺘﺎد. و إذا ﺗﺬﻛﺮت أﺛﻨﺎء اﻟﻠﯿﻞ أو ﻓﻲ اﻟﯿﻮم اﻟﺘﺎﻟﻰ، أﺗﺮك اﻟﺠﺮﻋﺔ اﻟﺘﻰ&nbsp;ﻧﺴﯿﺘﮭﺎ وﺧﺬ اﻟﺠﺮﻋﺔ اﻟ ُﻤﻌﺘﺎدة ﻟﻨﻔﺲ اﻟﯿﻮم.</p><p>&nbsp;</p><p dir="RTL">&nbsp;لا تاخذ ﺟﺮﻋﺔ&nbsp;ﻣﻀﺎﻋﻔﺔ ﻟﺘﻌﻮﯾﺾ اﻟﺠﺮﻋﺔ اﻟﺘﻰ ﻧﺴﯿﺘﮭﺎ.&nbsp;إذا ﻧﺴﯿﺖ أن ﺗﺄﺧﺬ اﻟﺠﺮﻋﺔ ، وﺗﺬﻛﺮت ﻗﺒﻞ ذھﺎﺑﻚ ﻟﻠﻨﻮم ﺧﺬھﺎ ﻣﺒﺎﺷﺮة.&nbsp;ﺛﻢ</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p>اذا ﺗﻮﻗﻔﺖ ﻋﻦ اﺳﺘﺨﺪام ﺳﺒﺮاﻟﯿﻜﺲ</p><p dir="RTL">ﻻ&nbsp;ﺗﺘﻮﻗﻒ ﻋﻦ أﺧﺬ ﺳﺒﺮاﻟﯿﻜﺲ ﺣﺘﻰ ﯾﻄﻠﺐ ﻣﻨﻚ اﻟﻄﺒﯿﺐ ذﻟﻚ.&nbsp;و ﻋﻨﺪ إﻛﻤﺎﻟﻚ ﻟﻠﻤﺪة اﻟﻌﻼﺟﯿﺔ، ﻓﺈﻧﮫ ﯾُﻨﺼﺢ ﺑﺘﻘﻠﯿﻞ اﻟﺠﺮﻋﺔ ﺗﺪرﯾﺠﯿﺎً&nbsp;ﻟﻌﺪة أﺳﺎﺑﯿﻊ.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ُﻣﻌﺘﺎد ﻋﻨﺪ اﻟﺘﻮﻗﻒ ﻋﻦ اﻟﻌﻼج ﺑﺴﺒﺮاﻟﯿﻜﺲ. وﻟﻜﻦ ﻣﺨﺎطﺮ ذﻟﻚ ﺗﺰداد ﻓﻲ ﺣﺎﻟﺔ إﺳﺘﺨﺪام ﺳﺒﺮاﻟﯿﻜﺲ ﻟﻤﺪة طﻮﯾﻠﺔ أو</p><p>&nbsp;</p><p dir="RTL">ُﻣﻔﺎﺟﻲء ﻓﻘﺪ ﺗﺸﻌﺮ ﺑﺰوال أﻋﺮاض اﻟﻤﺮض. و ھﺬه</p><p>&nbsp;</p><p dir="RTL">إذا ﺗﻮﻗﻔﺖ ﻋﻦ إﺳﺘﺨﺪام ﺳﺒﺮاﻟﯿﻜﺲ وﺧﺎﺻﺔً&nbsp;اذا ﻛﺎن ذﻟﻚ ﺑﺸﻜﻞ</p><p>&nbsp;</p><p dir="RTL">ﺑﺠﺮﻋﺎت ﻋﺎﻟﯿﺔ أو ﺗﻢ ﺗﻘﻠﯿﻞ اﻟﺠﺮﻋﺔ ﺑﺼﻮرة ﺳﺮﯾﻌﺔ. ﻣﻌﻀﻢ اﻟﻤﺮﺿﻰ ﯾﺸﻌﺮون ﺑﺄن اﻷﻋﺮاض اﻟﻤﺮﺿﯿﺔ ﻗﺪ ﺧﻔﺖ و زاﻟﺖ ﺧﻼل أﺳﺒﻮﻋﯿﻦ. و اﻟﺒﻌﺾ اﻵﺧﺮ ﻗﺪ ﺗﻜﻮن ﻟﺪﯾﮭﻢ اﻷﻋﺮاض ﺷﺪﯾﺪة او ﻗﺪ ﺗﻄﻮل اﻟﻤﺪة إﻟﻰ (3-2) أﺷﮭﺮ. ﻓﻲ</p><p dir="RTL">ﺣﺎﻟﺔ ﺷﻌﻮرك ﺑﺄﻋﺮاض اﻟﺘﻮﻗﻒ ﻋﻦ اﻟﻌﻼج ﺑﺴﺒﺮاﻟﯿﻜﺲ ﻓﺄﺗﺼﻞ ﺑﺎﻟﻄﺒﯿﺐ. ﻗﺪ ﯾﻨﺼﺤﻚ اﻟﻄﺒﯿﺐ ﺑﺎﻟﻌﻮدة إﻟﻰ أﺧﺬ اﻷﻗﺮاص ﻣﺮة ﺛﺎﻧﯿﺔ و إﯾﻘﺎﻓﮭﺎ ﺑﺒﻂء.</p><p>&nbsp;</p><p dir="RTL">ﻣﻦ أﻋﺮاض اﻟﺘﻮﻗﻒ ﻋﻦ اﻟﻌﻼج : اﻟﺸﻌﻮر ﺑﺎﻟﺪوران ) ﻋﺪم اﻟﺜﺒﺎت و ﻓﻘﺪان اﻟﺘﻮازن( اﻟﺸﻌﻮر ﺑﻮﺧﺰ اﻟﺪﺑﻮس أو اﻹﺑﺮة ، اﻹﺣﺴﺎس ﺑﺄن ﻟﺪﯾﻚ ﺣﺮوق )وھﺬا ﻏﯿﺮ ﺷﺎﺋﻊ( أو ﺻﺪﻣﺔ ﻛﮭﺮﺑﺎﺋﯿﺔ، إﺿﻄﺮاﺑﺎت اﻟﻨﻮم ) اﻷﺣﻼم اﻟﻤﺰﻋﺠﺔ،</p><p>&nbsp;</p><p dir="RTL">اﻟﻜﻮاﺑﯿﺲ&nbsp;، ﻋﺪم اﻟﻤﻘﺪرة ﻋﻠﻰ اﻟﻨﻮم,(&nbsp;اﻟﺸﻌﻮر ﺑﺎﻟﻘﻠﻖ ، اﻟﺼﺪاع ، اﻟﺸﻌﻮر ﺑﺎﻟﻐﺜﯿﺎن، اﻟﺘﻌ&nbsp;ُﺮق )&nbsp;وﯾﺸﻤﻞ اﻟﺘﻌ&nbsp;ُﺮق اﻟﯿﻠﻲ,(&nbsp;ﻋﺪم اﻟﺸﻌﻮر ﺑﺎﻟﺮاﺣﺔ أو اﻟﮭﯿﺠﺎن، اﻟﺮﺟﻔﺔ، اﻻرﺗﺒﺎك أو ﻓﻘﺪان اﻹﺗﺠﺎه ، اﻟﺸﻌﻮر ﺑﺎﻟﻌﺎطﻔﺔ أو ﺳﺮﻋﺔ اﻟﻐﻀﺐ،</p><p dir="RTL">اﻹﺳﮭﺎل، اﺿﻄﺮاﺑﺎت اﻟﺮؤﯾﺔ ، اﻟﺮﺟﻔﺎن أو ﺧﻔﻘﺎن اﻟﻘﻠﺐ.</p><p dir="RTL">إذا ﻛﺎن ﻟﺪﯾﻚ أي إﺳﺘﻔﺴﺎرات إﺿﺎﻓﯿﺔ ﻋﻦ إﺳﺘﺨﺪام ھﺬا اﻟﻤﺴﺘﺤﻀﺮ ﻓﯿُﺮﺟﻰ اﻹﺗﺼﺎل ﺑﺎﻟﻄﺒﯿﺐ او اﻟﺼﯿﺪﻟﻰ.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻣﺜﻞ&nbsp;ﺟﻤﯿﻊ اﻷدوﯾﺔ ، ﻗﺪ ﯾُﺴﺒﺐ ھﺬا اﻟﺪواء ﺑﻌﺾ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ و ﻻ ﯾﺤﺼﻞ ذﻟﻚ ﻣﻊ ﻛﻞ اﻟﻤﺮﺿﻰ.</p><p dir="RTL">ھﺬه اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ ﻋﺎدةً&nbsp;ﺗﺘﻼﺷﻰ ﺑﻌﺪ أﺳﺎﺑﯿﻊ ﻗﻠﯿﻠﺔ ﻣﻦ اﻟﻌﻼج. و ﯾﺠﺐ أن ﺗﻌﻠﻢ ﺑﺄن اﻟﻜﺜﯿﺮ ھﺬه اﻷﺛﺎر ﻗﺪ ﺗﻜﻮن ﻣﻦ أﻋﺮاض ﻣﺮﺿﻚ و وﺳﻮف ﺗﺘﺤﺴﻦ ﻣﻊ اﻟﻌﻼج .</p><p>&nbsp;</p><p>&nbsp;</p><p>ٌي ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ ﻋﻠﯿﻚ ﺧﻼل ﻓﺘﺮة اﻟﻌﻼج:</p><p>&nbsp;</p><p dir="RTL"><strong>راﺟﻊ طﺒﯿﺒﻚ ﻓﻲ ﺣﺎﻟﺔ ظﮭﻮر أ</strong></p><p>&nbsp;</p><p dir="RTL">ﻏﯿﺮ ﺷﺎﺋﻌﺔ ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ 100 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; ﻧﺰﯾﻒ ﻏﯿﺮ ُﻣﻌﺘﺎد ، وﯾﺸﻤﻞ اﻟﻨﺰﯾﻒ اﻟﻤ ِﻌﺪي أو اﻟﻤﻌﻮي.</p><p dir="RTL">ﻧﺎدرة ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ 1000 ﻣﺴﺘﺨﺪم( :</p><p dir="RTL">&middot;&nbsp; ﺗﻮرم ﻓﻲ اﻟﺠﻠﺪ أو اﻟﻠﺴﺎن أو اﻟﺸﻔﺎه أو اﻟﺒﻠﻌﻮم أو اﻟﻮﺟﮫ أو ﺷﻌﺮت ﺑﺼﻌﻮﺑﺎت ﻓﻲ اﻟﺘﻨﻔﺲ أو اﻟﺒﻠﻊ ، ﻓﺄﺗﺼﻞ ﺑﺎﻟﻄﺒﯿﺐ او ﺗﻮﺟﮫ إﻟﻰ اﻟﻤﺴﺘﺸﻔﻰ ﻣﺒﺎﺷﺮةً.</p><p>&nbsp;</p><p dir="RTL">ُﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ.</p><p>&nbsp;</p><p dir="RTL">ُﺤﻤﻰ&nbsp;أو ﺳﺮﻋﺔ اﻟﻐﻀﺐ أو اﻻرﺗﺒﺎك أو إرﺗﻌﺎش أو ﺗﻘﻠﺼﺎت ﻟﻠﻌﻀﻼت، ﻓﺈن ذﻟﻚ ﻗﺪ ﯾﻜﻮن ﻋﻼﻣﺔ ﻟﺤﺎﻟﺔ ﺗﺴﻤﻰ</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; اذا ﺷﻌﺮت ﺑﺎﻟ</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Textbox_x0020_8" o:spid="_x0000_s1030" type="#_x0000_t202"
 style='width:762.6pt;height:12.7pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAY8BnetgDAAD4HQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWUFv2zYUvg/ofyB4Wg+pZbdJHaNK
kWZzUSBogzj9AQxN2UIpUiMZx+5ttx2KFCgKrIcBPbRYgB5a7CoB7d9IfwX/wh4pyRbcLp0dDAM2
GbBNiuTje9/73pPEd+fuNOFowpSOpQhx+0aAERNUDmMxCvHjo/5GFyNtiBgSLgUL8YxpfHfn2nd3
SG+kSDqOKQIJQvdIiMfGpL1WS9MxS4i+IVMmYCySKiEGumrUGipyCpIT3uoEwVYrIbHAOwtRPxBD
0ImK1xDFJX3ChntETIgGkZz26ldKHTm9umTSE5P7Kh2kB8ppTh9ODhSKhyEG5ARJACLcKgfKadBt
La0aLQRMI5W4+TKK0NRLmblfL4NNDaJwcXuruxl0YAMKY+2tdme7nEDHj76yjI5/vHwhqFNsC42a
Kjp1iojJl7YBCQrbjkClYzlF3bmRbjIy03sS9Gx7Z+p0H5yhC7MBn0Kch6CSrEv0rmD83AbSS5U2
95lMkGuEWDFqvCJksq9NoUY1xRmoJY+H/Zhz31Gj4z2u0ITwEPe7/e3+tjMNpNemuV6psZkOPErO
4uHMSTiGf4AAYsg8gp+Iy9MQUx6nGI2lerp87RSiJsT6pxOiGEb8gdDe6aZqqKpxXDWU4XsStAu8
UULunhgZxaVhxe5OD67NwMw488zxOjrPJETtg2Nu3+4CfaBz6HcjfATRrjAC2Qu30Xss8pik9MDo
AhJPNG9/bXQ3MpfM86OwpETMh4kCVThxOYWojcEu5JSnsG87AKV0ClG50dksuPOXvgn850vfkB6L
IvB44WqAgZhYIDNLWUQoRONRnDCNHrJTdCgTIjBKiZAaBiCgOsFWcDPYDG7BtwOtWzAaGzrukyTm
LtSA93RMlGZAqyomyT8mHDADnByyZsfmz+2HTzZ776gIaLsxN/I30Sy4UqMwMLjO9P8Zmmg1FD25
GyZWTHxj82fAxM+/fP55NRyr2G7Y6OO3iu1vsJGJjceDWoZs2FjLi9dXY2CDXQ07m+erodfE7/zG
X783fyN+l59wGg7WOfjho83f2vw3m//ekHHNp9CGjOs/wdexs9mvNn9ls3cWWNk8aq/9VlTHtEmO
q71R1rG7OLf5a5u9cukxe39xfvFHkyKbFPkvn0PA219zp173vKge3U1mvHJmfOHPxM5sfm6zs4t3
62XH5qTR4TY/aWxoeVVawvsM3LOzM5u9sdnLy0nZHO4snajXqdj7fgk8JoYHRJHDefXga/D9l87/
Fwb7I38o4wA+i1rTiWaD9BCqHUWJqihGwQxXuWst1Tz90rJG6wqr9f7OnwAAAP//AwBQSwMEFAAG
AAgAAAAhAOFRNx/PBgAA5hsAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZzW/cRBS/
I/E/jHxvs9/NRt1U2c1uA23aKNkW9Thrz9rTjD3WzGzSvaH2iISEKIgDlbhxQEClVuJS/ppAERSp
/wJvZmyvJ+uQtI2gguaQtZ9/877fm6/LV+7FDB0QISlPel79Ys1DJPF5QJOw590ajy6sekgqnASY
8YT0vDmR3pX199+7jNd8RtMJxyIYRyQmCBglcg33vEipdG1lRfpAxvIiT0kC36ZcxFjBqwhXAoEP
QUDMVhq1WmclxjTx1oGj0oyGDP4lSmqCz8SeZkNQgmOQfnM6pT4x2GC/rhFyLgdMoAPMeh7wDPjh
mNxTHmJYKvjQ82rmz1tZv7yC17JBTJ0wtjRuZP6ycdmAYL9hZIpwUgitj1rdS5sFfwNgahk3HA4H
w3rBzwCw74OlVpcyz9Zotd7PeZZA9nGZ96DWrrVcfIl/c0nnbr/fb3czXSxTA7KPrSX8aq3T2mg4
eAOy+PYSvtXfGAw6Dt6ALL6zhB9d6nZaLt6AIkaT/SW0DuholHEvIFPOtirhqwBfrWXwBQqyocgu
LWLKE3VSrsX4LhcjAGggw4omSM1TMsU+5OQAxxNBsRaA1wgufbEkXy6RtCwkfUFT1fM+THHilSAv
n33/8tkTdHT/6dH9n44ePDi6/6Nl5IzawklYHvXi28/+fPQx+uPJNy8eflGNl2X8rz988svPn1cD
oXwW5j3/8vFvTx8//+rT3797WAHfEHhSho9pTCS6QQ7RLo/BMOMVV3MyEa82YhxhWh6xkYQSJ1hL
qeA/VJGDvjHHLIuOo0efuB68LaB9VAGvzu46Cu9FYqZoheRrUewAtzlnfS4qvXBNyyq5eTxLwmrh
YlbG7WJ8UCV7gBMnvsNZCn0zT0vH8EFEHDV3GE4UDklCFNLf+D4hFdbdodTx6zb1BZd8qtAdivqY
VrpkTCdONi0GbdEY4jKvshni7fhm+zbqc1Zl9SY5cJFQFZhVKD8mzHHjVTxTOK5iOcYxKzv8OlZR
lZJ7c+GXcUOpINIhYRwNAyJl1ZibAuwtBf0aho5VGfZtNo9dpFB0v4rndcx5GbnJ9wcRjtMq7B5N
ojL2A7kPKYrRDldV8G3uVoh+hzjg5MRw36bECffp3eAWDR2VFgmiv8yEjiW0aqcDxzT5u3bMKPRj
mwPn146hAT7/+lFFZr2tjXgD5qSqStg61n5Pwh1vugMuAvr299xNPEt2CKT58sTzruW+a7nef77l
nlTPZ220i94KbVevG+yi2CyR4xNXyFPK2J6aM3JdmkWyhHkiGAFRjzM7QVLsmNIIHrO+7uBCgc0Y
JLj6iKpoL8IpLLDrnmYSyox1KFHKJWzsDLmSt8bDIl3ZbWFbbxhsP5BYbfPAkpuanO8LCjZmtgnN
5jMX1NQMziqseSljCma/jrC6VurM0upGNdPqHGmFyRDDZdOAWHgTFiAIli3g5Q7sxbVo2JhgRgLt
dzv35mExUTjPEMkIBySLkbZ7OUZ1E6Q8V8xJAORORYz0Ju8Ur5WkdTXbN5B2liCVxbVOEJdH702i
lGfwIkq6bo+VI0vKxckSdNjzuu1G20M+TnveFPa08BinEHWp13yYhXAa5Cth0/7UYjZVvohmNzfM
LYI6HFNYvy8Z7PSBVEi1iWVkU8N8ylKAJVqS1b/RBreelwE2019Di+YqJMO/pgX40Q0tmU6Jr8rB
LlG07+xr1kr5TBGxFwWHaMJmYhdD+HWqgj0BlXA0YTqCfoFzNO1t88ltzlnRlU+vDM7SMUsjnLVb
XaJ5JVu4qeNCB/NWUg9sq9TdGPfqppiSPydTymn8PzNFzydwUtAMdAR8OJQVGOl67XlcqIhDF0oj
6o8ELBxM74BsgbNY+AxJBSfI5leQA/1ra87yMGUNGz61S0MkKMxHKhKE7EBbMtl3CrN6NndZlixj
ZDKqpK5MrdoTckDYWPfAjp7bPRRBqptukrUBgzuef+57VkGTUC9yyvXm9JBi7rU18E+vfGwxg1Fu
HzYLmtz/hYoVs6odb4bnc2/ZEP1hscxq5VUBwkpTQTcr+9dU4RWnWtuxlixutHPlIIrLFgOxWBCl
cN6D9D+Y/6jwmb1t0BPqmO9Cb0Vw0aCZQdpAVl+wCw+kG6QlTmDhZIk2mTQr69ps6aS9lk/W57zS
LeQec7bW7CzxfkVnF4szV5xTi+fp7MzDjq8t7URXQ2SPlyiQpvlGxgSm6tZpG6doEtZ7Htz8QKDv
wRPcHXlAa2haQ9PgCS6EYLFkb3F6XvaQU+C7pRSYZk5p5phWTmnllHZOgcVZdl+SUzrQqfQVB1yx
6R8P5bcZsILLbj/ypupcza3/BQAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNs
aXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQ
kSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXT
cvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHi
i0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQ
SwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlw
ZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVs
cy8ucmVsc1BLAQItABQABgAIAAAAIQBjwGd62AMAAPgdAAAfAAAAAAAAAAAAAAAAACACAABjbGlw
Ym9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAOFRNx/PBgAA5hsAABoA
AAAAAAAAAAAAAAAANQYAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAh
AJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAPA0AAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9k
cmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAAA/DgAAAAA=
" fillcolor="#f8f9f9" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText dir=RTL style='margin-right:1.4pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='color:black;
    letter-spacing:-.25pt'>ﻏﯿﺮ</span><span lang=AR-SA style='color:black;
    letter-spacing:-.2pt'> </span><span lang=AR-SA style='color:black'>ﻣﻌﺮوف<span
    style='letter-spacing:-.2pt'> </span></span><span dir=LTR></span><span
    dir=LTR style='color:black'><span dir=LTR></span>)</span><span lang=AR-SA
    style='color:black'>ﻻ<span style='letter-spacing:-.2pt'> </span>ﯾﻤﻜﻦ<span
    style='letter-spacing:-.2pt'> </span>ﺗﻘﺪﯾﺮ<span style='letter-spacing:-.2pt'>
    </span>اﻟﺘﻜﺮار<span style='letter-spacing:-.2pt'> </span>ﻣﻦ<span
    style='letter-spacing:-.2pt'> </span>اﻟﺒﯿﺎﻧﺎت<span style='letter-spacing:
    -.25pt'> </span>اﻟﻤﺘﺎﺣﺔ</span><span dir=LTR></span><span dir=LTR
    style='color:black'><span dir=LTR></span>:(<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="1019" height="19" alt="Text Box: ﻏﯿﺮ ﻣﻌﺮوف )ﻻ ﯾﻤﻜﻦ ﺗﻘﺪﯾﺮ اﻟﺘﻜﺮار ﻣﻦ اﻟﺒﯿﺎﻧﺎت اﻟﻤﺘﺎﺣﺔ:(" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:762.6pt;height:12.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">اﻟﺘﺤﺬﯾﺮات واﻻﺣﺘﯿﺎطﺎت</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; ﺻﻌﻮﺑﺔ اﻟﺘﺒﻮل</p><p dir="RTL">&middot;&nbsp; ﻧﻮﺑﺎت اﻟﺼﺮع، اﻗﺮأ اﻟﻘﺴﻢ 2 اﻟﺨﺎص ﺑـ</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; اﺻﻔﺮار اﻟﺠﻠﺪ و إﺑﯿﻀﺎض اﻟﻌﯿﻦ ھﻲ ﻋﻼﻣﺎت ﻋﻠﻰ إﺧﺘﻼل وظﺎﺋﻒ اﻟﻜﺒﺪ أو إﻟﺘﮭﺎب اﻟﻜﺒﺪ اﻟﻮﺑﺎﺋﻲ.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_9" o:spid="_x0000_s1029" type="#_x0000_t202" style='position:absolute;
  margin-left:41.1pt;margin-top:11.3pt;width:762.6pt;height:36.7pt;z-index:-15726592;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText dir=RTL style='margin-right:1.35pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><span dir=LTR style='color:black;
     letter-spacing:-.5pt'>•</span><span dir=RTL></span><span style='color:
     black;letter-spacing:-.15pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>ﻋﺪم<span style='letter-spacing:-.15pt'> </span>اﻧﺘﻈﺎم<span
     style='letter-spacing:-.15pt'> </span>ﺿﺮﺑﺎت<span style='letter-spacing:
     -.2pt'> </span>اﻟﻘﻠﺐ<span style='letter-spacing:-.15pt'> </span>،<span
     style='letter-spacing:-.2pt'> </span>واﻹﻏﻤﺎء<span style='letter-spacing:
     -.15pt'> </span>اﻟﺬي<span style='letter-spacing:-.2pt'> </span>ﻗﺪ<span
     style='letter-spacing:-.15pt'> </span>ﯾﻜﻮن<span style='letter-spacing:
     -.2pt'> </span>ﻣﻦ<span style='letter-spacing:-.15pt'> </span>اﻷﻋﺮاض<span
     style='letter-spacing:-.2pt'> </span>اﻟﺘﻲ<span style='letter-spacing:-.15pt'>
     </span>ﺗﮭﺪد<span style='letter-spacing:-.2pt'> </span>اﻟﺤﯿﺎة</span><span
     dir=LTR style='color:black'><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:11.35pt;margin-right:4.15pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='color:black;
     letter-spacing:-.2pt'>ﺣﺎﻟﺔ </span><span lang=AR-SA style='color:black'>ﺗﻌﺮف<span
     style='letter-spacing:-.2pt'> </span>ﺑﺎﺳﻢ<span style='letter-spacing:-.15pt'>
     </span>ﺗﻮرﺳﺎد<span style='letter-spacing:-.2pt'> </span>دي<span
     style='letter-spacing:-.2pt'> </span>ﺑﻮاﻧﺖ</span><span dir=LTR
     style='color:black'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="51" alt="Text Box: • ﻋﺪم اﻧﺘﻈﺎم ﺿﺮﺑﺎت اﻟﻘﻠﺐ ، واﻹﻏﻤﺎء اﻟﺬي ﻗﺪ ﯾﻜﻮن ﻣﻦ اﻷﻋﺮاض اﻟﺘﻲ ﺗﮭﺪد اﻟﺤﯿﺎة
ﺣﺎﻟﺔ ﺗﻌﺮف ﺑﺎﺳﻢ ﺗﻮرﺳﺎد دي ﺑﻮاﻧﺖ
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Textbox_x0020_10" o:spid="_x0000_s1028" type="#_x0000_t202" style='width:762.6pt;
 height:48pt;visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText dir=RTL style='margin-top:11.3pt;margin-right:4.15pt;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span dir=LTR style='color:black;
    position:relative;top:-.5pt;mso-text-raise:.5pt;letter-spacing:-.5pt'>•</span><span
    dir=RTL></span><span style='color:black;position:relative;top:-.5pt;
    mso-text-raise:.5pt;letter-spacing:-.3pt'><span dir=RTL></span><span
    style='mso-spacerun:yes'> </span></span><span lang=AR-SA style='color:black;
    position:relative;top:-.5pt;mso-text-raise:.5pt'>أﻓﻜﺎر<span
    style='letter-spacing:-.3pt'> </span>ﻹﯾﺬاء<span style='letter-spacing:-.25pt'>
    </span>ﻧﻔﺴﻚ<span style='letter-spacing:-.3pt'> </span>أو<span
    style='letter-spacing:-.3pt'> </span>ﻗﺘﻞ<span style='letter-spacing:-.3pt'>
    </span>ﻧﻔﺴﻚ<span style='letter-spacing:-.35pt'> </span>،<span
    style='letter-spacing:-.3pt'> </span>اﻧﻈﺮ<span style='letter-spacing:-.3pt'>
    </span>أﯾ</span><span lang=AR-SA style='color:black;letter-spacing:3.7pt;
    mso-font-width:150%'><span style='mso-spacerun:yes'> </span></span><span
    lang=AR-SA style='color:black;letter-spacing:-4.4pt'>ً<span
    style='position:relative;top:-.5pt;mso-text-raise:.5pt'>ﻀﺎ</span></span><span
    lang=AR-SA style='color:black;position:relative;top:-.5pt;mso-text-raise:
    .5pt;letter-spacing:-.3pt'><span style='mso-spacerun:yes'> </span></span><span
    lang=AR-SA style='color:black;position:relative;top:-.5pt;mso-text-raise:
    .5pt'>اﻟﻘﺴﻢ<span style='letter-spacing:-.3pt'> </span></span><span dir=LTR></span><span
    dir=LTR style='color:black;position:relative;top:-.5pt;mso-text-raise:.5pt'><span
    dir=LTR></span>2</span><span dir=RTL></span><span style='color:black;
    position:relative;top:-.5pt;mso-text-raise:.5pt;letter-spacing:-.25pt'><span
    dir=RTL></span><span style='mso-spacerun:yes'> </span></span><span dir=LTR></span><span
    dir=LTR style='color:black;position:relative;top:-.5pt;mso-text-raise:.5pt'><span
    dir=LTR></span>&quot;</span><span lang=AR-SA style='color:black;position:
    relative;top:-.5pt;mso-text-raise:.5pt'>ﺗﺤﺬﯾﺮات<span style='letter-spacing:
    -.3pt'> </span>واﻻﺣﺘﯿﺎطﺎت</span><span dir=LTR></span><span dir=LTR
    style='color:black;position:relative;top:-.5pt;mso-text-raise:.5pt'><span
    dir=LTR></span>&quot;</span><span dir=LTR style='color:black'><o:p></o:p></span></p>
    <p class=MsoBodyText dir=RTL style='margin-top:10.85pt;margin-right:1.4pt;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span dir=LTR style='color:black;
    letter-spacing:-.5pt'>•</span><span dir=RTL></span><span style='color:black;
    letter-spacing:-.2pt'><span dir=RTL></span> </span><span lang=AR-SA
    style='color:black'>ﺗﻮرم<span style='letter-spacing:-.2pt'> </span>ﻣﻔﺎﺟﺊ<span
    style='letter-spacing:-.2pt'> </span>ﻓﻲ<span style='letter-spacing:-.2pt'> </span>اﻟﺠﻠﺪ<span
    style='letter-spacing:-.15pt'> </span>أو<span style='letter-spacing:-.2pt'>
    </span>اﻟﻐﺸﺎء<span style='letter-spacing:-.2pt'> </span>اﻟﻤﺨﺎطﻲ<span
    style='letter-spacing:-.2pt'> </span></span><span dir=LTR></span><span
    dir=LTR style='color:black'><span dir=LTR></span>)</span><span lang=AR-SA
    style='color:black'>وذﻣﺔ<span style='letter-spacing:-.2pt'> </span>وﻋﺎﺋﯿﺔ</span><span
    dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>(<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="1019" height="67" alt="Text Box: • أﻓﻜﺎر ﻹﯾﺬاء ﻧﻔﺴﻚ أو ﻗﺘﻞ ﻧﻔﺴﻚ ، اﻧﻈﺮ أﯾ ًﻀﺎ اﻟﻘﺴﻢ 2 &quot;ﺗﺤﺬﯾﺮات واﻻﺣﺘﯿﺎطﺎت&quot;
• ﺗﻮرم ﻣﻔﺎﺟﺊ ﻓﻲ اﻟﺠﻠﺪ أو اﻟﻐﺸﺎء اﻟﻤﺨﺎطﻲ )وذﻣﺔ وﻋﺎﺋﯿﺔ(
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:762.6pt;height:48pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>ﺑﺎﻻﺿﺎﻓﺔ اﻟﻰ اﻵﺛﺎراﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺬﻛﻮرة ﺑﺎﻷﻋﻠﻰ ﻓﻘﺪ ﺗﻢ رﺻﺪ ﺑﻌﺾ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻹﺿﺎﻓﯿﺔ ﻛﺎﻟﺘﺎﻟﻲ:</p><p dir="RTL">ﺷﺎﺋﻌﺔ ﺟﺪاً&nbsp;) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ اﻛﺜﺮ ﻣﻦ 1 ﻓﻲ ﻛﻞ 10 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; اﻟﺸﻌﻮر ﺑﺎﻹﻋﯿﺎء ) اﻟﻐﺜﯿﺎن(</p><p dir="RTL">ﺷﺎﺋﻌﺔ ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ ﻛﻞ 10 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; إﻧﺴﺪاد أو ﺳﯿﻼن اﻷﻧﻒ ) إﻟﺘﮭﺎب اﻟﺠﯿﻮب اﻷﻧﻔﯿﺔ(</p><p dir="RTL">&middot;&nbsp; زﯾﺎدة أو ﻧﻘﺼﺎن اﻟﺸﮭﯿﺔ</p><p dir="RTL">&middot;&nbsp; اﻟﻘﻠﻖ ، ﻋﺪم اﻟﺮاﺣﺔ ، اﻷﺣﻼم اﻟﻤﺰﻋﺠﺔ ، اﻟﺪوﺧﺔ ، ﺻﻌﻮﺑﺎت ﻓﻰ اﻟﻨﻮم ، اﻟﺪوﺧﺔ ، اﻟﺘﺜﺎؤب,&nbsp;اﻟ&nbsp;ُﺮﻋﺎش,&nbsp;اﻟﺸﻌﻮر ﺑﺎﻟﻮﺧﺰ ﻓﻲ اﻟﺠﻠﺪ</p><p dir="RTL">&middot;&nbsp; اﻹﺳﮭﺎل ، اﻹﻣﺴﺎك، اﻟﻘﻲء، ﺟﻔﺎف اﻟﻔﻢ</p><p dir="RTL">&middot;&nbsp; زﯾﺎدة اﻟﺘﻌ&nbsp;ُﺮق</p><p dir="RTL">&middot;&nbsp; أﻟﻢ ﻓﻰ اﻟﻌﻀﻼت واﻟﻤﻔﺎﺻﻞ</p><p dir="RTL">&middot;&nbsp; اﻻﺿﻄﺮاﺑﺎت اﻟﺠﻨﺴﯿﺔ )ﺗﺄﺧﺮ اﻟﻘﺬف، ﻣﺸﺎﻛﻞ اﻻﻧﺘﺼﺎب، ﻗﻠﺔ اﻟﺮﻏﺒﺔ اﻟﺠﻨﺴﯿﺔ و ﻗﺪ ﯾﺤﺼﻞ ﺻﻌﻮﺑﺔ ﻓﻲ اﻟﺘﮭﯿﺞ اﻟﺠﻨﺴﻲ ﻟﺪى اﻟﻨﺴﺎء(</p><p dir="RTL">&middot;&nbsp; اﻟﻮھﻦ ، اﻟﺤﻤﻰ</p><p dir="RTL">&middot;&nbsp; زﯾﺎدة اﻟﻮزن</p><p dir="RTL">ﻏﯿﺮ ﺷﺎﺋﻌﺔ ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ ﻛﻞ 100 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; اﻟﻄﻔﺢ اﻟﻘﺮاﺻﻰ، اﻟﻄﻔﺢ اﻟﺠﻠﺪي، اﻟﺤﻜﺔ</p><p dir="RTL">&middot;&nbsp; طﺤﻦ اﻻﺳﻨﺎن ، اﻟﺘﮭﯿﺞ، اﻟﻌﺼﺒﯿﺔ ، ﻣﻮﺟﺎت ھﻠﻊ، ﺣﺎﻟﺔ ارﺗﺒﺎك</p><p dir="RTL">&middot;&nbsp; أﺿﻄﺮاب اﻟﻨﻮم, إﺿﻄﺮاب ﻓﻲ ﺣﺎﺳﺔ اﻟﺘﺬوق, اﻹﻏﻤﺎء</p><p dir="RTL">&middot;&nbsp; ﺗﻮﺳﻊ ﺣﺪﻗﺔ اﻟﻌﯿﻦ ، اﺿﻄﺮاب اﻟﺮؤﯾﺔ ، ﺟﺮﯾﺎن اﻟﺪﻣﻮع.</p><p dir="RTL">&middot;&nbsp; ﺗﺴﺎﻗﻂ اﻟﺸﻌﺮ</p><p dir="RTL">&middot;&nbsp; ازدﯾﺎد اﻟﻨﺰف ﺧﻼل اﻟﺪورة اﻟﺸﮭﺮﯾﺔ</p><p dir="RTL">&middot;&nbsp; ﻋﺪم اﻧﺘﻈﺎم ﻣﺪة اﻟﺪورة اﻟﺸﮭﺮﯾﺔ</p><p dir="RTL">&middot;&nbsp; ﻧﻘﺼﺎن اﻟﻮزن</p><p dir="RTL">&middot;&nbsp; ﺳﺮﻋﺔ ﺧﻔﻘﺎن اﻟﻘﻠﺐ</p><p dir="RTL">&middot;&nbsp; ﺗﻮرم اﻟﺬراﻋﯿﻦ او اﻟﺴﺎﻗﯿﻦ</p><p dir="RTL">&middot;&nbsp; ﻧﺰﯾﻒ اﻻﻧﻒ</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﻧﺎدرة ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ ﻛﻞ 1000 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; اﻟﻌﺪواﻧﯿﺔ ، ﻓﻘﺪان اﻟﺸﺨﺼﯿﺔ ، اﻟﮭﻠﻮﺳﺔ</p><p dir="RTL">&middot;&nbsp; ﺑُﻂء ﺧﻔﻘﺎن اﻟﻘﻠﺐ.</p><p dir="RTL">ﻏﯿﺮ ﻣﻌﺮوﻓﺔ ) ﻻ ﯾﻤﻜﻦ ﺗﻮﻗﻊ ﺗﻜﺮار ذﻟﻚ ﻣﻦ اﻟﻤﻌﻠﻮﻣﺎت اﻟﻤﺘﻮﻓﺮة:(</p><p dir="RTL">&middot;&nbsp; إﻧﺨﻔﺎض ﻣﺴﺘﻮى اﻟﺼﻮدﯾﻮم ﻓﻰ اﻟﺪم )ﻣﻦ أﻋﺮاض ذﻟﻚ اﻟﺸﻌﻮر ﺑﺎﻹﻋﯿﺎء ﻣﻊ وھﻦ اﻟﻌﻀﻼت او اﻻرﺗﺒﺎك(</p><p dir="RTL">&middot;&nbsp; اﻟﺪوﺧﺔ ﻋﻨﺪ اﻟﻮﻗﻮف ﺑﺴﺒﺐ إﻧﺨﻔﺎض ﺿﻐﻂ اﻟﺪم</p><p dir="RTL">&middot;&nbsp; إﺧﺘﻼل ﻓﻲ وظﺎﺋﻒ اﻟﻜﺒﺪ )زﯾﺎدة ﻛﻤﯿﺔ اﻧﺰﯾﻤﺎت اﻟﻜﺒﺪ ﻓﻰ اﻟﺪم (</p><p dir="RTL">&middot;&nbsp; اﺿﻄﺮاﺑﺎت اﻟﺤﺮﻛﺔ ) اﻟﺤﺮﻛﺎت اﻟﻼإرادﯾﺔ ﻟﻠﻌﻀﻼت(</p><p dir="RTL">&middot;&nbsp; أﻟﻢ ﻋﻨﺪ اﻹﻧﺘﺼﺎب ) اﻟﻘُﺴﺎح(</p><p dir="RTL">&middot;&nbsp; ﻋﻼﻣﺎت ﻧﺰﯾﻒ ﻏﯿﺮ طﺒﯿﻌﻲ ﻣﺜﻞ ﻣﻦ اﻟﺠﻠﺪ واﻷﻏﺸﯿﺔ اﻟﻤﺨﺎطﯿﺔ )اﻟﻜﺪﻣﺔ(</p><p dir="RTL">&middot;&nbsp; ﻧﺰﯾﻒ ﻣﮭﺒﻠﻲ ﻏﺰﯾﺮ ﺑﻌﺪ اﻟﻮﻻدة ﺑﻘﻠﯿﻞ )ﻧﺰﯾﻒ ﻣﺎ ﺑﻌﺪ اﻟﻮﻻدة( ، اﻧﻈﺮ &quot;اﻟﺤﻤﻞ و اﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ واﻟﺨﺼﻮﺑﺔ ﻓﻲ اﻟﻘﺴﻢ 2 ﻟﻤﺰﯾﺪ ﻣﻦ اﻟﻤﻌﻠﻮﻣﺎت.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_11" o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:41.1pt;margin-top:3.55pt;width:762.6pt;height:20.4pt;z-index:-15725568;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText align=right dir=RTL style='margin-left:274.35pt;
     text-align:left;direction:rtl;unicode-bidi:embed'><span dir=LTR
     style='font-size:18.0pt;font-family:"Courier New";color:#212121;
     letter-spacing:-.1pt'>•</span><span lang=AR-SA style='color:black;
     letter-spacing:-.1pt'>زﯾﺎدة</span><span lang=AR-SA style='color:black;
     letter-spacing:-.2pt'> </span><span lang=AR-SA style='color:black'>إﻓﺮاز<span
     style='letter-spacing:-.2pt'> </span>ھﺮﻣﻮن<span style='letter-spacing:
     -.15pt'> </span>ﯾﺴﻤﻰ<b><span style='letter-spacing:-.25pt'> </span></b></span><b><span
     dir=LTR style='color:black'>ADH</span></b><span dir=RTL></span><span
     style='color:black;letter-spacing:-.2pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>،<span style='letter-spacing:-.2pt'> </span>ﻣﻤﺎ<span
     style='letter-spacing:-.2pt'> </span>ﯾﺠﻌﻞ<span style='letter-spacing:-.15pt'>
     </span>اﻟﺠﺴﻢ<span style='letter-spacing:-.2pt'> </span>ﯾﺤﺘﻔﻆ<span
     style='letter-spacing:-.15pt'> </span>ﺑﺎﻟﻤﺎء<span style='letter-spacing:
     -.2pt'> </span>و<span style='letter-spacing:-.15pt'> </span>ﯾﺨﻔﻒ<span
     style='letter-spacing:-.15pt'> </span>اﻟﺪم<span style='letter-spacing:
     -.2pt'> </span>،<span style='letter-spacing:-.2pt'> </span>ﻣﻤﺎ<span
     style='letter-spacing:-.15pt'> </span>ﯾﻘﻠﻞ<span style='letter-spacing:
     -.2pt'> </span>ﻣﻦ<span style='letter-spacing:-.15pt'> </span>ﻛﻤﯿﺔ<span
     style='letter-spacing:-.2pt'> </span>اﻟﺼﻮدﯾﻮم<span style='letter-spacing:
     -.2pt'> </span></span><span dir=LTR></span><span dir=LTR style='color:
     black'><span dir=LTR></span>)</span><span lang=AR-SA style='color:black'>إﻓﺮاز<b><span
     style='letter-spacing:-.15pt'> </span></b></span><b><span dir=LTR
     style='color:black'>ADH</span></b><span dir=RTL></span><span
     style='color:black;letter-spacing:-.15pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>ﻏﯿﺮ<span style='letter-spacing:-.2pt'> </span>اﻟﻤﻨﺎﺳﺐ</span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>(<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="30" alt="Text Box: •زﯾﺎدة إﻓﺮاز ھﺮﻣﻮن ﯾﺴﻤﻰ ADH ، ﻣﻤﺎ ﯾﺠﻌﻞ اﻟﺠﺴﻢ ﯾﺤﺘﻔﻆ ﺑﺎﻟﻤﺎء و ﯾﺨﻔﻒ اﻟﺪم ، ﻣﻤﺎ ﯾﻘﻠﻞ ﻣﻦ ﻛﻤﯿﺔ اﻟﺼﻮدﯾﻮم )إﻓﺮاز ADH ﻏﯿﺮ اﻟﻤﻨﺎﺳﺐ(" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp; زﯾﺎدة ﻣﺴﺘﻮﯾﺎت ھﺮﻣﻮن اﻟﺒﺮوﻻﻛﺘﯿﻦ ﻓﻲ اﻟﺪم</p><p dir="RTL">&middot;&nbsp; ﺗﺪﻓﻖ اﻟﻠﺒﻦ ﻋﻨﺪ اﻟﺮﺟﺎل و اﻟﻨﺴﺎء اﻟﻐﯿﺮ ﻣﺮﺿﻌﺎت</p><p dir="RTL">&middot;&nbsp; اﻟﮭﻮس</p><p dir="RTL">&middot;&nbsp; ﻟﻮﺣﻆ إزدﯾﺎد إﺣﺘﻤﺎﻻت ﻣﺨﺎطﺮ ﻛﺴﻮر اﻟﻌﻈﺎم ﻟﺪى اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﺄﺧﺬون ﻣﺜﻞ ھﺬا اﻟﻨﻮع ﻣﻦ اﻷدوﯾﺔ.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_12" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:41.1pt;margin-top:11.3pt;width:762.6pt;height:36.7pt;z-index:-15725056;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText dir=RTL style='margin-right:1.4pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><span dir=LTR style='color:black;
     letter-spacing:-.5pt'>•</span><span dir=RTL></span><span style='color:
     black;letter-spacing:-.15pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>ﺗﻐﯿﯿﺮ<span style='letter-spacing:-.15pt'> </span>ﻓﻲ<span
     style='letter-spacing:-.2pt'> </span>ﻧﻈﻢ<span style='letter-spacing:-.15pt'>
     </span>اﻟﻘﻠﺐ<span style='letter-spacing:-.2pt'> </span></span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>)</span><span
     lang=AR-SA style='color:black'>ﯾﺴﻤﻰ<span style='letter-spacing:-.15pt'> </span></span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>&quot;</span><span
     lang=AR-SA style='color:black'>إطﺎﻟﺔ<span style='letter-spacing:-.15pt'> </span>ﻓﺘﺮة<span
     style='letter-spacing:-.2pt'> </span></span><span dir=LTR></span><span
     dir=LTR style='color:black'><span dir=LTR></span>&quot;QT</span><span
     dir=RTL></span><span style='color:black;letter-spacing:-.15pt'><span
     dir=RTL></span> </span><span lang=AR-SA style='color:black'>،<span
     style='letter-spacing:-.15pt'> </span>ﯾﻈﮭﺮ<span style='letter-spacing:
     -.2pt'> </span>ﻋﻠﻰ<span style='letter-spacing:-.15pt'> </span>ﺗﺨﻄﯿﻂ<span
     style='letter-spacing:-.2pt'> </span>اﻟﻘﻠﺐ</span><span dir=LTR
     style='color:black'><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:11.35pt;margin-right:4.1pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='color:black;
     letter-spacing:-.2pt'>ﻗﯿﺎس</span><span lang=AR-SA style='color:black;
     letter-spacing:-.25pt'> </span><span lang=AR-SA style='color:black'>اﻟﻨﺸﺎط<span
     style='letter-spacing:-.25pt'> </span>اﻟﻜﮭﺮﺑﺎﺋﻲ<span style='letter-spacing:
     -.3pt'> </span>ﻟﻠﻘﻠﺐ</span><span dir=LTR></span><span dir=LTR
     style='color:black'><span dir=LTR></span>.(<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="51" alt="Text Box: • ﺗﻐﯿﯿﺮ ﻓﻲ ﻧﻈﻢ اﻟﻘﻠﺐ )ﯾﺴﻤﻰ &quot;إطﺎﻟﺔ ﻓﺘﺮة &quot;QT ، ﯾﻈﮭﺮ ﻋﻠﻰ ﺗﺨﻄﯿﻂ اﻟﻘﻠﺐ
ﻗﯿﺎس اﻟﻨﺸﺎط اﻟﻜﮭﺮﺑﺎﺋﻲ ﻟﻠﻘﻠﺐ.(
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﯾﻀﺎف إﻟﻰ ذﻟﻚ، ﻋﺪد ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﻌﻠﻮم ﺣﺪوﺛﮭﺎ ﻣﻊ اﻷدوﯾﺔ اﻟﺘﻰ ﺗﻌﻤﻞ ﺑﻨﻔﺲ اﻟﻄﺮﯾﻘﺔ اﻟﺘﻲ ﯾﻌﻤﻞ ﺑﮭﺎ اس ﺳﺘﺎﻟﻮﺑﺮام ) اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻲ ﻣﺴﺘﺤﻀﺮ ﺳﺒﺮاﻟﯿﻜﺲ( ﻛﺎﻟﺘﺎﻟﻲ:</p><p dir="RTL">&middot;&nbsp; اﻟﺘﻤﻠﻞ ﻣﻦ اﻟﺠﻠﻮس</p><p dir="RTL">&middot;&nbsp; ﻓﻘﺪان اﻟﺸﮭﯿﺔ</p><p>&nbsp;</p><p>ﻓﻲ ﺣﺎﻟﺔ ﺣﺪوث أي اﺛﺎر ﺟﺎﻧﺒﯿﺔ ﻓﯿﺮﺟﻰ إﺧﺒﺎر اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ. ھﺬا ﯾﺸﻤﻞ اﻻﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﻰ ﻟﻢ ﺗﺬﻛﺮ ﻓﻲ ھﺬه اﻟﻨﺸﺮة.</p><p dir="RTL">ﻣﺜﻞ&nbsp;ﺟﻤﯿﻊ اﻷدوﯾﺔ ، ﻗﺪ ﯾُﺴﺒﺐ ھﺬا اﻟﺪواء ﺑﻌﺾ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ و ﻻ ﯾﺤﺼﻞ ذﻟﻚ ﻣﻊ ﻛﻞ اﻟﻤﺮﺿﻰ.</p><p dir="RTL">ھﺬه اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ ﻋﺎدةً&nbsp;ﺗﺘﻼﺷﻰ ﺑﻌﺪ أﺳﺎﺑﯿﻊ ﻗﻠﯿﻠﺔ ﻣﻦ اﻟﻌﻼج. و ﯾﺠﺐ أن ﺗﻌﻠﻢ ﺑﺄن اﻟﻜﺜﯿﺮ ھﺬه اﻷﺛﺎر ﻗﺪ ﺗﻜﻮن ﻣﻦ أﻋﺮاض ﻣﺮﺿﻚ و وﺳﻮف ﺗﺘﺤﺴﻦ ﻣﻊ اﻟﻌﻼج .</p><p>&nbsp;</p><p>&nbsp;</p><p>ٌي ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﺎﻟﯿﺔ ﻋﻠﯿﻚ ﺧﻼل ﻓﺘﺮة اﻟﻌﻼج:</p><p>&nbsp;</p><p dir="RTL"><strong>راﺟﻊ طﺒﯿﺒﻚ ﻓﻲ ﺣﺎﻟﺔ ظﮭﻮر أ</strong></p><p>&nbsp;</p><p dir="RTL">ﻏﯿﺮ ﺷﺎﺋﻌﺔ ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ 100 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; ﻧﺰﯾﻒ ﻏﯿﺮ ُﻣﻌﺘﺎد ، وﯾﺸﻤﻞ اﻟﻨﺰﯾﻒ اﻟﻤ ِﻌﺪي أو اﻟﻤﻌﻮي.</p><p dir="RTL">ﻧﺎدرة ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ 1000 ﻣﺴﺘﺨﺪم( :</p><p dir="RTL">&middot;&nbsp; ﺗﻮرم ﻓﻲ اﻟﺠﻠﺪ أو اﻟﻠﺴﺎن أو اﻟﺸﻔﺎه أو اﻟﺒﻠﻌﻮم أو اﻟﻮﺟﮫ أو ﺷﻌﺮت ﺑﺼﻌﻮﺑﺎت ﻓﻲ اﻟﺘﻨﻔﺲ أو اﻟﺒﻠﻊ ، ﻓﺄﺗﺼﻞ ﺑﺎﻟﻄﺒﯿﺐ او ﺗﻮﺟﮫ إﻟﻰ اﻟﻤﺴﺘﺸﻔﻰ ﻣﺒﺎﺷﺮةً.</p><p>&nbsp;</p><p dir="RTL">ُﻣﺘﻼزﻣﺔ اﻟﺴﯿﺮوﺗﻮﻧﯿﻦ.</p><p>&nbsp;</p><p dir="RTL">ُﺤﻤﻰ&nbsp;أو ﺳﺮﻋﺔ اﻟﻐﻀﺐ أو اﻻرﺗﺒﺎك أو إرﺗﻌﺎش أو ﺗﻘﻠﺼﺎت ﻟﻠﻌﻀﻼت، ﻓﺈن ذﻟﻚ ﻗﺪ ﯾﻜﻮن ﻋﻼﻣﺔ ﻟﺤﺎﻟﺔ ﺗﺴﻤﻰ</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; اذا ﺷﻌﺮت ﺑﺎﻟ</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Textbox_x0020_8" o:spid="_x0000_s1030" type="#_x0000_t202"
 style='width:762.6pt;height:12.7pt;visibility:visible;mso-wrap-style:square;
 mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText dir=RTL style='margin-right:1.4pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='color:black;
    letter-spacing:-.25pt'>ﻏﯿﺮ</span><span lang=AR-SA style='color:black;
    letter-spacing:-.2pt'> </span><span lang=AR-SA style='color:black'>ﻣﻌﺮوف<span
    style='letter-spacing:-.2pt'> </span></span><span dir=LTR></span><span
    dir=LTR style='color:black'><span dir=LTR></span>)</span><span lang=AR-SA
    style='color:black'>ﻻ<span style='letter-spacing:-.2pt'> </span>ﯾﻤﻜﻦ<span
    style='letter-spacing:-.2pt'> </span>ﺗﻘﺪﯾﺮ<span style='letter-spacing:-.2pt'>
    </span>اﻟﺘﻜﺮار<span style='letter-spacing:-.2pt'> </span>ﻣﻦ<span
    style='letter-spacing:-.2pt'> </span>اﻟﺒﯿﺎﻧﺎت<span style='letter-spacing:
    -.25pt'> </span>اﻟﻤﺘﺎﺣﺔ</span><span dir=LTR></span><span dir=LTR
    style='color:black'><span dir=LTR></span>:(<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="1019" height="19" alt="Text Box: ﻏﯿﺮ ﻣﻌﺮوف )ﻻ ﯾﻤﻜﻦ ﺗﻘﺪﯾﺮ اﻟﺘﻜﺮار ﻣﻦ اﻟﺒﯿﺎﻧﺎت اﻟﻤﺘﺎﺣﺔ:(" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:762.6pt;height:12.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">اﻟﺘﺤﺬﯾﺮات واﻻﺣﺘﯿﺎطﺎت</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; ﺻﻌﻮﺑﺔ اﻟﺘﺒﻮل</p><p dir="RTL">&middot;&nbsp; ﻧﻮﺑﺎت اﻟﺼﺮع، اﻗﺮأ اﻟﻘﺴﻢ 2 اﻟﺨﺎص ﺑـ</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp; اﺻﻔﺮار اﻟﺠﻠﺪ و إﺑﯿﻀﺎض اﻟﻌﯿﻦ ھﻲ ﻋﻼﻣﺎت ﻋﻠﻰ إﺧﺘﻼل وظﺎﺋﻒ اﻟﻜﺒﺪ أو إﻟﺘﮭﺎب اﻟﻜﺒﺪ اﻟﻮﺑﺎﺋﻲ.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_9" o:spid="_x0000_s1029" type="#_x0000_t202" style='position:absolute;
  margin-left:41.1pt;margin-top:11.3pt;width:762.6pt;height:36.7pt;z-index:-15726592;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText dir=RTL style='margin-right:1.35pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><span dir=LTR style='color:black;
     letter-spacing:-.5pt'>•</span><span dir=RTL></span><span style='color:
     black;letter-spacing:-.15pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>ﻋﺪم<span style='letter-spacing:-.15pt'> </span>اﻧﺘﻈﺎم<span
     style='letter-spacing:-.15pt'> </span>ﺿﺮﺑﺎت<span style='letter-spacing:
     -.2pt'> </span>اﻟﻘﻠﺐ<span style='letter-spacing:-.15pt'> </span>،<span
     style='letter-spacing:-.2pt'> </span>واﻹﻏﻤﺎء<span style='letter-spacing:
     -.15pt'> </span>اﻟﺬي<span style='letter-spacing:-.2pt'> </span>ﻗﺪ<span
     style='letter-spacing:-.15pt'> </span>ﯾﻜﻮن<span style='letter-spacing:
     -.2pt'> </span>ﻣﻦ<span style='letter-spacing:-.15pt'> </span>اﻷﻋﺮاض<span
     style='letter-spacing:-.2pt'> </span>اﻟﺘﻲ<span style='letter-spacing:-.15pt'>
     </span>ﺗﮭﺪد<span style='letter-spacing:-.2pt'> </span>اﻟﺤﯿﺎة</span><span
     dir=LTR style='color:black'><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:11.35pt;margin-right:4.15pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='color:black;
     letter-spacing:-.2pt'>ﺣﺎﻟﺔ </span><span lang=AR-SA style='color:black'>ﺗﻌﺮف<span
     style='letter-spacing:-.2pt'> </span>ﺑﺎﺳﻢ<span style='letter-spacing:-.15pt'>
     </span>ﺗﻮرﺳﺎد<span style='letter-spacing:-.2pt'> </span>دي<span
     style='letter-spacing:-.2pt'> </span>ﺑﻮاﻧﺖ</span><span dir=LTR
     style='color:black'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="51" alt="Text Box: • ﻋﺪم اﻧﺘﻈﺎم ﺿﺮﺑﺎت اﻟﻘﻠﺐ ، واﻹﻏﻤﺎء اﻟﺬي ﻗﺪ ﯾﻜﻮن ﻣﻦ اﻷﻋﺮاض اﻟﺘﻲ ﺗﮭﺪد اﻟﺤﯿﺎة
ﺣﺎﻟﺔ ﺗﻌﺮف ﺑﺎﺳﻢ ﺗﻮرﺳﺎد دي ﺑﻮاﻧﺖ
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:shape
 id="Textbox_x0020_10" o:spid="_x0000_s1028" type="#_x0000_t202" style='width:762.6pt;
 height:48pt;visibility:visible;mso-wrap-style:square;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText dir=RTL style='margin-top:11.3pt;margin-right:4.15pt;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span dir=LTR style='color:black;
    position:relative;top:-.5pt;mso-text-raise:.5pt;letter-spacing:-.5pt'>•</span><span
    dir=RTL></span><span style='color:black;position:relative;top:-.5pt;
    mso-text-raise:.5pt;letter-spacing:-.3pt'><span dir=RTL></span><span
    style='mso-spacerun:yes'> </span></span><span lang=AR-SA style='color:black;
    position:relative;top:-.5pt;mso-text-raise:.5pt'>أﻓﻜﺎر<span
    style='letter-spacing:-.3pt'> </span>ﻹﯾﺬاء<span style='letter-spacing:-.25pt'>
    </span>ﻧﻔﺴﻚ<span style='letter-spacing:-.3pt'> </span>أو<span
    style='letter-spacing:-.3pt'> </span>ﻗﺘﻞ<span style='letter-spacing:-.3pt'>
    </span>ﻧﻔﺴﻚ<span style='letter-spacing:-.35pt'> </span>،<span
    style='letter-spacing:-.3pt'> </span>اﻧﻈﺮ<span style='letter-spacing:-.3pt'>
    </span>أﯾ</span><span lang=AR-SA style='color:black;letter-spacing:3.7pt;
    mso-font-width:150%'><span style='mso-spacerun:yes'> </span></span><span
    lang=AR-SA style='color:black;letter-spacing:-4.4pt'>ً<span
    style='position:relative;top:-.5pt;mso-text-raise:.5pt'>ﻀﺎ</span></span><span
    lang=AR-SA style='color:black;position:relative;top:-.5pt;mso-text-raise:
    .5pt;letter-spacing:-.3pt'><span style='mso-spacerun:yes'> </span></span><span
    lang=AR-SA style='color:black;position:relative;top:-.5pt;mso-text-raise:
    .5pt'>اﻟﻘﺴﻢ<span style='letter-spacing:-.3pt'> </span></span><span dir=LTR></span><span
    dir=LTR style='color:black;position:relative;top:-.5pt;mso-text-raise:.5pt'><span
    dir=LTR></span>2</span><span dir=RTL></span><span style='color:black;
    position:relative;top:-.5pt;mso-text-raise:.5pt;letter-spacing:-.25pt'><span
    dir=RTL></span><span style='mso-spacerun:yes'> </span></span><span dir=LTR></span><span
    dir=LTR style='color:black;position:relative;top:-.5pt;mso-text-raise:.5pt'><span
    dir=LTR></span>&quot;</span><span lang=AR-SA style='color:black;position:
    relative;top:-.5pt;mso-text-raise:.5pt'>ﺗﺤﺬﯾﺮات<span style='letter-spacing:
    -.3pt'> </span>واﻻﺣﺘﯿﺎطﺎت</span><span dir=LTR></span><span dir=LTR
    style='color:black;position:relative;top:-.5pt;mso-text-raise:.5pt'><span
    dir=LTR></span>&quot;</span><span dir=LTR style='color:black'><o:p></o:p></span></p>
    <p class=MsoBodyText dir=RTL style='margin-top:10.85pt;margin-right:1.4pt;
    margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
    direction:rtl;unicode-bidi:embed'><span dir=LTR style='color:black;
    letter-spacing:-.5pt'>•</span><span dir=RTL></span><span style='color:black;
    letter-spacing:-.2pt'><span dir=RTL></span> </span><span lang=AR-SA
    style='color:black'>ﺗﻮرم<span style='letter-spacing:-.2pt'> </span>ﻣﻔﺎﺟﺊ<span
    style='letter-spacing:-.2pt'> </span>ﻓﻲ<span style='letter-spacing:-.2pt'> </span>اﻟﺠﻠﺪ<span
    style='letter-spacing:-.15pt'> </span>أو<span style='letter-spacing:-.2pt'>
    </span>اﻟﻐﺸﺎء<span style='letter-spacing:-.2pt'> </span>اﻟﻤﺨﺎطﻲ<span
    style='letter-spacing:-.2pt'> </span></span><span dir=LTR></span><span
    dir=LTR style='color:black'><span dir=LTR></span>)</span><span lang=AR-SA
    style='color:black'>وذﻣﺔ<span style='letter-spacing:-.2pt'> </span>وﻋﺎﺋﯿﺔ</span><span
    dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>(<o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="1019" height="67" alt="Text Box: • أﻓﻜﺎر ﻹﯾﺬاء ﻧﻔﺴﻚ أو ﻗﺘﻞ ﻧﻔﺴﻚ ، اﻧﻈﺮ أﯾ ًﻀﺎ اﻟﻘﺴﻢ 2 &quot;ﺗﺤﺬﯾﺮات واﻻﺣﺘﯿﺎطﺎت&quot;
• ﺗﻮرم ﻣﻔﺎﺟﺊ ﻓﻲ اﻟﺠﻠﺪ أو اﻟﻐﺸﺎء اﻟﻤﺨﺎطﻲ )وذﻣﺔ وﻋﺎﺋﯿﺔ(
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:762.6pt;height:48pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>&nbsp;</p><p>ﺑﺎﻻﺿﺎﻓﺔ اﻟﻰ اﻵﺛﺎراﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺬﻛﻮرة ﺑﺎﻷﻋﻠﻰ ﻓﻘﺪ ﺗﻢ رﺻﺪ ﺑﻌﺾ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻹﺿﺎﻓﯿﺔ ﻛﺎﻟﺘﺎﻟﻲ:</p><p dir="RTL">ﺷﺎﺋﻌﺔ ﺟﺪاً&nbsp;) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ اﻛﺜﺮ ﻣﻦ 1 ﻓﻲ ﻛﻞ 10 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; اﻟﺸﻌﻮر ﺑﺎﻹﻋﯿﺎء ) اﻟﻐﺜﯿﺎن(</p><p dir="RTL">ﺷﺎﺋﻌﺔ ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ ﻛﻞ 10 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; إﻧﺴﺪاد أو ﺳﯿﻼن اﻷﻧﻒ ) إﻟﺘﮭﺎب اﻟﺠﯿﻮب اﻷﻧﻔﯿﺔ(</p><p dir="RTL">&middot;&nbsp; زﯾﺎدة أو ﻧﻘﺼﺎن اﻟﺸﮭﯿﺔ</p><p dir="RTL">&middot;&nbsp; اﻟﻘﻠﻖ ، ﻋﺪم اﻟﺮاﺣﺔ ، اﻷﺣﻼم اﻟﻤﺰﻋﺠﺔ ، اﻟﺪوﺧﺔ ، ﺻﻌﻮﺑﺎت ﻓﻰ اﻟﻨﻮم ، اﻟﺪوﺧﺔ ، اﻟﺘﺜﺎؤب,&nbsp;اﻟ&nbsp;ُﺮﻋﺎش,&nbsp;اﻟﺸﻌﻮر ﺑﺎﻟﻮﺧﺰ ﻓﻲ اﻟﺠﻠﺪ</p><p dir="RTL">&middot;&nbsp; اﻹﺳﮭﺎل ، اﻹﻣﺴﺎك، اﻟﻘﻲء، ﺟﻔﺎف اﻟﻔﻢ</p><p dir="RTL">&middot;&nbsp; زﯾﺎدة اﻟﺘﻌ&nbsp;ُﺮق</p><p dir="RTL">&middot;&nbsp; أﻟﻢ ﻓﻰ اﻟﻌﻀﻼت واﻟﻤﻔﺎﺻﻞ</p><p dir="RTL">&middot;&nbsp; اﻻﺿﻄﺮاﺑﺎت اﻟﺠﻨﺴﯿﺔ )ﺗﺄﺧﺮ اﻟﻘﺬف، ﻣﺸﺎﻛﻞ اﻻﻧﺘﺼﺎب، ﻗﻠﺔ اﻟﺮﻏﺒﺔ اﻟﺠﻨﺴﯿﺔ و ﻗﺪ ﯾﺤﺼﻞ ﺻﻌﻮﺑﺔ ﻓﻲ اﻟﺘﮭﯿﺞ اﻟﺠﻨﺴﻲ ﻟﺪى اﻟﻨﺴﺎء(</p><p dir="RTL">&middot;&nbsp; اﻟﻮھﻦ ، اﻟﺤﻤﻰ</p><p dir="RTL">&middot;&nbsp; زﯾﺎدة اﻟﻮزن</p><p dir="RTL">ﻏﯿﺮ ﺷﺎﺋﻌﺔ ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ ﻛﻞ 100 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; اﻟﻄﻔﺢ اﻟﻘﺮاﺻﻰ، اﻟﻄﻔﺢ اﻟﺠﻠﺪي، اﻟﺤﻜﺔ</p><p dir="RTL">&middot;&nbsp; طﺤﻦ اﻻﺳﻨﺎن ، اﻟﺘﮭﯿﺞ، اﻟﻌﺼﺒﯿﺔ ، ﻣﻮﺟﺎت ھﻠﻊ، ﺣﺎﻟﺔ ارﺗﺒﺎك</p><p dir="RTL">&middot;&nbsp; أﺿﻄﺮاب اﻟﻨﻮم, إﺿﻄﺮاب ﻓﻲ ﺣﺎﺳﺔ اﻟﺘﺬوق, اﻹﻏﻤﺎء</p><p dir="RTL">&middot;&nbsp; ﺗﻮﺳﻊ ﺣﺪﻗﺔ اﻟﻌﯿﻦ ، اﺿﻄﺮاب اﻟﺮؤﯾﺔ ، ﺟﺮﯾﺎن اﻟﺪﻣﻮع.</p><p dir="RTL">&middot;&nbsp; ﺗﺴﺎﻗﻂ اﻟﺸﻌﺮ</p><p dir="RTL">&middot;&nbsp; ازدﯾﺎد اﻟﻨﺰف ﺧﻼل اﻟﺪورة اﻟﺸﮭﺮﯾﺔ</p><p dir="RTL">&middot;&nbsp; ﻋﺪم اﻧﺘﻈﺎم ﻣﺪة اﻟﺪورة اﻟﺸﮭﺮﯾﺔ</p><p dir="RTL">&middot;&nbsp; ﻧﻘﺼﺎن اﻟﻮزن</p><p dir="RTL">&middot;&nbsp; ﺳﺮﻋﺔ ﺧﻔﻘﺎن اﻟﻘﻠﺐ</p><p dir="RTL">&middot;&nbsp; ﺗﻮرم اﻟﺬراﻋﯿﻦ او اﻟﺴﺎﻗﯿﻦ</p><p dir="RTL">&middot;&nbsp; ﻧﺰﯾﻒ اﻻﻧﻒ</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﻧﺎدرة ) ﻗﺪ ﯾﺆﺛﺮ ﻓﻲ 1 ﻣﻦ ﻛﻞ 1000 ﻣﺴﺘﺨﺪم:(</p><p dir="RTL">&middot;&nbsp; اﻟﻌﺪواﻧﯿﺔ ، ﻓﻘﺪان اﻟﺸﺨﺼﯿﺔ ، اﻟﮭﻠﻮﺳﺔ</p><p dir="RTL">&middot;&nbsp; ﺑُﻂء ﺧﻔﻘﺎن اﻟﻘﻠﺐ.</p><p dir="RTL">ﻏﯿﺮ ﻣﻌﺮوﻓﺔ ) ﻻ ﯾﻤﻜﻦ ﺗﻮﻗﻊ ﺗﻜﺮار ذﻟﻚ ﻣﻦ اﻟﻤﻌﻠﻮﻣﺎت اﻟﻤﺘﻮﻓﺮة:(</p><p dir="RTL">&middot;&nbsp; إﻧﺨﻔﺎض ﻣﺴﺘﻮى اﻟﺼﻮدﯾﻮم ﻓﻰ اﻟﺪم )ﻣﻦ أﻋﺮاض ذﻟﻚ اﻟﺸﻌﻮر ﺑﺎﻹﻋﯿﺎء ﻣﻊ وھﻦ اﻟﻌﻀﻼت او اﻻرﺗﺒﺎك(</p><p dir="RTL">&middot;&nbsp; اﻟﺪوﺧﺔ ﻋﻨﺪ اﻟﻮﻗﻮف ﺑﺴﺒﺐ إﻧﺨﻔﺎض ﺿﻐﻂ اﻟﺪم</p><p dir="RTL">&middot;&nbsp; إﺧﺘﻼل ﻓﻲ وظﺎﺋﻒ اﻟﻜﺒﺪ )زﯾﺎدة ﻛﻤﯿﺔ اﻧﺰﯾﻤﺎت اﻟﻜﺒﺪ ﻓﻰ اﻟﺪم (</p><p dir="RTL">&middot;&nbsp; اﺿﻄﺮاﺑﺎت اﻟﺤﺮﻛﺔ ) اﻟﺤﺮﻛﺎت اﻟﻼإرادﯾﺔ ﻟﻠﻌﻀﻼت(</p><p dir="RTL">&middot;&nbsp; أﻟﻢ ﻋﻨﺪ اﻹﻧﺘﺼﺎب ) اﻟﻘُﺴﺎح(</p><p dir="RTL">&middot;&nbsp; ﻋﻼﻣﺎت ﻧﺰﯾﻒ ﻏﯿﺮ طﺒﯿﻌﻲ ﻣﺜﻞ ﻣﻦ اﻟﺠﻠﺪ واﻷﻏﺸﯿﺔ اﻟﻤﺨﺎطﯿﺔ )اﻟﻜﺪﻣﺔ(</p><p dir="RTL">&middot;&nbsp; ﻧﺰﯾﻒ ﻣﮭﺒﻠﻲ ﻏﺰﯾﺮ ﺑﻌﺪ اﻟﻮﻻدة ﺑﻘﻠﯿﻞ )ﻧﺰﯾﻒ ﻣﺎ ﺑﻌﺪ اﻟﻮﻻدة( ، اﻧﻈﺮ &quot;اﻟﺤﻤﻞ و اﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ واﻟﺨﺼﻮﺑﺔ ﻓﻲ اﻟﻘﺴﻢ 2 ﻟﻤﺰﯾﺪ ﻣﻦ اﻟﻤﻌﻠﻮﻣﺎت.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_11" o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;
  margin-left:41.1pt;margin-top:3.55pt;width:762.6pt;height:20.4pt;z-index:-15725568;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText align=right dir=RTL style='margin-left:274.35pt;
     text-align:left;direction:rtl;unicode-bidi:embed'><span dir=LTR
     style='font-size:18.0pt;font-family:"Courier New";color:#212121;
     letter-spacing:-.1pt'>•</span><span lang=AR-SA style='color:black;
     letter-spacing:-.1pt'>زﯾﺎدة</span><span lang=AR-SA style='color:black;
     letter-spacing:-.2pt'> </span><span lang=AR-SA style='color:black'>إﻓﺮاز<span
     style='letter-spacing:-.2pt'> </span>ھﺮﻣﻮن<span style='letter-spacing:
     -.15pt'> </span>ﯾﺴﻤﻰ<b><span style='letter-spacing:-.25pt'> </span></b></span><b><span
     dir=LTR style='color:black'>ADH</span></b><span dir=RTL></span><span
     style='color:black;letter-spacing:-.2pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>،<span style='letter-spacing:-.2pt'> </span>ﻣﻤﺎ<span
     style='letter-spacing:-.2pt'> </span>ﯾﺠﻌﻞ<span style='letter-spacing:-.15pt'>
     </span>اﻟﺠﺴﻢ<span style='letter-spacing:-.2pt'> </span>ﯾﺤﺘﻔﻆ<span
     style='letter-spacing:-.15pt'> </span>ﺑﺎﻟﻤﺎء<span style='letter-spacing:
     -.2pt'> </span>و<span style='letter-spacing:-.15pt'> </span>ﯾﺨﻔﻒ<span
     style='letter-spacing:-.15pt'> </span>اﻟﺪم<span style='letter-spacing:
     -.2pt'> </span>،<span style='letter-spacing:-.2pt'> </span>ﻣﻤﺎ<span
     style='letter-spacing:-.15pt'> </span>ﯾﻘﻠﻞ<span style='letter-spacing:
     -.2pt'> </span>ﻣﻦ<span style='letter-spacing:-.15pt'> </span>ﻛﻤﯿﺔ<span
     style='letter-spacing:-.2pt'> </span>اﻟﺼﻮدﯾﻮم<span style='letter-spacing:
     -.2pt'> </span></span><span dir=LTR></span><span dir=LTR style='color:
     black'><span dir=LTR></span>)</span><span lang=AR-SA style='color:black'>إﻓﺮاز<b><span
     style='letter-spacing:-.15pt'> </span></b></span><b><span dir=LTR
     style='color:black'>ADH</span></b><span dir=RTL></span><span
     style='color:black;letter-spacing:-.15pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>ﻏﯿﺮ<span style='letter-spacing:-.2pt'> </span>اﻟﻤﻨﺎﺳﺐ</span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>(<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="30" alt="Text Box: •زﯾﺎدة إﻓﺮاز ھﺮﻣﻮن ﯾﺴﻤﻰ ADH ، ﻣﻤﺎ ﯾﺠﻌﻞ اﻟﺠﺴﻢ ﯾﺤﺘﻔﻆ ﺑﺎﻟﻤﺎء و ﯾﺨﻔﻒ اﻟﺪم ، ﻣﻤﺎ ﯾﻘﻠﻞ ﻣﻦ ﻛﻤﯿﺔ اﻟﺼﻮدﯾﻮم )إﻓﺮاز ADH ﻏﯿﺮ اﻟﻤﻨﺎﺳﺐ(" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&middot;&nbsp; زﯾﺎدة ﻣﺴﺘﻮﯾﺎت ھﺮﻣﻮن اﻟﺒﺮوﻻﻛﺘﯿﻦ ﻓﻲ اﻟﺪم</p><p dir="RTL">&middot;&nbsp; ﺗﺪﻓﻖ اﻟﻠﺒﻦ ﻋﻨﺪ اﻟﺮﺟﺎل و اﻟﻨﺴﺎء اﻟﻐﯿﺮ ﻣﺮﺿﻌﺎت</p><p dir="RTL">&middot;&nbsp; اﻟﮭﻮس</p><p dir="RTL">&middot;&nbsp; ﻟﻮﺣﻆ إزدﯾﺎد إﺣﺘﻤﺎﻻت ﻣﺨﺎطﺮ ﻛﺴﻮر اﻟﻌﻈﺎم ﻟﺪى اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﺄﺧﺬون ﻣﺜﻞ ھﺬا اﻟﻨﻮع ﻣﻦ اﻷدوﯾﺔ.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_12" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:41.1pt;margin-top:11.3pt;width:762.6pt;height:36.7pt;z-index:-15725056;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="#f8f9f9" stroked="f">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText dir=RTL style='margin-right:1.4pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><span dir=LTR style='color:black;
     letter-spacing:-.5pt'>•</span><span dir=RTL></span><span style='color:
     black;letter-spacing:-.15pt'><span dir=RTL></span> </span><span
     lang=AR-SA style='color:black'>ﺗﻐﯿﯿﺮ<span style='letter-spacing:-.15pt'> </span>ﻓﻲ<span
     style='letter-spacing:-.2pt'> </span>ﻧﻈﻢ<span style='letter-spacing:-.15pt'>
     </span>اﻟﻘﻠﺐ<span style='letter-spacing:-.2pt'> </span></span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>)</span><span
     lang=AR-SA style='color:black'>ﯾﺴﻤﻰ<span style='letter-spacing:-.15pt'> </span></span><span
     dir=LTR></span><span dir=LTR style='color:black'><span dir=LTR></span>&quot;</span><span
     lang=AR-SA style='color:black'>إطﺎﻟﺔ<span style='letter-spacing:-.15pt'> </span>ﻓﺘﺮة<span
     style='letter-spacing:-.2pt'> </span></span><span dir=LTR></span><span
     dir=LTR style='color:black'><span dir=LTR></span>&quot;QT</span><span
     dir=RTL></span><span style='color:black;letter-spacing:-.15pt'><span
     dir=RTL></span> </span><span lang=AR-SA style='color:black'>،<span
     style='letter-spacing:-.15pt'> </span>ﯾﻈﮭﺮ<span style='letter-spacing:
     -.2pt'> </span>ﻋﻠﻰ<span style='letter-spacing:-.15pt'> </span>ﺗﺨﻄﯿﻂ<span
     style='letter-spacing:-.2pt'> </span>اﻟﻘﻠﺐ</span><span dir=LTR
     style='color:black'><o:p></o:p></span></p>
     <p class=MsoBodyText dir=RTL style='margin-top:11.35pt;margin-right:4.1pt;
     margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;text-align:right;
     direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='color:black;
     letter-spacing:-.2pt'>ﻗﯿﺎس</span><span lang=AR-SA style='color:black;
     letter-spacing:-.25pt'> </span><span lang=AR-SA style='color:black'>اﻟﻨﺸﺎط<span
     style='letter-spacing:-.25pt'> </span>اﻟﻜﮭﺮﺑﺎﺋﻲ<span style='letter-spacing:
     -.3pt'> </span>ﻟﻠﻘﻠﺐ</span><span dir=LTR></span><span dir=LTR
     style='color:black'><span dir=LTR></span>.(<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="1019" height="51" alt="Text Box: • ﺗﻐﯿﯿﺮ ﻓﻲ ﻧﻈﻢ اﻟﻘﻠﺐ )ﯾﺴﻤﻰ &quot;إطﺎﻟﺔ ﻓﺘﺮة &quot;QT ، ﯾﻈﮭﺮ ﻋﻠﻰ ﺗﺨﻄﯿﻂ اﻟﻘﻠﺐ
ﻗﯿﺎس اﻟﻨﺸﺎط اﻟﻜﮭﺮﺑﺎﺋﻲ ﻟﻠﻘﻠﺐ.(
" src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﯾﻀﺎف إﻟﻰ ذﻟﻚ، ﻋﺪد ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﻌﻠﻮم ﺣﺪوﺛﮭﺎ ﻣﻊ اﻷدوﯾﺔ اﻟﺘﻰ ﺗﻌﻤﻞ ﺑﻨﻔﺲ اﻟﻄﺮﯾﻘﺔ اﻟﺘﻲ ﯾﻌﻤﻞ ﺑﮭﺎ اس ﺳﺘﺎﻟﻮﺑﺮام ) اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ﻓﻲ ﻣﺴﺘﺤﻀﺮ ﺳﺒﺮاﻟﯿﻜﺲ( ﻛﺎﻟﺘﺎﻟﻲ:</p><p dir="RTL">&middot;&nbsp; اﻟﺘﻤﻠﻞ ﻣﻦ اﻟﺠﻠﻮس</p><p dir="RTL">&middot;&nbsp; ﻓﻘﺪان اﻟﺸﮭﯿﺔ</p><p>&nbsp;</p><p>ﻓﻲ ﺣﺎﻟﺔ ﺣﺪوث أي اﺛﺎر ﺟﺎﻧﺒﯿﺔ ﻓﯿﺮﺟﻰ إﺧﺒﺎر اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ. ھﺬا ﯾﺸﻤﻞ اﻻﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﻰ ﻟﻢ ﺗﺬﻛﺮ ﻓﻲ ھﺬه اﻟﻨﺸﺮة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﯾُﺤﻔﻆ ﺑﻌﯿﺪاً&nbsp;ﻋﻦ ُﻣﺘﻨﺎول اﻷطﻔﺎل.</p><p dir="RTL">ﻻ ﺗﺴﺘﺨﺪم ھﺬا اﻟﺪواء ﺑﻌﺪ إﻧﺘﮭﺎء ﺗﺎرﯾﺦ اﻟﺼﻼﺣﯿﺔ و اﻟﻤﻜﺘﻮب ﻋﻠﻰ اﻟﻌﻠﺒﺔ اﻟﺨﺎرﺟﯿﺔ ﺑﻌﺪ ﻛﻠﻤﺔ EXP . ﺗﺎرﯾﺦ اﻹﻧﺘﮭﺎء ﯾﺸﯿﺮ اﻟﻰ آﺧﺮ ﯾﻮم ﻓﻰ اﻟﺸﮭﺮ.</p><p dir="RTL">ﯾُﺤﻔﻆ&nbsp;ﻓﻲ درﺟﺔ ﺣﺮارة أﻗﻞ ﻣﻦ 30&nbsp;درﺟﺔ ﻣﺌﻮﯾﺔ.</p><p dir="RTL">ﯾﺠﺐ ﻋﺪم اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ ﻣﻦ ﺧﻼل ﻣﺠﺎري اﻟﻤﯿﺎة أو اﻟﻨﻔﺎﯾﺎت اﻟﻤﻨﺰﻟﯿﺔ . إﺳﺎل اﻟﺼﯿﺪﻟﻲ ﻋﻦ ﻛﯿﻔﯿﺔ اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ اﻟﺘﻲ ﻟﻢ ﺗﻌﺪ ﺗﺴﺘﺨﺪﻣﮭﺎ. ھﺬه اﻹﺟﺮاءات ﺗﺴﺎﻋﺪ ﻓﻰ ﺣﻤﺎﯾﺔ اﻟﺒﯿﺌﺔ.</p><p>.6</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">اﻟﻣﺎدة اﻟﻔﻌَﺎﻟﺔ ھﻲ اس ﺳﯾﺗﺎﻟوﺑرام. ﻛل ﻗرص&nbsp; ُﻣﻐﻠف ﻣن ﺳﯾﺑراﻟﻛس ﯾﺣﺗوى ﻋﻠﻰ 5 ﻣﻠﺟم، 10ﻣﻠﺟم، 15 ﻣﻠﺟم او 20ﻣﻠﺟم اس ﺳﯾﺗﺎﻟوﺑرام اوﻛﺳﺎﻟﯾت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اﻟﻣﻛوﻧﺎت اﻻﺧرى ھﻰ:</p><p>أﺳﺎﺳﯾﺔ: ﻣﺎﯾﻛروﻛرﯾﺳﺗﺎﻟﯾن ﺳﯾﻠوﻟوز<strong>ﺳﻠﯾﺳﻲ</strong> ، ﺗﺎﻟك ،ﻛروزﻛﺎرﻣﯾﻠوز اﻟﺻودﯾوم و ﺳﺗﯾﺎرات اﻟﻣﺎﻏﻧﺳﯾوم.</p><p dir="RTL">اﻟطﺑﻘﺔ اﻟﺧﺎرﺟﯾﺔ: ھﺎﯾﺑروﻣﯾﻠوز، ﻣﺎﻛروﻗول400 وﺛﻧﺎﺋﻲ أﻛﺳﯾد اﻟﺗﯾﺗﺎﻧﯾوم )إي.(171-</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﯾﻘدم ﺳﯾﺑراﻟﻛس 5 ﻣﻠﺟم ، 10 ﻣﻠﺟم ، 15 ﻣﻠﺟم ، 20 ﻣﻠﺟم ﻓﻰ أﻗراص ﻣﻐﻠﻔﺔ. وﺻف ھذه اﻷﻗراص ﻛﺎﻟﺗﺎﻟﻲ:</p><p dir="RTL">5 ﻣﻠﺟم : أﻗراص ﻣﺳﺗدﯾرة ، ﺑﯾﺿﺎء ﻣﺣدﺑﺔ اﻟوﺟﮭﯾن ﻣﻐﻠﻔﺔ ﻋﻠﯾﮭﺎ ﺣرﻓﻲ &quot; EK &quot; ﻓﻲ ﺟﺎﻧب واﺣد.</p><p>&nbsp;</p><p dir="RTL">10 ﻣﻠﺟم : أﻗراص ﺑﯾﺿﺎوﯾﺔ ، ﺑﯾﺿﺎء ﻣﻐﻠﻔﺔ. اﻷﻗراص ﻣﻘﺳﻣﺔ و ﻋﻠﯾﮭﺎ ﺣرﻓﻲ E&quot; &quot; و L&quot; &quot; ﻋﻠﻰ ﻛل ﻗﺳم ﻓﻲ ﺟﺎﻧب واﺣد.</p><p>&nbsp;</p><p dir="RTL">15 ﻣﻠﺟم : أﻗراص ﺑﯾﺿﺎوﯾﺔ ، ﺑﯾﺿﺎء ﻣﻐﻠﻔﺔ. اﻷﻗراص ﻣﻘﺳﻣﺔ و ﻋﻠﯾﮭﺎ ﺣرﻓﻲ E&quot; &quot; و M&quot; &quot; ﻋﻠﻰ ﻛل ﻗﺳم ﻓﻲ ﺟﺎﻧب واﺣد.</p><p dir="RTL">20 ﻣﻠﺟم : أﻗراص ﺑﯾﺿﺎوﯾﺔ ، ﺑﯾﺿﺎء ﻣﻐﻠﻔﺔ اﻷﻗراص ﻣﻘﺳﻣﺔ و ﻋﻠﯾﮭﺎ ﺣرﻓﻲ E&quot; &quot; و N&quot; &quot; ﻋﻠﻰ ﻛل ﻗﺳم ﻓﻲ ﺟﺎﻧب واﺣد.</p><p>&nbsp;</p><p dir="RTL">ﺳﯾﺑراﻟﻛس ﻣﺗوﻓر ﻓﻲ ﻋﺑوات ﺑﺎﻷﺣﺟﺎم اﻟﺗﺎﻟﯾﺔ :</p><p>&nbsp;</p><p dir="RTL"><u>ﺷراﺋط</u><u> </u><u>داﺧل ﻋﺑوة ورﻗﯾﺔ ﺗﺣﺗوي ﻋﻠﻰ</u> :</p><p dir="RTL">14 أو 28 أو 98 ﻗرص.</p><p>&nbsp;</p><p dir="RTL">ﻗد ﻻ ﺗﻛون ﻛل اﻟﺗراﻛﯾز أو اﻟﻌﺑوات ﻣﺗوﻓرة أو ﻣﺳوﻗﺔ ﻓﻲ ﺑﻠدك.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك حق&nbsp;التسويق</strong><br />شركة أجا للصناعات الدوائية المحدودة<br />حائل<br />المملكة العربية السعودية</p><p><strong>الشركة المصعنة</strong></p><p>اتش لوندبيك ايه /اس<br />اوتليافيج 9<br />2500 فالبي<br />الدنمارك</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة ھذه النشرة في يناير 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CIPRALEX 5 mg film-coated tablets
CIPRALEX 10 mg film-coated tablets
CIPRALEX 15 mg film-coated tablets
CIPRALEX 20 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cipralex 5 mg:	Each tablet contains 5 mg escitalopram (as 6.39 mg escitalopram oxalate) Cipralex 10 mg:	Each tablet contains 10 mg escitalopram (as 12.77 mg escitalopram oxalate) Cipralex 15 mg:	Each tablet contains 15 mg escitalopram (as 19.16 mg escitalopram oxalate) Cipralex 20 mg:	Each tablet contains 20 mg escitalopram (as 25.54 mg escitalopram oxalate)
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets
Cipralex 5 mg:	Round, white, film-coated tablet marked with "EK" on one side.
Cipralex 10 mg:	Oval, white, scored, film-coated tablet marked with "E” and “L" on each side of the score on one side of the tablet.
Cipralex 15 mg:	Oval, white, scored, film-coated tablet marked with "E” and “M" on each side of the score on one side of the tablet.
Cipralex 20 mg:	Oval, white, scored, film-coated tablet marked with "E” and “N" on each side of the score on one side of the tablet.
The 10, 15 and 20 mg tablets can be divided into equal doses.
 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depressive episodes.<br />Treatment of panic disorder with or without agoraphobia.<br />Treatment of social anxiety disorder (social phobia).<br />Treatment of generalised anxiety disorder.<br />Treatment of obsessive-compulsive disorder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Safety of daily doses above 20 mg has not been demonstrated.</p><p>Cipralex is administered as a single daily dose and may be taken with or without food. <u>Major depressive episodes</u></p><p>Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.</p><p>&nbsp;</p><p>Usually 2-4 weeks are necessary to obtain antidepressant response. After the symptoms resolve, treatment for at least 6 months is required for consolidation of the response.</p><p>&nbsp;</p><p><u>Panic disorder with or without agoraphobia</u></p><p>An initial dose of 5 mg is recommended for the first week before increasing the dose to 10 mg daily. The dose may be further increased, up to a maximum of 20 mg daily, dependent on individual patient response.</p><p>Maximum effectiveness is reached after about 3 months. The treatment lasts several months. <u>Social anxiety disorder</u></p><p>Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be</p><p>increased to a maximum of 20 mg daily.</p><p>&nbsp;</p><p>Usually 2-4 weeks are necessary to obtain symptom relief. Treatment for 3 months is recommended to consolidate response. Long-term treatment of responders for 6 months has been shown to prevent relapse and can be considered on an individual basis; treatment benefits should be re-evaluated at regular intervals.</p><p>&nbsp;</p><p><u>Generalised anxiety disorder</u></p><p>Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.</p><p>&nbsp;</p><p>Treatment for 3 months is recommended to consolidate response. Long-term treatment of responders for 6 months has been shown to prevent relapse and can be considered on an individual basis; treatment benefits should be re-evaluated at regular intervals.</p><p>&nbsp;</p><p><u>Obsessive-compulsive disorder (OCD)</u></p><p>Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be increased to 20 mg daily.</p><p>&nbsp;</p><p>Long-term treatment of patients responding to a 16-week open treatment phase has been studied for at least 24 weeks in patients receiving 10 or 20 mg/day. As OCD is a chronic disease, patients should be treated for a sufficient period to ensure that they are symptom free. This period may be several months or even longer.</p><p>&nbsp;</p><p><u>Elderly patients (&gt; 65 years of age)</u></p><p>Initial treatment with half the usually recommended dose and a lower maximum dose should be considered (see section 5.2).</p><p>&nbsp;</p><p><u>Children and adolescents (&lt;18 years)</u></p><p>Cipralex should not be used in the treatment of children and adolescents under the age of 18 years, see section 4.4.</p><p>&nbsp;</p><p><u>Reduced renal function</u></p><p>Dosage adjustment is not necessary in patients with mild or moderate renal impairment. Caution is advised&nbsp;in&nbsp;patients&nbsp;with&nbsp;severely&nbsp;reduced&nbsp;renal&nbsp;function&nbsp;(CLCR less&nbsp;than&nbsp;30&nbsp;ml/min.)&nbsp;(see&nbsp;section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Reduced hepatic function</u></p><p>An initial dose of 5 mg daily for the first two weeks of treatment is recommended. Depending on individual patient response, the dose may be increased to 10 mg daily (see section 5.2).</p><p><u>Poor metabolisers of CYP2C19</u></p><p>For patients who are known to be poor metabolisers with respect to CYP2C19, an initial dose of 5 mg daily during the first two weeks of treatment is recommended. Depending on individual patient response, the dose may be increased to 10 mg daily (see section 5.2).</p><p>&nbsp;</p><p><u>Discontinuation symptoms</u></p><p>When stopping treatment with Cipralex the dose should be gradually reduced over a period of at least one to two weeks in order to avoid possible discontinuations symptoms (see section 4.4 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant treatment with non-selective, irreversible monoamine oxidase inhibitors (MAO- inhibitors) (see section 4.5).

Concomitant treatment with pimozide.
 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Antidepressants should not be used in the treatment of children and adolescents under age of 18 years. Suicide related behaviours (suicide attempt and suicidal thoughts), and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms.</p><p>&nbsp;</p><p>The following special warnings and precautions apply to the therapeutic class of SSRIs (<u>S</u>elective <u>S</u>erotonin <u>R</u>e-uptake <u>I</u>nhibitors).</p><p>&nbsp;</p><p><u>Paradoxical anxiety</u></p><p>Some patients with panic disorder may experience increased anxiety symptoms at the beginning of treatment with antidepressants. This paradoxical reaction usually subsides within the first two weeks of treatment. A low starting dose is advised to reduce the likelihood of an anxiogenic effect (see section 4.2).</p><p>&nbsp;</p><p><u>Seizures</u></p><p>Escitalopram should be discontinued if a patient develops seizures for the first time, or if there is an increase in seizure frequency (in patients with a previous diagnosis of epilepsy). SSRIs should be avoided in patients with unstable epilepsy, and patients with controlled epilepsy should be closely monitored.</p><p>&nbsp;</p><p><u>Mania</u></p><p>SSRIs should be used with caution in patients with a history of mania/hypomania. SSRIs should be discontinued in any patient entering a manic phase.</p><p><u>Diabetes</u></p><p>In patients with diabetes, treatment with an SSRI may alter glycaemic control. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p>&nbsp;</p><p><u>Suicide/suicidal thoughts or clinical worsening</u></p><p>Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide- related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>&nbsp;</p><p>Other psychiatric conditions for which escitalopram is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta analysis of</p><p>&nbsp;</p><p>placebo controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p>&nbsp;</p><p><u>Akathisia/psychomotor restlessness</u></p><p>The use of SSRIs/SNRIs has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p>&nbsp;</p><p><u>Hyponatraemia</u></p><p>Hyponatraemia, probably due to inappropriate antidiuretic hormone secretion (SIADH), has been reported rarely with the use of SSRIs and generally resolves on discontinuation of therapy. Caution should be exercised in patients at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.</p><p>&nbsp;</p><p><u>Haemorrhage</u></p><p>There have been reports of cutaneous bleeding abnormalities, such as ecchymoses and purpura, with SSRIs. SSRIs/SNRIs may increase the risk of postpartum haemorrhage (see sections 4.6, 4.8). Caution is advised in patients taking SSRIs, particularly with concomitant use of oral anticoagulants; medicinal products known to affect platelet function (e.g. atypical antipsychotics and phenothiazines, most tricyclic antidepressants, acetylsalicylic acid and non-steroidal anti- inflammatory medicinal products (NSAIDs), ticlopidine and dipyridamole); and in patients with known bleeding tendencies.</p><p><u>ECT (electroconvulsive therapy)</u></p><p>There is limited clinical experience of concurrent administration of SSRIs and ECT; therefore caution is advisable.</p><p><u>Reversible, selective MAO-A inhibitors</u></p><p>The combination of escitalopram with MAO-A inhibitors is generally not recommended due to the risk of onset of a serotonin syndrome (see section 4.5).</p><p><u>Serotonin syndrome</u></p><p>Caution is advisable if escitalopram is used concomitantly with medicinal products with serotonergic effects such as triptans (including sumatriptan), opioids (including tramadol), and tryptophan.</p><p>In rare cases, serotonin syndrome has been reported in patients using SSRIs concomitantly with serotonergic medicinal products. A combination of symptoms, such as agitation, tremor, myoclonus and hyperthermia may indicate the development of this condition. If this occurs, treatment with the SSRI and the serotonergic medicinal product should be discontinued immediately and symptomatic treatment initiated.</p><p>&nbsp;</p><p><u>St. John&acute;s Wort</u></p><p>Concomitant use of SSRIs and herbal remedies containing St. John&acute;s Wort (<em>Hypericum perforatum</em>) may result in an increased incidence of adverse reactions (see section 4.5).</p><p><u>Discontinuation symptoms seen when stopping treatment</u></p><p>Discontinuation symptoms when stopping treatment are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials adverse events seen on treatment discontinuation occurred in approximately 25% of patients treated with escitalopram and 15% of patients taking placebo.</p><p>The risk of discontinuation symptoms may be dependent on several factors including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these symptoms are mild to moderate, however, in some patients they may be severe in intensity.</p><p>They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.</p><p>Generally these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that escitalopram should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&rsquo;s needs (see &ldquo;Discontinuation symptoms seen when stopping treatment&rdquo;, section 4.2).</p><p>Angle-Closure Glaucoma</p><p>SSRIs including escitalopram may have an effect on pupil size resulting in mydriasis. This mydriatic effect has the potential to narrow the eye angle resulting in increased intraocular pressure and angle-closure glaucoma, especially in patients pre-disposed. Escitalopram should therefore be used with caution in patients with angle-closure glaucoma or history of glaucoma.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacodynamic interactions</p><p><u>Contraindicated combinations:</u></p><p><em>Non-selective, irreversible MAOIs</em></p><p>Cases of serious reactions have been reported in patients receiving an SSRI in combination with a non-selective irreversible monoamine oxidase inhibitor (MAOI), and in patients who have recently discontinued SSRI treatment and have been started on MAOI treatment (see section 4.3). In some cases, the patient developed serotonin syndrome (see section 4.8).</p><p>Escitalopram is contraindicated in combination with non-selective irreversible MAOIs. Escitalopram may be started 14 days after discontinuing treatment with an irreversible MAOI. At</p><p>&nbsp;</p><p>least 7 days should elapse after discontinuing escitalopram treatment, before starting a non- selective irreversible MAOI.</p><p><em>Pimozide</em></p><p>Co-administration of a single dose of pimozide 2 mg to subjects treated with racemic citalopram</p><p>40 mg/day for 11 days caused an increase in AUC and Cmax of pimozide, although not consistently throughout the study. The co-administration of pimozide and citalopram resulted in a mean increase in the QTc interval of approximately 10 msec. Due to the interaction noted at a low dose of pimozide, concomitant administration of escitalopram and pimozide is contraindicated.</p><p>&nbsp;</p><p><u>Combinations requiring precautions for use:</u></p><p>&nbsp;</p><p><em>Reversible, selective MAO-A inhibitor (moclobemide)</em></p><p>Due to the risk of serotonin syndrome, the combination of escitalopram with a MAO-A inhibitor is not recommended (see section 4.4). If the combination proves necessary, it should be started at the minimum recommended dosage and clinical monitoring is strongly recommended.</p><p>&nbsp;</p><p>Escitalopram may be started at least one day after discontinuing treatment with the reversible MAOI (RIMA), moclobemide.</p><p>&nbsp;</p><p><em>Selegiline</em></p><p>In combination with selegiline (irreversible MAO-B inhibitor), caution is required due to the risk of developing serotonin syndrome.</p><p><em>Serotonergic medicinal products</em></p><p>Co-administration with serotonergic medicinal products e.g. . opioids (including tramadol)and triptans (including sumatriptan) may lead to serotonin syndrome.</p><p><em>Medicinal products lowering the seizure threshold</em></p><p>SSRIs can lower the seizure threshold. Caution is advised when concomitantly using other medicinal products capable of lowering the seizure threshold (e.g. antidepressants (tricyclics, SSRIs) neuroleptics (phenothiazines, thioxanthenes, butyrophenones) mefloquine, bupropion, and tramadol).</p><p>&nbsp;</p><p><em>Lithium, tryptophan</em></p><p>There have been reports of enhanced effects when SSRIs have been given together with lithium or tryptophan, therefore concomitant use of SSRIs with these medicinal products should be undertaken with caution.</p><p>&nbsp;</p><p><em>St. John&rsquo;s Wort</em></p><p>Concomitant use of SSRIs and herbal remedies containing St. John&acute;s Wort (<em>Hypericum perforatum</em>) may result in an increased incidence of adverse reactions (see section 4.4).</p><p>&nbsp;</p><p><em>Haemorrhage</em></p><p>Altered anti-coagulant effects may occur when escitalopram is combined with oral anticoagulants. Patients receiving oral anticoagulant therapy should receive careful coagulation monitoring when escitalopram is started or stopped (see section 4.4).</p><p>&nbsp;</p><p>Concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) may increase bleeding- tendency (see section 4.4).</p><p>&nbsp;</p><p><em>Alcohol</em></p><p>No pharmacodynamic or pharmacokinetic interactions are expected between escitalopram and alcohol. However, as with other psychotropic medicinal products, the combination with alcohol is not advisable.</p><p>&nbsp;</p><p>Pharmacokinetic interactions</p><p><strong>&nbsp;</strong></p><p><u>Influence of other medicinal products on the pharmacokinetics of escitalopram</u></p><p>&nbsp;</p><p>The metabolism of escitalopram is mainly mediated by CYP2C19. CYP3A4 and CYP2D6 may also contribute to the metabolism although to a smaller extent. The metabolism of the major metabolite S-DCT (demethylated escitalopram) seems to be partly catalysed by CYP2D6.</p><p>&nbsp;</p><p>Co-administration of escitalopram with omeprazole (a CYP2C19 inhibitor) resulted in moderate (approximately 50%) increase in the plasma concentrations of escitalopram.</p><p>&nbsp;</p><p>Co-administration of escitalopram with cimetidine (moderately potent general enzyme-inhibitor) resulted in moderate (approximately 70%) increase in the plasma concentrations of escitalopram.</p><p>&nbsp;</p><p>Caution should thus be exercised at the upper end of the dose range of escitalopram when used concomitantly with CYP2C19 inhibitors (e.g. omeprazole, fluoxetine, fluvoxamine, lansoprazole, ticlopidine) and with cimetidine.</p><p>A reduction in the dose of escitalopram may be necessary based on clinical judgement. <u>Effect of escitalopram on the pharmacokinetics of other medicinal products</u></p><p>Escitalopram is an inhibitor of the enzyme CYP2D6. Caution is recommended when escitalopram is co-administered with medicinal products that are mainly metabolised by this enzyme, and that have a narrow therapeutic index, e.g. flecainide, propafenone and metoprolol (when used in cardiac failure), or some CNS acting medicinal products that are mainly metabolised by CYP2D6, e.g. antidepressants such as desipramine, clomipramine and nortriptyline or antipsychotics like risperidone, thioridazine and haloperidol. Dosage adjustment may be warranted.</p><p>Co-administration with desipramine or metoprolol resulted in a twofold increase in the plasma levels of these two CYP2D6 substrates.</p><p>&nbsp;</p><p><em>In vitro </em>studies have demonstrated that escitalopram may also cause weak inhibition of CYP2C19. Caution is recommended with concomitant use of medicinal products that are metabolised by CYP2C19.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Limited clinical data are available regarding exposure to escitalopram during pregnancy. Animal studies have shown reproductive toxicity (see section 5.3)</p><p>Escitalopram should not be used during pregnancy unless clearly needed and after careful consideration of the risk/benefit ratio.</p><p>&nbsp;</p><p>Newborns should be observed if maternal use of escitalopram continues into the later stages of pregnancy, particularly in the third trimester. If escitalopram is used until or shortly before birth, discontinuation effects in the newborn are possible.</p><p>&nbsp;</p><p>The following symptoms may occur in the newborn after maternal SSRI/SNRI use in later stages of pregnancy: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying, somnolence and difficulty sleeping. These symptoms could be due to either discontinuation effects or excess serotonergic activity. In a majority of instances, such complications begin immediately or soon (&lt;24 hours) after delivery.</p><p>&nbsp;</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur.</p><p>&nbsp;</p><p>Observational data indicate an increased risk (less than 2-fold) of postpartum haemorrhage following SSRI/SNRI exposure within the month prior to birth (see sections 4.4, 4.8).</p><p><u>Breast-feeding</u></p><p>It is expected that escitalopram will be excreted into human milk and breast-feeding is not recommended during the treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Animal data have shown that citalopram may affect sperm quality. Human case reports with some SSRIs have shown that an effect on sperm quality is reversible.</p><p>Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although Cipralex has been shown not to affect intellectual function or psychomotor performance, any psychoactive medicinal product may impair judgement or skills. Patients should be cautioned about the potential risk of an influence on their ability to drive a car and operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are most frequent during the first or second week of treatment and usually decrease in intensity and frequency with continued treatment.</p><p>&nbsp;</p><p>Adverse reactions known for SSRIs and also reported for escitalopram in either placebo-controlled clinical studies or as spontaneous post-marketing events are listed below by system organ class and frequency.</p><p>Frequencies are taken from clinical studies; they are not placebo-corrected. Frequencies are defined as: very common (&sup3;1/10), common (&sup3;1/100 to &lt;1/10), uncommon (&sup3;1/1000 to &pound;1/100), rare (&sup3;1/10000 to &pound;1/1000), very rare (&pound;1/10000), or not known (can not be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System</strong><strong> </strong><strong>organ</strong><strong> </strong><strong>class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Inappropriate ADH secretion, Hyperprolactineamia<sup>4</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Decreased appetite, increased appetite, weight increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hyponatraemia, anorexia<sup>1</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anxiety, restlessness, abnormal dreams, libido decreased</p><p>Female: anorgasmia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Bruxism, agitation, nervousness, panic attack, confusional state</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Aggression, depersonalisation, hallucination</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Mania, suicidal ideation, suicidal behaviour<sup>2</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Insomnia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; somnolence,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness, paraesthesia, tremor</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Taste disturbance, sleep disorder, syncope</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Serotonin syndrome</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Dyskinesia, movement disorder, convulsion, psychomotor restlessness/akathisia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Mydriasis, visual disturbance</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Tachycardia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Electrocardiogram QT prolonged</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sinusitis, yawning</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Epistaxis</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="3" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Diarrhoea, constipation, vomiting, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastrointestinal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemorrhages&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (including rectal haemorrhage)</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hepatitis, liver function test abnormal</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Sweating increased</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Urticaria, alopecia, rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Ecchymosis, angioedemas</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and connective tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Urinary retention</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Male: ejaculation disorder, impotence</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Female: metrorrhagia, menorrhagia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Galactorrhoea</p><p>Female: postpartum haemorrhage<sup>3</sup> Male: priapism</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue, pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>1</sup> These events have been reported for the therapeutic class of SSRIs.</p><p>&nbsp;</p><p><sup>2</sup> Cases of suicidal ideation and suicidal behaviours have been reported during escitalopram therapy or early after treatment discontinuation (see section 4.4).</p><p>&nbsp;</p><p><sup>3</sup>This event has been reported for the therapeutic class of SSRIs/SNRIs (see sections 4.4, 4.6).</p><p>&nbsp;</p><p><sup>4</sup>This event has been reported for the therapeutic class of SSRIs/SNRIs.</p><p>Post-Marketing Experience</p><p>Adverse Reactions Reported Subsequent to the Marketing of Escitalopram</p><p>The following additional adverse reactions have been identified from spontaneous reports of escitalopram received worldwide. These adverse reactions have been chosen for inclusion because of a combination of seriousness, frequency of reporting, or potential causal connection to escitalopram and have not been listed elsewhere in labeling. However, because these adverse reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events include:</p><p>Endocrine Disorders: Hyperprolactinemia</p><p>&nbsp;</p><p>Cases of QT-prolongation have been reported during the post-marketing period, predominantly in patients with pre-existing cardiac disease. In a double-blind, placebo-controlled ECG study in</p><p>&nbsp;</p><p>healthy subjects, the change from baseline in QTc (Fridericia-correction) was 4.3 msec at the 10 mg/day dose and 10.7 msec at the 30 mg/day dose.</p><p>&nbsp;</p><p>Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.</p><p>&nbsp;</p><p><u>Discontinuation symptoms seen when stopping treatment</u></p><p>Discontinuation of SSRIs/SNRIs (particularly when abrupt) commonly leads to discontinuation symptoms. Dizziness, sensory disturbances (including paraesthesia and electric shock sensations), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, confusion, sweating, headache, diarrhoea, palpitations, emotional instability, irritability, and visual disturbances are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged. It is therefore advised that when escitalopram treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see section 4.2 and 4.4).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Textbox_x0020_3" o:spid="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:72.5pt;
 margin-top:41.85pt;width:278.05pt;height:68.4pt;z-index:15729152;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:0;mso-wrap-distance-top:0;
 mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAcAxYSFUEAABgHQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWUtv2zgQvi+w/4HgafcQW/IrtVGl
mzp1USBIjTjFnmmKsohQpJakFTu/foekZKvetJum7cW1jTiUOBrNfJwXh6/fbAqBKqYNVzLBcSfC
iEmqUi5XCf50Nzt7hZGxRKZEKMkSvGUGv7n4/bfXZLLSpMw5RcBBmglJcG5tOel2Dc1ZQUxHlUzC
XKZ0QSxc6lU31eQBOBei24uiUbcgXOKLPasrYglaa/4CVkLRe5ZOiayIAZaCTtp3ahkF/X7OZCKr
97pclHPtJKc31VwjniYYkJOkAIhwt56oyeCye/DUas9gk+nC0assQ5sEj3tRHA8x2iZ4ODgfjqJh
YMc2FlGY7w/7ca8PBBQoXo3gG9Xvyz9+nQPN332dBwgZhIFBS0BTOvFk9V+N+43GdyDdUm1Qf6e6
I0Z281aByLFfYlNewxKZAAagFth5YBrOpsb0x0CyU4dMSm3se6YK5AYJ1oxaLxOpro0NEjUkTlch
0QOI3YvHtehK8HTGhXCTRq+WU6FRRQSsuf84reFtpk3m+F0Rkwc6P1WTCRmoa2XtZuEBdmClW/eG
JfwH9MAp7Uf4yYQCaajgJUa50o+H9x7ADRNs/lkTzTASH6TxtmibgW4Gy2agrZgqJ70HQarLtVUZ
r4EIb/cwGLuwW8FAO4DQ/4BYBdHXCR71en0weLi4bfiYkr5lmSOD0dyaoLk3XwdOe/Yys4d03ooD
nZ+FYQ2QdzMNbxbExSQmzz4tICY9uhWKggosy2BJw1rC8hHLJbLbkmWEgj/e8YIZdMMe0K0qiMSo
JFIZmIh68B1F/WgYDeCvB6MBzHJL8xkpuAAPiyH80Zxow8Buak9j5KcxB61BU4eNvbjLGboBVZQk
As1BhoJQVfEVBxwoQ1MmrWbIGR6A6R50j/0PWAiWIcFn8RHD9sfNfPrn5AAWJtM50eT2l7GivcLe
NoL3OgNxcTm4cH/QG4P/7HwYicrHBMRlCrYFZlJT1K76hHO3nHY/+wznhhi3XjzuYoT3Yx9lluuZ
kvanuZd77xQ8ybs0KBjSlSVLCB3e6cgSlQriZ3w+PofMi4hYQVUk6sjdED47NgV3O2JnW8yuLg9c
7RSBXhSTj9hIpkSIFxnJEDunPMrkfrKRULM0xY6rZpg+TNvPiyUnM2lq4V+gvIvH8DmIJvti5wt7
hGPNw3vFT1Vee4d2qvK+e5vb3om+O4NGnXhZcD7mrea3JvF1giU0UV1DVfN7aEBItfAjuNPel3/W
SPqs3zTon8fTwVP9pqOpksgkF1zeTwWn93XbVj+nawv9U07ZlaLrAmqJ0F/WzPWClDQ5Lw1GeuL6
tPpDGtcI7notsqSdVK9Xf5ksJZ2VqjqGnJJMaGuekszTbcBTkvmhSeZvtjTcssm3BtVT5Gw60+2U
7Y7iDJzFkZR1WjGtewpqXwpqgN7+CGZt2KK8hTOFQB3OaIDCnYV1D84Wfeldn4W6A8z29cW/AAAA
//8DAFBLAwQUAAYACAAAACEA4VE3H88GAADmGwAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEu
eG1s7FnNb9xEFL8j8T+MfG+z381G3VTZzW4Dbdoo2Rb1OGvP2tOMPdbMbNK9ofaIhIQoiAOVuHFA
QKVW4lL+mkARFKn/Am9mbK8n65C0jaCC5pC1n3/zvt+br8tX7sUMHRAhKU96Xv1izUMk8XlAk7Dn
3RqPLqx6SCqcBJjxhPS8OZHelfX337uM13xG0wnHIhhHJCYIGCVyDfe8SKl0bWVF+kDG8iJPSQLf
plzEWMGrCFcCgQ9BQMxWGrVaZyXGNPHWgaPSjIYM/iVKaoLPxJ5mQ1CCY5B+czqlPjHYYL+uEXIu
B0ygA8x6HvAM+OGY3FMeYlgq+NDzaubPW1m/vILXskFMnTC2NG5k/rJx2YBgv2FkinBSCK2PWt1L
mwV/A2BqGTccDgfDesHPALDvg6VWlzLP1mi13s95lkD2cZn3oNautVx8iX9zSeduv99vdzNdLFMD
so+tJfxqrdPaaDh4A7L49hK+1d8YDDoO3oAsvrOEH13qdlou3oAiRpP9JbQO6GiUcS8gU862KuGr
AF+tZfAFCrKhyC4tYsoTdVKuxfguFyMAaCDDiiZIzVMyxT7k5ADHE0GxFoDXCC59sSRfLpG0LCR9
QVPV8z5MceKVIC+fff/y2RN0dP/p0f2fjh48OLr/o2XkjNrCSVge9eLbz/589DH648k3Lx5+UY2X
ZfyvP3zyy8+fVwOhfBbmPf/y8W9PHz//6tPfv3tYAd8QeFKGj2lMJLpBDtEuj8Ew4xVXczIRrzZi
HGFaHrGRhBInWEup4D9UkYO+Mccsi46jR5+4HrwtoH1UAa/O7joK70VipmiF5GtR7AC3OWd9Liq9
cE3LKrl5PEvCauFiVsbtYnxQJXuAEye+w1kKfTNPS8fwQUQcNXcYThQOSUIU0t/4PiEV1t2h1PHr
NvUFl3yq0B2K+phWumRMJ042LQZt0RjiMq+yGeLt+Gb7NupzVmX1JjlwkVAVmFUoPybMceNVPFM4
rmI5xjErO/w6VlGVkntz4ZdxQ6kg0iFhHA0DImXVmJsC7C0F/RqGjlUZ9m02j12kUHS/iud1zHkZ
ucn3BxGO0yrsHk2iMvYDuQ8pitEOV1Xwbe5WiH6HOODkxHDfpsQJ9+nd4BYNHZUWCaK/zISOJbRq
pwPHNPm7dswo9GObA+fXjqEBPv/6UUVmva2NeAPmpKpK2DrWfk/CHW+6Ay4C+vb33E08S3YIpPny
xPOu5b5rud5/vuWeVM9nbbSL3gptV68b7KLYLJHjE1fIU8rYnpozcl2aRbKEeSIYAVGPMztBUuyY
0gges77u4EKBzRgkuPqIqmgvwikssOueZhLKjHUoUcolbOwMuZK3xsMiXdltYVtvGGw/kFht88CS
m5qc7wsKNma2Cc3mMxfU1AzOKqx5KWMKZr+OsLpW6szS6kY10+ocaYXJEMNl04BYeBMWIAiWLeDl
DuzFtWjYmGBGAu13O/fmYTFROM8QyQgHJIuRtns5RnUTpDxXzEkA5E5FjPQm7xSvlaR1Nds3kHaW
IJXFtU4Ql0fvTaKUZ/AiSrpuj5UjS8rFyRJ02PO67UbbQz5Oe94U9rTwGKcQdanXfJiFcBrkK2HT
/tRiNlW+iGY3N8wtgjocU1i/Lxns9IFUSLWJZWRTw3zKUoAlWpLVv9EGt56XATbTX0OL5iokw7+m
BfjRDS2ZTomvysEuUbTv7GvWSvlMEbEXBYdowmZiF0P4daqCPQGVcDRhOoJ+gXM07W3zyW3OWdGV
T68MztIxSyOctVtdonklW7ip40IH81ZSD2yr1N0Y9+qmmJI/J1PKafw/M0XPJ3BS0Ax0BHw4lBUY
6XrteVyoiEMXSiPqjwQsHEzvgGyBs1j4DEkFJ8jmV5AD/WtrzvIwZQ0bPrVLQyQozEcqEoTsQFsy
2XcKs3o2d1mWLGNkMqqkrkyt2hNyQNhY98COnts9FEGqm26StQGDO55/7ntWQZNQL3LK9eb0kGLu
tTXwT698bDGDUW4fNgua3P+FihWzqh1vhudzb9kQ/WGxzGrlVQHCSlNBNyv711ThFada27GWLG60
c+UgissWA7FYEKVw3oP0P5j/qPCZvW3QE+qY70JvRXDRoJlB2kBWX7ALD6QbpCVOYOFkiTaZNCvr
2mzppL2WT9bnvNIt5B5zttbsLPF+RWcXizNXnFOL5+nszMOOry3tRFdDZI+XKJCm+UbGBKbq1mkb
p2gS1nse3PxAoO/BE9wdeUBraFpD0+AJLoRgsWRvcXpe9pBT4LulFJhmTmnmmFZOaeWUdk6BxVl2
X5JTOtCp9BUHXLHpHw/ltxmwgstuP/Km6lzNrf8FAAD//wMAUEsDBBQABgAIAAAAIQBTq9v87QAA
AM0BAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzrJHBagMh
EEDvhf6DzL26m0MpIW5yaAs59FLSDxh01pWso6gJyd9XGkobCPTSy4Az+uY5s1qfwiyOlIuPrKGX
HQhiE61np+Fj9/rwBKJUZItzZNJwpgLr4f5u9U4z1vaoTD4V0ShcNEy1pqVSxUwUsMiYiFtljDlg
bcfsVEKzR0dq0XWPKv9mwHDFFFurIW/tAsTunFrnv9lxHL2h52gOgbjeaKFq86IGxOyoapDykrnE
XjZXULc1+v/UmNqH8ux5/6MS0M81LjkZafPBbcpoUbp4lAW/L71F28bwcqqUGb9E1dUShk8AAAD/
/wMAUEsBAi0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50
X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAAA2AQAA
X3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAcAxYSFUEAABgHQAAHwAAAAAAAAAAAAAAAAAgAgAA
Y2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQDhUTcfzwYAAOYb
AAAaAAAAAAAAAAAAAAAAALIGAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAI
AAAAIQBTq9v87QAAAM0BAAAqAAAAAAAAAAAAAAAAALkNAABjbGlwYm9hcmQvZHJhd2luZ3MvX3Jl
bHMvZHJhd2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAA7g4AAAAA
" filled="f" strokeweight=".33864mm">
 <v:path arrowok="t"/>
 <v:textbox inset="0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp; SFDA Call Center: 19999</p><p>-&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>To report any side effect(s): Saudi Arabia:</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other GCC States:</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="Textbox_x0020_4" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:72.5pt;margin-top:14.3pt;width:280.05pt;height:21.4pt;z-index:-15728640;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokeweight=".33864mm">
  <v:path arrowok="t"/>
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:.05pt;margin-right:0in;margin-bottom:
     0in;margin-left:1.8pt;margin-bottom:.0001pt'>- Please contact the relevant
     competent <span style='letter-spacing:-.1pt'>authority.</span><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="378" height="33" alt="Text Box: - Please contact the relevant competent authority." src="file:///C:/Users/101623/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Toxicity</u></p><p>Clinical data on escitalopram overdose are limited and many cases involve concomitant overdoses of other drugs. In the majority of cases mild or no symptoms have been reported. Fatal cases of escitalopram overdose have rarely been reported with escitalopram alone; the majority of cases have involved overdose with concomitant medications. Doses between 400 and 800mg of escitalopram alone have been taken without any severe symptoms.</p><p><u>Symptoms</u></p><p>&nbsp;</p><p>Symptoms seen in reported overdose of escitalopram include symptoms mainly related to the central nervous system (ranging from dizziness, tremor, and agitation to rare cases of serotonin syndrome, convulsion, and coma), the gastrointestinal system (nausea/vomiting), and the cardiovascular system (hypotension, tachycardia, QT prolongation, and arrhythmia) and electrolyte/fluid balance conditions (hypokalaemia, hyponatraemia).</p><p>&nbsp;</p><p><u>Treatment</u></p><p>There is no specific antidote. Establish and maintain an airway, ensure adequate oxygenation and respiratory function. Gastric lavage and the use of activated charcoal should be considered. Gastric lavage should be carried out as soon as possible after oral ingestion. Cardiac and vital signs monitoring are recommended along with general symptomatic supportive measures.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacotherapeutic group</u><em>: </em>antidepressants, selective serotonin reuptake inhibitors ATC-code: N 06 AB 10</p><p><u>Mechanism of action</u></p><p>Escitalopram is a selective inhibitor of serotonin (5-HT) re-uptake with high affinity for the primary binding site. It also binds to an allosteric site on the serotonin transporter, with a 1000 fold lower affinity. Allosteric modulation of the serotonin transporter enhances binding of escitalopram to the primary binding site, resulting in more complete serotonin reuptake inhibition.</p><p>Escitalopram has no or low affinity for a number of receptors including 5-HT1A, 5-HT2, DA D1 and D2 receptors, &alpha;1-, &alpha;2-, &beta;-adrenoceptors, histamine H1, muscarine cholinergic, benzodiazepine, and opioid receptors.</p><p>The inhibition of 5-HT re-uptake is the only likely mechanism of action explaining the pharmacological and clinical effects of escitalopram.</p><p>Escitalopram is the S-enantiomer of the racemate (citalopram) and is the enantiomer to which the therapeutic activity is attributed. Pharmacological studies have shown that the R-enantiomer is not inert but counteracts the serotonin-enhancing and consequent pharmacological properties of the S-enantiomer.</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p><em>Major Depressive Episodes</em></p><p>Escitalopram has been found to be effective in the acute treatment of major depressive episodes in three out of four double-blind, placebo controlled short-term (8-weeks) studies.</p><p>The antidepressant effect was evident as early as after two weeks for both 10 and 20 mg doses of escitalopram. After 8 weeks of therapy, escitalopram 20 mg was superior to citalopram 40 mg. A</p><p>&nbsp;</p><p>dose-response relationship for escitalopram was clearly seen in the severely depressed patients indicating that they are likely to benefit from a higher dose of escitalopram (20 mg) than the usual starting dose (10 mg).</p><p>&nbsp;</p><p>In a long-term (24-week) double-blind study of escitalopram 10 mg vs citalopram 20 mg, escitalopram was as least as effective as citalopram, and half as many escitalopram patients withdrew because of adverse effects. In a long-term relapse prevention study, 274 patients who had responded during an initial 8-week open label treatment phase with escitalopram 10 or 20 mg/day, were randomised to continuation with escitalopram at the same dose, or to placebo, for up to 36 weeks. In this study, patients receiving continued escitalopram experienced a significantly longer time to relapse over the subsequent 36 weeks compared to those receiving placebo.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Panic disorder</em></p><p>The efficacy of escitalopram in the treatment of panic disorder was demonstrated in a 10-week flexible dose study that compared 5-20 mg/day escitalopram to placebo and racemic citalopram 10-40 mg/day.</p><p>Escitalopram was statistically significantly superior to placebo as demonstrated by measurement of panic attack frequency, severity, duration, and accompanying symptoms. Citalopram was also efficacious compared to placebo in the majority of efficacy measures.</p><p>For the majority of treatment emergent adverse events reported for at least 5% of patients, reporting frequencies were higher in the citalopram group than in the escitalopram group<strong>.</strong></p><p><em>Social Anxiety Disorder</em></p><p>Escitalopram was effective in both three short-term (12-week) studies and in responders in a 6 months relapse prevention study in social anxiety disorder.</p><p>In a placebo-controlled long-term study (24 weeks) efficacy of 5, 10 and 20 mg escitalopram has been demonstrated.</p><p>Escitalopram 20 mg/day was statistically significantly superior to paroxetine 20 mg/day as well as to the 5 mg/day and 10 mg/day doses of escitalopram in the treatment of social anxiety. Transient discontinuation symptoms were seen (lasting for less than 2 weeks in all active treatment groups), with significantly higher levels in paroxetine patients than in escitalopram patients (P&le; 0.05).</p><p>&nbsp;</p><p>In pooled data comprising 670 escitalopram-treated patients and 341 placebo-treated patients, there were 58.1% vs 40.2 % responders (CGI-I score of 1 or 2) and 24.8% vs 12.9% remitters (CGI-S score of 1 or 2) (P&le;0.001).</p><p><em>Generalised anxiety disorder</em></p><p>Escitalopram in doses of 10 and 20 mg/day was effective in four out of four placebo-controlled studies. 5 mg/day was not effective.</p><p>&nbsp;</p><p>In pooled data from three studies with similar 8-week design and comprising 421 escitalopram- treated patients and 419 placebo-treated patients, there were 47.5% vs 28.9% responders and 37.1% vs 20.8% remitters (P&le;0.001). Sustained effect was seen from week 1. In the fourth study (12 weeks), which included paroxetine, escitalopram 10mg/day was significantly superior to</p><p>&nbsp;</p><p>paroxetine 20 mg/day. Transient discontinuation symptoms were seen, with significantly higher levels for paroxetine than for escitalopram 5, 10 and 20 mg/day (P&le;0.01).</p><p>&nbsp;</p><p>Escitalopram 20 mg/day significantly reduced the risk of relapse in a 24- to 76-week randomised, continuation study in 373 patients who had responded during initial 12-week open label treatment.</p><p>&nbsp;</p><p><em>Obsessive-compulsive disorder</em></p><p>In the short-term (12 weeks), 20 mg/day escitalopram separated from placebo on the Y-BOCS total score and the Y-BOCS subscales scores of obsessions and rituals, and also on the NIMH- OCS total score. In the observed cases analysis, both 10 mg/day (p=0.005) and 20 mg/day (p&lt;0.001) escitalopram were effective.</p><p>&nbsp;</p><p>The long-term maintenance effect has been demonstrated in two studies; a 24 weeks placebo- controlled, dose-finding study and a 16 weeks placebo-controlled, relapse-prevention study.</p><p>In the long-term, 24-week, placebo-controlled, dose-finding study, both 10 mg/day (p&lt;0.05) and 20 mg/day (p&lt;0.01) escitalopram were significantly more effective than placebo, as measured by the primary outcome measure, the Y-BOCS total, as well as on the secondary subscales of the Y- BOCS obsessions and rituals, and the NIMH-OCS (10 mg/day (p&lt;0.01) and 20 mg/day (p&lt;0.001) escitalopram).</p><p>Maintenance of efficacy and prevention of relapse was demonstrated for 10 and 20 mg/day escitalopram in patients who responded to escitalopram in a 16-week open treatment phase and who were entering a 24-week (double blind placebo controlled randomized) relapse prevention trial. In the observed relapse prevention trial, both 10 mg/day (p=0.014) and 20 mg/day (p&lt;0.001) escitalopram showed significantly fewer relapses.</p><p>A significant and beneficial effect of escitalopram on quality of life was observed (as assessed by the SF-36 and SDS) in the OCD studies with escitalopram.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Absorption is almost complete and independent of food intake. Mean time to maximum concentration (mean&nbsp;Tmax)&nbsp;is&nbsp;4&nbsp;hours&nbsp;after&nbsp;multiple&nbsp;dosing.&nbsp;As&nbsp;with&nbsp;racemic&nbsp;citalopram,&nbsp;the&nbsp;absolute&nbsp;bio-availability of escitalopram is expected to be about 80%.</p><p><u>Distribution</u></p><p>The apparent volume of distribution (Vd,&beta;/F) after oral administration is about 12 to 26 L/kg. The plasma protein binding is below 80% for escitalopram and its main metabolites.</p><p><u>Biotransformation</u></p><p>Escitalopram is metabolised in the liver to the demethylated and didemethylated metabolites. Both of these are pharmacologically active. Alternatively, the nitrogen may be oxidised to form the N- oxide metabolite. Both parent substance and metabolites are partly excreted as glucuronides. After multiple dosing the mean concentrations of the demethyl and didemethyl metabolites are usually 28- 31% and &lt;5%, respectively, of the escitalopram concentration. Biotransformation of escitalopram to</p><p>&nbsp;</p><p>the demethylated metabolite is mediated primarily by CYP2C19. Some contribution by the enzymes CYP3A4 and CYP2D6 is possible.</p><p><u>Elimination</u></p><p>The elimination half-life (t&frac12; &beta;) after multiple dosing is about 30 hours and the oral plasma clearance (Cloral)&nbsp;is&nbsp;about&nbsp;0.6&nbsp;L/min.&nbsp;The&nbsp;major&nbsp;metabolites&nbsp;have&nbsp;a&nbsp;significantly&nbsp;longer&nbsp;half-life.&nbsp;Escitalopram and major metabolites are assumed to be eliminated by both the hepatic (metabolic) and the renal routes, with the major part of the dose excreted as metabolites in the urine.</p><p><u>Linearity</u></p><p>There is linear pharmacokinetics. Steady-state plasma levels are achieved in about 1 week. Average steady-state concentrations of 50 nmol/L (range 20 to 125 nmol/L) are achieved at a daily dose of 10 mg.</p><p><u>Elderly patients (&gt; 65 years)</u></p><p>Escitalopram appears to be eliminated more slowly in elderly patients compared to younger patients. Systemic exposure (AUC) is about 50 % higher in elderly compared to young healthy volunteers (see section 4.2).</p><p><u>Reduced hepatic function</u></p><p>In patients with mild or moderate hepatic impairment (Child-Pugh Criteria A and B), the half-life of escitalopram was about twice as long and the exposure was about 60% higher than in subjects with normal liver function (see section 4.2).</p><p><u>Reduced renal function</u></p><p>With racemic citalopram, a longer half-life and a minor increase in exposure have been observed in patients with reduced kidney function (CLcr 10-53 ml/min). Plasma concentrations of the metabolites have not been studied, but they may be elevated (see section 4.2).</p><p><u>Polymorphism</u></p><p>It has been observed that poor metabolisers with respect to CYP2C19 have twice as high a plasma concentration of escitalopram as extensive metabolisers. No significant change in exposure was observed in poor metabolisers with respect to CYP2D6 (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No complete conventional battery of preclinical studies was performed with escitalopram since the bridging toxicokinetic and toxicological studies conducted in rats with escitalopram and citalopram showed a similar profile. Therefore, all the citalopram information can be extrapolated to escitalopram</p><p>&nbsp;</p><p>In comparative toxicological studies in rats, escitalopram and citalopram caused cardiac toxicity, including congestive heart failure, after treatment for some weeks, when using dosages that caused general toxicity. The cardiotoxicity seemed to correlate with peak plasma concentrations rather than to systemic exposures (AUC). Peak plasma concentrations at no-effect-level were in excess (8-fold) of those achieved in clinical use, while AUC for escitalopram was only 3- to 4-fold higher than the exposure achieved in clinical use. For citalopram AUC values for the S-enantiomer were</p><p>&nbsp;</p><p>6- to 7-fold higher than exposure achieved in clinical use. The findings are probably related to an exaggerated influence on biogenic amines i.e. secondary to the primary pharmacological effects, resulting in haemodynamic effects (reduction in coronary flow) and ischaemia. However, the exact mechanism of cardiotoxicity in rats is not clear. Clinical experience with citalopram and the clinical trial experience with escitalopram do not indicate that these findings have a clinical correlate.</p><p>&nbsp;</p><p>Increased content of phospholipids has been observed in some tissues e.g. lung, epididymides and liver after treatment for longer periods with escitalopram and citalopram in rats. Findings in the epididymides and liver were seen at exposures similar to that in man. The effect is reversible after treatment cessation. Accumulation of phospholipids (phospholipidosis) in animals has been observed in connection with many cationic amphiphilic medicines. It is not known if this phenomenon has any significant relevance for man.</p><p>&nbsp;</p><p>In the developmental toxicity study in the rat embryotoxic effects (reduced foetal weight and reversible delay of ossification) were observed at exposures in terms of AUC in excess of the exposure achieved during clinical use. No increased frequency of malformations was noted. A pre- and postnatal study showed reduced survival during the lactation period at exposures in terms of AUC in excess of the exposure achieved during clinical use.</p><p>&nbsp;</p><p>Animal data have shown that some SSRIs induces a reduction of fertility index and pregnancy index, reduction in number in implantation and abnormal sperm at exposure well in excess of human exposure.</p><p>No animal data related to this aspect are available for escitalopram.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:</p><p>Microcrystalline cellulose,silicified Talc</p><p>Croscarmellose sodium Magnesium stearate</p><p>&nbsp;</p><p>Coating: Hypromellose Macrogol 400</p><p>Titanium dioxide (E 171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister: Transparent; PVC/PE/PVdC/Aluminium blister, pack with an outer carton; 14, 28, 56, 98 tablets - Unit dose; 49x1, 56x1, 98x1, 100x1, 500x1 tablets (5, 10, 15 and 20 mg)<br />Blister: White; PVC/PE/PVdC/Aluminium blister, pack with an outer carton; 14, 20, 28, 50, 100, 200 tablets (5, 10, 15 and 20 mg)<br />Polypropylene tablet container; 100 (5, 10, 15 and 20 mg), 200 (5 and 10 mg) tablets<br />High Density Polyethylene (HDPE) container; 100 (5, 10, 15 and 20 mg), 200 (5 and 10 mg) tablets<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AJA Pharmaceutical Industries Company, Ltd. 
Hail Industrial City MODON, Street No 32 
PO Box 6979, Hail 55414 
Kingdom of Saudi Arabia
Tel: +966 11 268 7900
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                January 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>